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 Abstract 
 
 
Forkhead-associated (FHA) domains have gained considerable prominence as 
ubiquitous phosphothreonine-dependent binding modules; however, their precise 
roles in Ser/Thr kinase pathways and mechanisms of regulation remain unclear.  
From experiments with Rv1827, an FHA domain–containing protein from 
Mycobacterium tuberculosis, a complete molecular description of an FHA-
mediated Ser/Thr protein kinase signalling process is derived.  First, binding of 
the FHA domain to each of three metabolic enzyme complexes regulates their 
catalytic activities but does not require priming phosphorylation.  However, 
phosphorylation of a threonine residue within a conserved N-terminal motif of 
Rv1827 triggers its intramolecular association with the FHA domain of Rv1827, 
thus blocking its interactions with each of the three enzymes.  The nuclear 
magnetic resonance structure of this inactivated form and further mutagenic 
studies show how a novel intramolecular phospho-switch blocks the access of the 
target enzymes to a common FHA interaction surface and how this shared 
surface accommodates three functionally related, but structurally diverse, binding 
partners.  Thus a remarkable and unsuspected versatility in the FHA domain that 
allows for the transformation of multiple kinase inputs into various downstream 
regulatory signals has been revealed. 
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Anything that happens, happens. 
 
Anything that, in happening, causes something else to happen, causes something else to 
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 1 Introduction 
1.1 Signal transduction 
1.1.1 Overview 
Signal transduction is the process by which biological systems transduce, assimilate, 
integrate and disseminate information at the molecular level.  This allows appropriate 
temporal and spatial biochemical responses to be elicited from a vast array of stimuli.  
Complex cellular processes such as responses to the extracellular environment, cell cycle 
progression, regulation of DNA repair, protein translation and monitoring of the 
metabolic status of the cell all require sensitive and dynamic signal transduction 
mechanisms in order to maintain stability of the system. 
 
Signals are primarily encoded and transmitted through protein-protein, protein-nucleic 
acid and protein-small molecule interactions.  However, they can also take the form of 
morphological gradients of molecules and hormones as well as environmental changes in 
pH, salinity and temperature.  Over the last forty years understanding of the underlying 
mechanisms and principles of molecular signal transduction has been and continues to be 
a principle aim of biological research. 
 
1.1.2 Historical perspective 
The first instances of the term ‘signal transduction’ as a way of describing cellular 
responses to stimuli began to appear in the literature in the early 1970s (Rensing, 1972).  
Arguably it was the discovery and initial characterization of G-proteins and G-protein 
coupled receptors by Martin Rodbell in the early 1980s that demonstrated a molecular 
14
basis for signal transduction for the first time (Rodbell, 1980).  The ensuing revolution in 
molecular biology of the 1980s and early 1990s began to identify molecular mechanisms 
in a multitude of cellular contexts and lead to an explosion of interest in signal 
transduction pathways as evidenced by the increasing number of publications on the 
subject (Figure 1.1).  Since then it has been adopted as a concept used to describe the 
molecular mechanisms underpinning dynamic biological behavior. 
 
The relatively recent advances in the fields of systems biology and computational biology 
suggest that molecular signal transduction may in fact be more broadly understood and 
modelled in terms of the general principles of biochemical oscillators (Novak and Tyson, 
2008).  Biochemical oscillatory behaviour is another way of describing how the 
components of macro-molecular biological networks interact with each other.  Instead of 
representing the flow of signals linearly in an A to B to C fashion, higher order properties 
and tendencies of the whole network are considered.  By considering signalling processes 
in this way it is becoming possible to understand how signal transduction pathways that 
control different aspects of cellular behaviour interact with each other.  After all, 
molecular signalling controlling one type of cellular event cannot be completely 
understood except in the context of all the signalling processes in operation.  This is 
clearly a formidable task.  Therefore by representing and modelling the properties of 
local reaction networks as simplified oscillatory motifs and modules, hypotheses can be 
made on how biological systems operate in ways that may have been obscured when 
considering one signalling process at a time. 
 
15
Figure 1.1.  Frequency of the term ‘signal transduction’ in the titles and abstracts of scientific 
papers.  Searches were performed at http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed . 
16
 1.1.3 Underlying principles of signal transduction – biochemical oscillators 
Interestingly, the concept of biological oscillators predates that of signal transduction and 
was first recognized in the oscillatory behavior of metabolic processes such as glycolysis 
(Hess and Boiteux, 1971; Pye and Chance, 1966), the horseradish peroxidase reaction 
(Olsen and Degn, 1977; Olsen and Degn, 1978) and cyclic AMP production (Gerisch et 
al., 1975).  Since then biochemical oscillations have been observed and described as the 
mechanisms at the root of circadian rhythms (Dunlap, 1999), gene regulatory networks 
and protein interaction networks (Momiji and Monk, 2008; Monk, 2003), metabolic 
networks (Higgins, 1964; Sel'kov, 1968) and cell cycle progression (Gerhart et al., 1984; 
Novak and Tyson, 2008).  More recently, synthetic gene regulatory networks with 
oscillatory behavior have been constructed in Escherichia coli based on a negative feedback 
loop composed of three repressor genes and their corresponding promoters.  Here, green 
fluorescent protein (GFP) expression was observed to oscillate autonomously on a time 
scale of hours.  This proof-of-principle approach demonstrates that considering signaling 
and interaction networks as having fundamental oscillatory behavior offers instructive 
new insight and biotechnological possibilities (Elowitz and Leibler, 2000). 
 
Currently, aspects of biological behavior are described from the atomic scale to that of 
populations of organisms, and at every level in between.  That descriptions of biological 
events at so many scales are made is testimony to how fascinated people are by its 
diversity and intricacy.  However, finding ways to describe how one level is related to 
another is not straight forward.  Indeed, categorizing biological processes into discrete 
scales at all is a minefield.  Therefore attempting to find scale-independent ways of 
17
characterizing biological systems will, in the long run, greatly aid our understanding of 
how they work. 
 
Biochemical oscillators display scale-independent characteristics such as periodicity, 
robustness and entrainment.  These are properties that transcend those of the individual 
molecules or reaction partners and involve the full topology of the reaction network 
(Novak and Tyson, 2008).  Description in this way is fundamentally different from the 
linear representations of reaction networks and signaling pathways that biologists are 
familiar with today.  However, current understanding can be used to build scale-
independent descriptions and models that may be applied outside their original context.  
It is hoped that this will help to unify our understanding of biological processes in 
general.  
 
Four general requirements for biochemical oscillators have been identified, and can be 
recognized as key properties of many well characterized signal transduction systems and 
processes.  These are negative feedback, temporal delay (produced by embedded positive 
feedback or a series of reaction intermediates), sufficient non-linearity in reaction kinetics 
(as a result of the complexity of the environment in which the reactions occur) and the 
appropriate balancing of the timescales of opposing chemical reactions. 
 
This combination of positive and negative feedback loops supports bistability, which is 
the ability of the system to adopt either of two alternative steady states (separated by 
unstable intermediate states) under identical conditions.  The state that the system falls 
into at any given time depends on hysteresis, which is the property of a bistable system to 
be switched between either steady state by a transient signal, and switched back again by 
another transient signal.  Therefore the state of the system depends not only on its 
18
present conditions but also on its recent history.  Early models of glycolytic oscillations 
fall into this class of oscillators (Higgins, 1964; Sel'kov, 1968), as well as models 
determining the lytic versus lysogenic switch of bacteriophage lambda (Atsumi and Little, 
2006a; Atsumi and Little, 2006b; Oppenheim et al., 2005). 
 
The reversibility of biochemical reactions in oscillatory systems and cell signaling 
processes is almost ubiquitous and is the basis of much of their inherent sensitivity and 
flexibility.  For example, proteins are post-translationally modified (by phosphorylation, 
acetylation, methylation, hydroxylation and ubiquitination etc.) and unmodified, G-
proteins cycle between GTP- and GDP-bound forms, second messengers are 
synthesized and degraded or released and sequestered, proteins are imported and 
exported across membranes and proteins are degraded and re-synthesized (Ferrell, 2002).  
Protein phosphorylation is the most widely employed reversible post-translational 
modification in signal transduction systems and it has been estimated that approximately 
30% of all eukaryotic proteins are phosphorylated on at least one residue at some point 
during their existence (Cohen, 2000).   
 
1.2 Signal transduction via protein phosphorylation 
1.2.1 Overview 
Protein phosphorylation has been implicated in virtually all basic cellular processes, 
ranging from metabolic regulation, cellular growth, division and differentiation, motility, 
intracellular trafficking, membrane translocation, muscle contraction, immunity, learning 
and memory (Manning et al., 2002a; Manning et al., 2002b; Ubersax and Ferrell, 2007).  
Protein kinases catalyze the transfer of the γ-phosphate of ATP to specific amino acid 
side chains within proteins.  The free energy of the phosphorylation reaction is -12 kcal 
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mol-1, making this form of post-translational modification extremely stable and resistant 
to uncatalyzed hydrolysis.  Serine/threonine protein kinases (STPKs) and tyrosine 
kinases phosphorylate the hydroxyl groups of serine/threonine or tyrosine residues, 
respectively.  Conversely, protein phosphatases dephosphorylate phosphorylated residues 
and are also classed according to their specificity: serine/threonine phosphatases, 
tyrosine phosphatases and dual specificity phosphatases that can dephosphorylate 
phosphorylated serine/threonine or tyrosine residues. 
 
The extent to which protein phosphorylation is used as a means to signal transduction 
lies with the diversity of effects that it can have on phosphorylated target proteins  Most 
are physical consequences of the addition of two negative charges and the possibility of 
engaging in up to four additional hydrogen bonds per phosphoryl group.  Thus protein 
phosphorylation may directly induce conformational changes by altering intramolecular 
electrostatic interactions, act to increase/decrease stability or solubility, create or ablate 
protein-protein interaction surfaces and activate or inhibit enzymatic activity.  The 
significance of the generation of phosphorylation-dependent binding surfaces will be 
discussed in more detail in section 1.4. 
 
1.3 The protein kinase domain 
Given that phosphorylation can have diverse effects on protein function, both protein 
kinases and phosphatases require robust mechanisms for specific target selection.  
Indeed, it has long been recognized that temporally and spatially aberrant eukaryotic 
protein kinase activity contributes to oncogenic disease states (Eckhart et al., 1979; 
Levinson et al., 1978).  The structures of several hundred protein kinase domains have 
been deposited in the protein data bank (www.rcsb.org/pdb) to date.  Many structures of 
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kinase domains have now been solved in both active and inactive conformations, as well 
as in complex with ATP and ATP analogues, regulatory subunits, and protein or peptide 
substrates.  This has lead to increased understanding at the structural level of the features 
that determine and maintain kinase specificity as well as their catalytic mechanisms. 
 
The canonical catalytic domain of classical protein kinases is approximately 250 amino 
acids in length and conforms to a conserved bilobal architectural fold.  This consists of a 
small N-terminal lobe (~85 amino acids) comprised of β-sheets and a larger C-terminal 
lobe (~170 amino acids) comprised mostly of α-helices.  ATP binds in a cleft at the 
interface of the two lobes with the adenosine moiety buried in a hydrophobic pocket.  
This results in orientation of the negatively charged phosphate backbone towards the 
solution.  Protein substrates bind along the cleft and conserved residues within the 
catalytic domain transfer the γ-phosphate of ATP onto the hydroxyl groups of 
serine/threonine or tyrosine residues. 
 
The structures of active kinase domains in the vicinity of the catalytic site are very similar 
as the conformation of catalytic residues must be constrained such that their orientation 
is favorable for phosphoryl transfer.  However, the conformations of inactive kinase 
domains vary greatly.  Diversity in the mechanisms by which an inactive kinase domain is 
converted into an active conformation is one way of providing signaling specificity and 
regulation of different kinase families (Canagarajah et al., 1997; Huse and Kuriyan, 2002; 
Jeffrey et al., 1995; Yamaguchi and Hendrickson, 1996).  Most specific kinase inhibitors 
exert their effect by binding to and maintaining the inactive conformation of the kinase, 
preventing conversion to the active state. 
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1.3.1 Catalysis and activation of the protein kinase domain 
There are several conserved architectural features of kinase domains that regulate their 
catalytic activity through conformational change.  One of these is called the phosphate-
binding loop (P-loop).  In the active kinase conformation the P-loop constrains ATP in 
the cleft between the N- and C-lobes of the kinase domain and consists of a glycine-rich 
sequence (GXGXΦG) where X is any amino acid and Φ is typically a tyrosine or 
phenylalanine residue.  The inherent flexibility conferred by the glycine residues facilitate 
interactions between the backbone of the P-loop and the phosphate groups of the ATP 
molecule, while the aromatic residue caps the site of phosphate transfer (Huse and 
Kuriyan, 2002).  The substrate peptide binds in an extended conformation along the 
solvent exposed side of the cleft and is positioned close to the ATP γ-phosphate.  
Conserved residues in the kinase catalytic loop execute the transfer of the ATP γ-
phosphate to the substrate peptide. 
 
As one of the first kinases to be studied in detail, Protein kinase A (PKA) has been used 
to exemplify the catalytic mechanism of STPKs.  In the residue numbering of PKA, the 
conserved Asp 166 is believed to act as a base for proton abstraction from the hydroxyl 
group of the substrate target residue resulting in its attack on the ATP γ-phosphate 
(Figure 1.2).  Asn 171 is thought to orientate Asp 166 for catalysis, and in conjunction 
with Asp 184 binds two divalent cations required for nucleotide recognition (Huse and 
Kuriyan, 2002).  Asp 184 is a component part of the highly conserved Asp-Phe-Gly 
(DFG) motif, by which the N-terminal end of the activation loop is defined.  
Furthermore the ATP α- and β-phosphates are coordinated by the side chains of Lys 72, 
which is itself coordinated by Glu 91.  Glu 91 resides in another conserved architectural  
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N-lobe
C-lobe
Activation loop
Peptide
αC helix
Hinge
region
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Glu 91
Catalytic cleft
Figure 1.2.  Structure of the kinase domain.  Cartoon representation of cAMP-Dependent Protein 
Kinase (Protein kinase A, PKA) in complex with a peptide inhibitor (orange) (pdb accession 
2CPK).  The αC helix is shown in green and the activation loop is shown in red.  Lys 72 and Glu 91 
are shown as sticks.  ATP and the substrate of the kinase bind at the cleft between the N- and C-
lobes. 
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feature of  kinase domains, the αC helix.  Appropriate orientation of the αC helix 
stabilizes residues forming the active catalytic site. 
 
Reorientation of the αC helix is another mechanism by which kinase activity can be 
regulated.  For example the binding of cyclin to the αC helix of cyclin-dependent kinases 
results in its rotation from an inactive to an active conformation (De Bondt et al., 1993; 
Jeffrey et al., 1995).  On the other hand, binding of the SH3 domain of Src kinases 
stabilizes an orientation of the αC helix in which Glu 91 does not interact with Lys 72 
resulting in poor ATP binding (Gonfloni et al., 2000; Moarefi et al., 1997; Sicheri et al., 
1997; Xu et al., 1997). 
 
Thus conversion of a kinase domain from an inactive to an active state can occur 
through subtle conformational changes brought about by several different mechanisms.  
In many kinases phosphorylation of the activation loop is the minimum requirement to 
produce full activity.  In the inactive conformation the activation loop occludes the 
catalytic site by collapsing into it and thereby preventing both cofactor and substrate 
from binding (Hubbard et al., 1994).  However, upon phosphorylation the activation 
loop adopts an open conformation in which the phosphate group of the modified 
residue forms an ion pair with an asparagine that directly precedes the catalytic Asp 166 
(Hubbard, 1997).  The number and position of the phosphorylated residues in the 
activation loop varies between kinases, but interaction with Asn 165 reinforces the 
orientation of the DFG motif and promotes catalysis.  In some cases the phosphorylated 
residue may be replaced with either glutamate or aspartate and catalytic activity is still 
conferred through the resultant similar ion pairing (Huang and Erikson, 1994; Orr and 
Newton, 1994).  In many cases phosphorylation of the activation loop and precise 
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orientation of αC helix are both required for the kinase to transition from a catalytically 
inactive to active state (Engh and Bossemeyer, 2001; Huse and Kuriyan, 2002). 
 
1.4 Phospho-protein interaction domains 
1.4.1 Overview 
Over the past twenty five years modular protein-protein interaction domains have 
emerged as fundamental components in cellular organization and provide a means of 
dynamically controlling information in signal transduction pathways (Pawson, 2004) and 
coupling oscillatory behaviors.  Protein interaction domains are often found as modules 
within the multi-domain architecture of regulatory proteins and generally serve to 
temporally and spatially regulate the sensory or enzymatic activity of the protein within 
the context of multi-molecular signaling complexes (Yaffe and Smerdon, 2004).  By 
mediation of specific protein-protein interactions alteration of protein synthesis, 
degradation and post-translational modifications are regulated.  These constitute 
important ways of conferring temporal control on such systems.  Spatial regulation 
mandates accurate targeting of proteins to sub-cellular compartments or organelles.  This 
is achieved via import/export sequences or through protein interaction domains that 
reversibly recognize specific peptide sequences, protein surfaces, lipids, nucleic acids 
and/or post-translationally modified peptides (Figure 1.3) (Pawson and Nash, 2000; 
Pawson and Nash, 2003; Yaffe and Smerdon, 2004).   
 
The versatility of interaction domain-containing proteins is exemplified by the signaling 
between transforming growth factor-β (TGF-β) receptor kinases and R-SMAD signal 
transducer proteins (Wrighton et al., 2009).  TGF-β is a signaling hormone, and along 
with its family members (the nodals, activins, bone morphogenic proteins (BMPs),  
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Figure 1.3.  Modular interaction domains used in signal transduction processes.  A selection of 
protein interaction domains and their ligands are shown.  The full names are given in the SMART 
(Simple Modular Architecture Research Tool) database (http://smart.embl-heidelberg.de/).  
Adapted from (Pawson and Nash, 2003). 
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myostatin, anti-Muellerian hormone (AMH) and others) controls eukaryotic cell division, 
differentiation, migration, adhesion, organization and programmed cell death (Massague 
and Gomis, 2006).  Upon binding of TGF-β to the extracellular domains of 
transmembrane TGF-β receptor kinases, auto-phosphorylation of exposed serine 
residues in a Gly/Ser-rich sequence in an intracellular juxta-membrane region occurs.  
The C-terminal MH2 (mothers against decapentaplegic homologue 2) domain of R-
SMAD then binds to the phosphorylated Gly/Ser-rich sequence.  After recruiting the 
scaffold protein SARA, the MH2 domain is subsequently phosphorylated by the TGF-β 
receptor kinase at a C-terminal serine.  Now in a phosphorylated form, the MH2 domain 
associates with two other phosphorylated MH2 domains, each binding to the C-terminal 
phosphorylation site of the adjacent molecule.  This trimer then dissociates from the 
TGF-β receptor kinase and is translocated to the nucleus where the N-terminal MH1 
(Mad homology 1) domains of the R-SMAD proteins bind to DNA, whilst the MH2 
domains associate with various transcriptional components altering gene expression 
(Miyazono et al., 2004; Wu et al., 2001).  This example is a demonstration of the multi-
level complexity in molecular signaling that can be readily achieved by linking protein 
interaction domains together in the same polypeptide chain. 
 
The Src homology (SH2) domain was the first phospho-interaction domain to be 
studied.  It was identified as a constituent part of the cytoplasmic tyrosine kinases Fps, 
Src and Abl (Sadowski et al., 1986).  The SH2 domains of these proteins were shown to 
confer specificity in tyrosine kinase signaling by mediating protein-pTyr interactions 
through a “dedicated non-catalytic domain” (DeClue et al., 1987; Koch et al., 1989; 
Pawson, 1988; Pawson et al., 1988; Sadowski et al., 1988).  Detailed studies have since 
been undertaken on the growing number of phosphoprotein-interaction domains and 
include pTyr-interaction domains such as SH2 and PTB-domains and pSer/pThr specific 
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interaction domains such as WW domains, 14-3-3 domains, the WD40 repeats in F-Box 
containing proteins, the polo-box domains of Polo-like kinases and FHA domains 
(Pawson, 2004; Yaffe and Smerdon, 2004). 
 
The atomic structures of isolated phospho-dependent interaction domains show that in 
general they fold in a manner that generates a ligand-binding surface with low internal 
mobility that is used to recognize a short phosphopeptide motif.  In the next section this 
and other features of phospho-interaction domains will be discussed using the FHA 
domain as a primary example. 
 
1.5 The Forkhead-associated domain 
1.5.1 Overview 
Forkhead-associated domains (FHA domains) were initially identified as a domain 
contained in a subset of members of the Forkhead transcription factor family (Hofmann 
and Bucher, 1995).  To date, FHA domains have been identified in more than 2000 
proteins (Pfam database) in prokaryotes and eukaryotes (Mahajan et al., 2008).  Since 
their discovery FHA domains have been implicated to play important signaling roles in 
DNA damage responses, cellular growth and cell cycle regulation (Mahajan et al., 2008).  
Their presence is highly correlated with that of STPKs, highlighting a functional linkage 
between these two classes of proteins. 
 
FHA domains are unique among phospho-interaction signaling domains as they are the 
only known domain to specifically recognize only pThr residues. Unlike FHA domains, 
WW and 14-3-3 domains do not discriminate between pThr- and pSer-containing 
ligands.  In vitro orientated peptide library screening has identified that specificity of FHA 
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interactions is usually determined by residues -4 to +3 relative to the pThr of the ligand 
(Yaffe and Smerdon, 2004).  FHA domains can be broadly categorized into those that 
bind to pTXXD motifs (where pT is phospho-threonine and X is any amino acid) and 
those that bind to pTXXΨ (where Ψ is a bulky non-polar residue such as isoleucine, 
leucine or valine).  However, recent research shows that as well as selectivity for the pThr 
+ 3 residue, several FHA domains employ more sophisticated means of selecting binding 
partners allowing greater functional versatility. 
 
1.5.2 Structure of FHA domains 
The structures of 16 unique FHA domains have been solved at atomic resolution by 
either nuclear magnetic spectroscopy (NMR) or x-ray crystallography in their free form, 
complexed with ligands or both (www.rcsb.org/pdb).  Sequence alignments predict that 
the core FHA domain homology region consists of 55-75 amino acids, forming 5 or 6 β-
strands that in turn fold into two β-sheets, which generates a twisted β-sandwich (Figure 
1.4 top left).  Flanking β-strands stacking antiparallel with the core homology region 
extend the surfaces of the β-sheets producing the 11 or 12 β-strands that are usually 
observed in FHA domains.  Buried hydrophobic sidechains exclude solvent from the 
centre of the β-sandwich and stabilize the tertiary structure.  The modular nature of FHA 
domains is highlighted by the way that the first and last β-strands are adjacent and run in 
an anti-parallel direction to each other.  Thus hydrogen bonding between the backbone 
of the N-terminal residue of the first β-strand and the C-terminal residue of the last β-
strand usually defines the domain limits. 
 
Defined in this way, the minimal FHA domain constructs reported so far range from 95 
(in the case of Ki67-FHA) to 121 amino acids in length (in the case of Rad53-FHA2).   
29
Standard FHA model
6
N C
12
3
4
5
8
9
1011
7
N C
Gly
Arg
Ser
His
Asn
6
N
C
12
3
4
5
8
9
1011
7
Rad 53 FHA1
N
1
2
7
8
1011
C
34 5 6
9
SMAD MH2
12
3
4
5
6
7 8 9
1011
1’
2’
3’
4’
5’6’
N C
Pellino
A
B
C
D
Figure 1.4.  Comparison of the domain topology and overall β-sandwich structure of FHA 
domains.  (A)  The standard FHA domain model.  left  FHA domain β-strands are represented by 
green arrows.  right The topological location of the five most highly conserved FHA domain 
residues are indicated with pink filled circles.  (B)  FHA domain topology of Rad53 FHA1.  The 
location of helical insertions are indicated with red filled circles.  (C)  Topology of the SMAD 
MH2 domain.  The β-sandwich architecture is similar to FHA domains, but MH2 domains lack 
the conserved FHA domain residues shown in A right.  (D)  Pellino protein domain topology.  As 
well as sharing core FHA domain β-sandwich topology, Pellino proteins contain an extra ‘wing’ 
insertion (light and dark blue) of β-strands.  In each schematic the N- and C-termini of the 
domains are indicated.  β-strand numbering starts at the N-terminal strand. 
30
This variability arises as a result of insertions of varying length in the loops between β-
strands and is shown for Rad53 FHA1 in Figure 1.4.  Red circles show the location of 
helical insertions into Rad53 FHA1 domains and the SMAD MH2 domain.  The MH2 
domain shares core FHA β-sandwich topology but differs in the locations of helical 
insertions, conservation of pThr-binding residues and biological function.  The similarity 
in core topology between FHA domains and MH2 domains can be viewed as a case of 
convergent evolution supporting differential biological function.  An interesting new 
class of FHA domain variants has recently been discovered in Pellino proteins (Figure 
1.4), in which two substantial sequence insertions between β2/β3 and β6/β7 extend from 
the FHA core and form a “wing” that juxtaposes the pThr binding surface (Lin et al., 
2008; Pennell and Smerdon, 2008).  The effect of the wing insertion on binding 
properties is currently not known. 
 
All functionally active FHA domains studied to date contain five highly conserved amino 
acids that are required for correct folding of the tertiary structure and pThr-binding 
surface formation (Figure 1.4 top right).  FHA domains bind phosphorylated peptides 
through direct contacts with the pThr-peptide backbone and sidechains and via hydrogen 
bonds with the pThr phosphate group.  The binding surface is formed from the loops 
between β-strands β3/β4, β4/β5, β6/β7 and β10/β11.  The structure of Rad53 FHA1 in 
complex with a pThr-peptide demonstrates the importance of the conserved phospho-
binding FHA domains residues (Arg 70, Ser 85, and Asn 107) (Figure 1.5).  The side 
chains of Arg 70 and Ser 85 directly contact the phosphate through a salt bridge and 
hydrogen bonds, respectively.  The hydroxyl of Ser 85 also forms a hydrogen bond with 
a backbone amide of the β6/β7 loop helping to stabilize the binding site.  Asn 107 
coordinates the pThr peptide backbone C-terminal to the phosphorylation site and in 
concert with other residues from the β6/β7 and β10/β11 loops helps to determine 
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binding specificity.  The conserved Gly 69 and His 88 provide additional architectural 
stabilization around the phospho-binding site. 
 
1.5.3 Binding specificity and functional versatility of FHA domains 
The development of orientated phosphopeptide library screens in the early 1990s has 
since facilitated the determination of ligand specificity of a variety of phosphopeptide 
binding domains including PTB, WW, WD40 repeats, 14-3-3 and FHA domains (Yaffe 
and Smerdon, 2004).  Selection specificity is deduced by applying a degenerate library of 
phosphorylated peptides to immobilized interaction domains and after incubation, 
unbound phosphopeptides are removed (Songyang and Liu, 2001).  Bound peptides are 
eluted and sequenced by automated Edman degradation.  Raw selection ratios are 
determined by comparison of the relative molar percentage of each amino acid at each 
Edman degradation sequencing cycle in the recovered peptides to that of each amino 
acid in the original peptide library mixture at the same position.  Thus if the original 
peptide library contains a central phosphorylated residue flanked by a degenerate series 
of residues at positions –3, -2, -1, +1, +2 and +3 relative to the fixed phosphorylated 
amino acid at position 0, binding preferences of phosphopeptide binding domains can be 
elucidated. 
 
A trend that emerged from orientated phosphopeptide library screening of FHA 
domains is their selection for the amino acid three residues C-terminal of the pThr (pThr 
+ 3).  FHA domains with specificity for the pThr + 3 residue fall broadly into those that 
select for pTXXD and those that select for pTXX(I/L/V).  However, specificity can be 
additionally determined by the sequence of residues in the loops of the binding surface.  
For example Rad53 FHA1 shows a clear preference for Asp at the pThr + 3 position as a 
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result of the presence of Arg 83 in the β4/β5 loop, with which it forms a salt bridge 
(Figure 1.5 and Figure 1.6).  However, Rad53 FHA2 binds preferentially to Ile or Leu at 
the pThr + 3 position even though it appears to have an Arg (Arg 617) in a structurally 
equivalent position (Figure 1.6) (Mahajan et al., 2008).  The FHA2 structure reveals that 
the Arg 617 guanidino group makes an intramolecular salt bridge with Asp 683, 
rendering it unavailable for intermolecular recognition and changing the pThr + 3 
preference from a charged residue to a non-polar residue (Byeon et al., 2001; Durocher 
and Jackson, 2002; Mahajan et al., 2008; Wang et al., 2000). 
 
FHA domains have also been identified that recognize residues N-terminal to the pThr 
of the ligand.  The structure of murine PNK-FHA complexed with a phosphopeptide 
derived from its biologically relevant binding partner XRCC4 reveals that residues N-
terminal to the pThr are cradled between the β2/β3 and β4/β5 loops and are essential 
for ligand binding (Figure 1.6) (Bernstein et al., 2005).  This may be explained by the 
complimentarity of basic residues on the FHA domain and acidic residues N-terminal to 
the pThr of the peptide.  
 
Dun1-FHA domain contains two pThr binding sites and has been proposed to act as a 
detector of multiply phosphorylated SQ-TQ clusters, such as those that precede each of 
the two FHA domains of Rad53 (Figure 1.6).  Rad53 FHA1 is preceded by four 
phosphorylatable TQ repeats at positions 5, 8, 12 and 15 which are important for Rad53 
dimerisation and activation (Lee et al., 2003b).  The structure of Dun1-FHA in complex 
with a Rad53-derived peptide phosphorylated at Thr 5 and Thr 8 determined by nuclear 
magnetic spectroscopy (NMR) shows that the N-terminal phosphorylation site binds 
primarily to the conserved Arg 60, aided by the non-conserved Arg 62 in the β3/β4 loop.  
The second binding site appears to be formed by the non-conserved Arg 102, assisted  
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Figure 1.5.  Structure Rad53 FHA1-phosphopeptide complex (1G6G).  (A)  The protein fold of the 
Rad53 FHA1 domain from Saccharomyces cerevisiae in complex with a synthetic phosphopeptide.  
The phospho-binding surface is formed by residues from the loops connecting the β3/β4, β4/β5, 
β6/β7 and β10/β11 strands.  (B)  Key FHA domain residues make direct contacts with the 
phosphothreonine (pThr) containing ligand.  The pThr-containing ligand and key FHA domain 
residues are shown in stick representation and hydrogen bonds are indicated with dashed lines. 
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possibly by Lys 100 located in the β6/β7 loop.  Interestingly the pThr + 6 residue (Ser 
11) has also been implicated in phosphopeptide binding, as evidenced by strong nuclear 
Overhauser effects (NOEs) between it and Lys 129 of the β10/β11 loop (Mahajan et al., 
2008). 
 
The N-terminal FHA domain of Ki67 antigen protein represents a unique case among 
FHA domains in that it has been shown to bind to multiply phosphorylated peptides 
using an extended binding surface (Figure 1.6).  The NMR structure of Ki67 complexed 
with a 43 amino acid peptide from hNIFK (residues 226-269) phosphorylated at Ser 230, 
Thr 234 and Thr 238 displays several novel features.  The phosphate group of pThr 238 
is coordinated by Arg 31 and Ser 45 and also Asn 67 of the β6/β7 loop which appears to 
play a role in binding residues at the pThr + 2 position.  However, interactions of 
residues in the β10/β11 and β1/β2 loops with the phosphopeptide stabilize a 14 residue 
α-helix in the region pThr + 4 to pThr + 18.  Residues in the region pThr + 27 to pThr 
+ 29 stack antiparallel with β4 thus extending the β-sheet towards β2 (Byeon et al., 2005; 
Li et al., 2004).  Thus despite being specific for pThr, FHA domains have evolved to use 
many other types of selection criteria to confer selectivity of binding of pThr-containing 
ligands. 
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Figure 1.6.  Binding specificity and functional versatility of FHA domains.  Cartoon representation of 
the structures of Rad53 FHA1 (1G6G), Rad53 FHA2 (1K2N), PNKP (2W3O), Dun1 (2JQL) and Ki67 
(2AFF) are shown (in green (loops), yellow/orange (β-strands) and red (α-helices)) in complex with 
their respective phosphopeptide ligands (blue).  pThr residues in the phosphopeptide ligands are 
shown as sticks. 
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 1.5.4 The possibility of phospho-independent FHA interactions? 
The scope of FHA binding specificity and function has recently been expanded through 
the bioinformatics approach of evolutionary trace analysis.  This technique is based on 
two hypotheses.  The first is that functional sites (catalytic sites, binding sites etc.) on 
proteins evolve through variations of a conserved architecture.  In this way architecture-
defining residues remain mostly invariant, but residues responsible for functional 
specificity could undergo many substitutions, each of which may be associated with a 
functional variation and evolutionary divergence (Lichtarge and Sowa, 2002).  The 
second hypothesis is that sequence homology trees approximate functional classification 
hierarchies.  Lichtarge and co-workers justify this second hypothesis with the reasonably 
intuitive assertion that proteins sharing greater sequence identity have diverged more 
recently than sequences with less similarity and as a result have had less time to diverge 
functionally (Lichtarge et al., 1996; Lichtarge and Sowa, 2002). 
 
When applied to FHA domains, evolutionary trace analysis predicts several discrete 
functional surfaces in addition to the canonical phospho-interaction surface (Lee et al., 
2003a).  Consistent with the structure of Ki67 FHA complexed with the hNIFK 
(residues 226-269) tri-phosphopeptide outlined above, β4 was predicted as a functional 
surface (Figure 1.7, C).  Another predicted FHA domain recognition site incorporating 
residues from β9 and the β5/β6 loop is the location of the Ile 157 mutation to Thr of 
Chk2 FHA in Li-Fraumeni cancer patients (Figure 1.7, B) (Lee et al., 2003a; Liang and 
Van Doren, 2008).  Mutation at this site, which is on the opposite side of the domain to 
the phospho-interaction surface, disrupts binding of BRCA1, CDC25A and p53, all of 
which have been implicated in human cancers(Li et al., 2002). 
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Figure 1.7.  Bioinformatically-predicted conserved FHA domain surfaces.  Conserved surfaces of the 
FHA domains are show in pink.  Phosphopeptide ligands are shown as in Figure 1.6.  (A)  PNKP 
FHA domain-phosphopeptide complex (2W3O) shown in the same orientation as in Figure 1.6, 
highlighting the location of the predicted surface formed from residues in β7 and β10.  (B)  Chk2 FHA 
domain in complex with a synthetic phosphopeptide (1GXC).  A predicted conserved surface is 
formed by residues from the loop connecting β5/β6 and from β9.  (C) left  Ki67 FHA domain-
phosphoepeptide complex (2AFF) in the same orientation as in Figure 1.6.  right  Ki67 FHA domain 
rotated by 90o showing the location of the conserved surface formed by β4, which stacks anti-parallel 
with the C-terminal end of the phosphopeptide ligand. 
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Another functional surface predicted by bioinformatics lies around the adjacent β7 and 
β10 strands (illustrated using PNK FHA domain in Figure 1.7, A).  To date, there have 
been no reports of FHA domains employing this surface to engage in functionally 
relevant phospho-independent interactions.  However, the crystal structure of human 
CHFr displays forms a chain-swapped dimer at this site such that the expected β7/β8 
hairpin straightens out into a single strand and hydrogen bonds with the equivalent 
strand of the other molecule of the dimer (Stavridi et al., 2002).  This swaps β9-β11 into a 
β-sandwich with strands β1-β7 from the other molecule.  The extent to which this chain 
swapped dimer feature is biologically relevant remains to be seen.  It may be that it is a 
crystallographic artifact.  The next section will address the phosphorylation signaling 
potential of M. tuberculosis, focusing on the kinases that have been studied in greatest 
detail. 
 
1.6 The phosphorylation-signaling potential of M. tuberculosis 
1.6.1 Overview 
Like many prokaryotes, M. tuberculosis possesses the capability of conducting signal 
transduction by means of reversible phosphorylation signaling.  Averaging between 1-2% 
of the genetic content across all bacteria, two-component systems are the most widely 
employed mechanism of phosphorylation signaling in prokaryotes (Wehenkel et al., 
2008).  In their simplest form, two-component systems consist of a sensor histidine 
kinase and a response regulator, although signaling cascades involving multiple histidine 
kinases and/or response regulators may function as part of complex histidyl-aspartyl 
phospho-relays.  As well as possessing 11 complete two-component systems, M. 
tuberculosis also has at its disposal 11 eukaryotic-like STPK genes (PknA to L, except C),  
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Figure 1.8.  The phosphorylation signaling potential of M . tuberculosis.  Schematic representation of 
the domain architecture of the Ser/Thr protein kinases, FHA domain-containing proteins and 
Ser/Thr protein phosphatase of M . tuberculosis.  PQQ, pyrroloquinoline quinine; TRP, 
tetratricopeptide; Trx, thioredoxin.  Figure adapted from (Av-Gay and Everett, 2000; Pallen et al., 
2002). 
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three phospho-protein phosphatases and 5 FHA domain-containing proteins (Figure 1.8) 
(Av-Gay and Everett, 2000; Pallen et al., 2002; Wehenkel et al., 2008). 
 
Little is known about the physiological roles and signaling mechanisms of the 
mycobacterial STPKs but they have been implicated in the regulation of growth, 
development, metabolism and interactions with host signaling processes.  Their low 
sequence identity of approximately 30% with human kinases makes them attractive 
therapeutic targets and, to date, the kinase inhibitors erbstatin and staurosporine have 
been shown to prevent phagocytosis of M. leprae by mouse macrophages (Prabhakaran et 
al., 2000). Additionally, the protein kinase inhibitor H7 was found to inhibit the growth 
of M. bovis Bacille Calmette Guerin (BCG) and M. smegmatis mc2 (Drews et al., 2001) 
 
1.6.2 Protein kinase characterization in Mycobacterium tuberculosis 
Of the 11 eukaryotic-like STPKs of M. tuberculosis, 9 are predicted to function as 
transmembrane receptor kinases, with an N-terminal kinase domain linked through a 
single transmembrane helix to one or more extracellular C-terminal domains thought to 
serve as signal sensors.  PknK and PknG possess no predicted transmembrane domain 
and are thought to be cytosolic kinases. 
 
1.6.3 PknB 
The structure of the PknB kinase domain was the first prokaryotic STPK to be solved by 
x-ray crystallography and confirms high architectural conservation of the overall fold and 
the catalytic site to eukaryotic kinase domains (Ortiz-Lombardia et al., 2003; Young et al., 
2003).  Again, like many eukaryotic kinase domains, phosphorylation of the activation 
loop of PknB has been found to regulate its catalytic activity.  At least two activation 
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loop threonines (Thr 171 and Thr 173) are fully phosphorylated in the active state.  
Dephosphorylation of Thr 171 and/or Thr 173 by their cognate phosphatase, PstP, or 
their substitution for alanine significantly decreases PknB kinase activity (Boitel et al., 
2003).  However, the available crystal structures of the PknB kinase domain show poor 
electron density in the region of the activation loop, suggesting that PknB employs an 
induced fit mechanism of binding acceptor substrates or other factors that modulate its 
activity (Boitel et al., 2003; Young et al., 2003).   
 
The C-terminal extracellular sensor domain of PknB consists of four repeated PASTA 
(Penicillin-binding protein And Ser/Thr kinase Associated) domains, frequently found in 
bacterial STPKs and high molecular weight penicillin-binding proteins (Boitel et al., 2003; 
Wehenkel et al., 2008; Yeats et al., 2002; Young et al., 2003).  The two PASTA domain 
repeats of Streptococcus pneumoniae Pbp2x (penicillin-binding protein 2x) were found to 
bind the β-lactam antibiotic cefuroxime.  This lead to the hypothesis that PASTA 
domains play a role in sensing stem peptides from unlinked peptidoglycans in the cell 
wall (Gordon et al., 2000; Jones and Dyson, 2006; Yeats et al., 2002).  As the specificity 
of PASTA domains for binding peptidoglycans is yet to be fully characterized, 
hypotheses about the actual functions of PknB remain speculative.  However, it has been 
linked with the regulation of cellular growth and morphology.  Over-expression of PknA 
or PknB in M. tuberculosis resulted in a broad, bulgy cell morphology while partial 
depletion of PknA or PknB using RNAi caused a narrow elongated morphology (Kang et 
al., 2005). 
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1.6.4 PknD 
The crystal structure of PknE and three independent crystal forms of PknB show that a 
conserved surface, on the opposite side of the N-lobe of the respective kinase domains 
relative to their catalytic sites, enables dimerisation (Boitel et al., 2003; Gay et al., 2006; 
Ortiz-Lombardia et al., 2003; Wehenkel et al., 2006; Young et al., 2003).  It has been 
suggested that back-to-back dimer formation in M. tuberculosis kinases promotes their 
activation in an analogous manner to the RNA-dependent antiviral protein PKR (Dar et 
al., 2005; Dey et al., 2005).  In this model, ligand binding to the extracellular receptor 
domains of PknB induces back-to-back dimer formation of the intracellular kinase 
domains.  This would result in reorientation of the αC helix, the C-terminal end of which 
contributes to the dimer interface and in so doing stabilizes the active conformation 
(Wehenkel et al., 2008).  Indeed, allosteric activation of PknD by dimerisation has 
recently been demonstrated (Greenstein et al., 2007).  In this study the authors 
constructed chimeric PknD kinase domain-fusion constructs that dimerised upon 
addition of rapamycin.  Phosphorylation activity was found to be stimulated upon 
dimerisation.  The previously unphosphorylated PknD kinase domains auto-
phosphorylated and were then able to phosphorylate substrates in vitro.  Activation and 
substrate specificity were shown to be attenuated by mutations at the dimer interface, 
although catalytically inactive mutants were shown to activate wild-type PknD kinase 
domain solely through dimerisation.  Once auto-phosphorylated, the PknD kinase 
domain does not require dimerisation to maintain its activity, supporting the model of 
kinase activation through ligand-induced dimer formation.   
 
Little is known about the function of PknD but genomic and expression data implicate it 
in sensing levels of extracellular phosphate (Av-Gay and Everett, 2000).  The 
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extracellular sensor domain of PknD was solved by x-ray crystallography and was found 
to form a highly symmetric six-bladed β-propeller.  This is tethered to the 
transmembrane domain via a flexible linker (Good et al., 2004).  The structure shows a 
concave surface that is the site for ligand/protein-binding for many other β-propeller 
structures.  The authors suggested that the quaternary structure of the intracellular kinase 
domain could be altered through the binding of multivalent ligands.  However, the 
structure fails to provide clues as to how a signal could be transmitted to the intracellular 
kinase domain. Close inspection suggests that there would be little conformational 
alteration upon ligand binding and the flexibility of the transmembrane linker would 
appear to limit the propagation of any conformational change. 
 
1.6.5 PknG 
Of the two soluble cytosolic M. tuberculosis kinases PknG is the best studied.  PknG is 
part of a putative operon containing proteins involved in glutamate uptake that is 
conserved within the mycobacteria and closely related actinomycetes.  The PknG kinase 
domain is situated between an N-terminal rubredoxin-like domain and a C-terminal 
tetratricopeptide (TPR) domain.  The TPR domain appears to be responsible for 
dimerisation of PknG in the crystal structure of a truncated construct of PknG lacking 
the N-terminal rubredoxin-like domain and in complex with the ATP-competitive 
inhibitor AX20017 (Scherr et al., 2007).  This structure shows that AX20017 binds deep 
into a cleft shaped by a unique set of amino acids distinct from those found in human 
kinases, making PknG an attractive target for the design of anti-mycobacterial drugs.  
PknG has also been reported to be secreted within macrophage phagosomes where it 
inhibited phagosome-lysosome fusion, thereby mediating intracellular survival of 
mycobacteria (Walburger et al., 2004). 
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 Determination of the auto-catalytic activity of PknG and its sites of auto-
phosphorylation remains an active field of research.  In vitro kinase assays performed by 
Cowley and co-workers reported that PknG auto-phosphorylated within its kinase 
domain as well as on the C-terminal TPR domain (Cowley et al., 2004).  However, 
O’Hare and colleagues have reported that PknG has no phosphorylated residues in its 
catalytic domain or C-terminal TPR domain.   They found phosphorylation sites solely in 
the N-terminal region of the protein at Thr 23, Ser 31/Thr 32 and within the Thr 63/Thr 
64/Ser 65 motif.  Additionally a construct in which the N-terminal 73 residues had been 
deleted failed to incorporate radiolabeled ATP, yet was still catalytically active against 
substrate peptides (O'Hare et al., 2008).  Consistent with this is the finding that no 
phosphorylated residues were found in the PknG crystal structure which lacked the N-
terminal 73 residues (Scherr et al., 2007).  From these data it seems that PknG auto-
phosphorylation sites lie within the N-terminal 73 residues and that phosphorylation of 
the catalytic domain is not required for activity.  This contrasts with PknB which, like 
many eukaryotic kinase domains, requires activation loop phosphorylation for catalytic 
activity against substrates. 
 
M. tuberculosis PknG and its homologue in the related actinomycete C. glutamicum share 
approximately 45% sequence identity and have been implicated in the regulation of 
intracellular glutamate levels.  C. glutamicum PknG has been shown to exert regulation of 
glutamate metabolism through phosphorylation of the small FHA domain-containing 
protein OdhI.  In its unphosphorylated state, OdhI binds to and inhibits the putative E1 
subunit (OdhA) of the α-ketoglutarate dehydrogenase complex (Niebisch et al., 2006).  
Recent work has demonstrated similar findings in M. tuberculosis and M. smegmatis, 
showing that through phosphorylation of the mycobacterial homologue of OdhI 
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(Rv1827, also referred to as GarA) inhibition of the homologue of OdhA (α-
ketoglutarate decarboxylase; KGD; Rv1248c) is relieved (O'Hare et al., 2008).  Despite 
sharing approximately 58% sequence identity with OdhA, KGD has been found to 
function as an α-ketoglutarate decarboxylase in a variant tricarboxylic cycle that appears 
to have been evolutionarily optimized for mycobacterial persistence in infected 
macrophages (Tian et al., 2005a). 
 
The phosphorylation-mediated regulation of core metabolic activity within M. tuberculosis 
is currently poorly understood.  However, recent advances in this active field of research 
will be discussed more detail within the context of the results presented in subsequent 
chapters. 
 
1.7 Research objectives 
Since its identification as an FHA domain-containing culture filtrate protein, Rv1827 has 
been shown to be a substrate for at least two mycobacterial Ser/Thr protein kinases 
(Villarino et al., 2005). Furthermore, phosphorylation of Rv1827 has been implicated in 
the regulation of core metabolic processes in mycobacteria and the closely related 
actinomycete C. glutamicum (Niebisch et al., 2006; O'Hare et al., 2008).  However, a 
molecular mechanism that links phosphorylation signaling with metabolic regulation 
through the phosphorylation state of Rv1827 has not been forthcoming. 
 
Therefore, the principal objective of this investigation was structural and functional 
characterization of Rv1827.  This began with the identification of Rv1827 interaction 
partners in M. tuberculosis cell-free extracts, and confirmed the metabolic context of 
Rv1827 activity to be regulation of glutamate metabolism.  Then, through a combination 
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of biochemical, biophysical and structural analyses we determined that abrogation of 
Rv1827 interactions with its metabolic binding partners was caused by a 
phosphorylation-induced intramolecular association of the N-terminus of Rv1827 with 
its FHA domain.  This lead us to propose a mechanistic description of Rv1827 
functionality that explains how phosphorylation signaling is coupled to the regulation of 
a branching point in mycobacterial central metabolism. 
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2 Materials and Methods 
2.1 Bioinformatics 
2.1.1 Protein and DNA information 
Sequence information on selected M. tuberculosis genes, their flanking regions and the 
proteins encoded therein was obtained from the Tuberculist Web Server 
(http://genolist.pasteur.fr/TubercuList/).  This resource is provided by the Institut 
Pasteur and is an online M. tuberculosis genome database. 
 
The properties of proteins that can be calculated from their amino acid sequences (in the 
presence and absence of N-terminal tags) such as theoretical isoelectric point (pI), molar 
extinction coefficient, proportion of each amino acid and molecular weight are useful to 
know when attempting purification or biophysical/biochemical analysis.  The protein 
sequences of target genes were analysed using DNASTAR Lasergene 8 and the website 
calculator PROTParam, available from the ExPASy Proteomics Server 
(http://www.expasy.ch/tools/protparam.html). 
 
Other ExPASy proteomics tools (http://www.expasy.ch/tools/) were also used for 
analysis of nucleotide and gene sequences.  Protein sequence alignments were generated 
using the ClustalW2 general purpose multiple sequence alignment program 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). 
 
2.1.2 Sequence homology searches 
Protein sequence homologues were identified using the NCBI BLAST (Basic Local 
Alignment Search Tool) or PSI-BLAST (Position-Specific Iterated BLAST) servers 
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(http://www.ncbi.nlm.nih.gov/BLAST/) with filtering of low complexity regions.  
These are regions of sequence which have an amino acid distribution bias and can affect 
the accuracy of the BLAST results.  Searches for sequence homologues were made 
against the non-redundant database, which comprises all non-redundant GenBank CDS 
translations plus the PDB (Protein Data Bank; http://www.rcsb.org/pdb/), SwissProt, 
PIR and PRF. 
 
2.2 Molecular biology 
2.2.1 Plasmid construction 
pGEX 6P1 vector (GE Healthcare Life Sciences) containing a 486bp BamHI/HindIII 
fragment encoding the full length M. tuberculosis Rv1827 protein (162 residues) was 
provided by Dr. D. Patel (NIMR).  This was used as the template from which truncated 
constructs were generated and on which site-directed mutagenesis was performed.  
pGEX 6P1 vector containing a 2265bp EcoRI/XhoI fragment encoding full length M. 
tuberculosis PknG protein was provided by Dr. K. Lougheed (NIMR).  pGEX 6P1 vector 
with a 996bp LIC (ligation-independent cloning) fragment encoding the intracellular 
segment of M. tuberculosis PknB protein (332 residues) and pGEX 6P1 vector with a 
837bp LIC fragment encoding the kinase domain of PknB protein (279 residues) were 
provided by Dr. D. Patel (NIMR). 
 
2.2.2 Bacterial strains 
E. coli NovaBlue and TOP10 Singles Competent Cells (Novagen) were used for initial 
cloning and DNA purification procedures (see section 2.2.7 for transformation 
protocols). E. coli Rosetta 2 (DE3) pLysS and E. coli BL21 (DE3) competent cells 
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(Novagen) were used in the expression of all protein constructs (Table 2.1). The DE3 
lysogen contains the T7 polymerase gene under the control of the lacUV5 promoter.  
Addition of IPTG (isopropyl-β-D-thiogalactopyranoside) (Peirce) induces constitutive 
expression of T7 polymerase.  For expression vectors under the control of a T7 
promoter, the polymerase transcribes the mRNA at high copy number resulting in over-
expression of the desired protein. 
 
E. coli strains Genotype 
NovaBlue 
 
endA1 hsdR17(rK12– mK12 +) supE44 thi-1 recA1 gyrA96 
relA1 lac F'[proA+B+ lacI qZΔM15::Tn10] (TetR) 
 
TOP10 
 
F- mcrA Δ(mrr-hsd RMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) 
endA1 nupG (Invitrogen) 
 
BL21 (DE3) 
 
B, F-, hsdSB (rB-, mB-), gal, dcm, ompT, λ(DE3 (Novagen) 
 
Rosetta 2 (DE3) pLysS 
 
F– ompT hsdSB(rB  mB – B ) gal dcm (DE3) pLysS pRARE2  
(Cam ) 
– 3
R
 
 
Table 2.1.  Genotypes of E. coli strains used for cloning and protein expression. 
 
2.2.3 DNA manipulation and analysis 
Agarose gels were prepared and run according to standard procedures (Sambrook, 1989).  
All plasmid DNA was purified from overnight cultures of E. coli NovaBlue Singles 
competent cells (Novagen) using either QIAprep Spin Miniprep or Midiprep Kits from 
Qiagen, according to the manufacturer’s instructions.  Final DNA concentrations were 
determined by UV spectrophotometry at 260nm. 
 
50
2.2.4 Polymerase chain reaction (PCR) 
PCR reactions were carried out using an MJ Research DNA Engine Dyad Peltier thermal 
cycler and the KOD Hot Start DNA Polymerase kit (Novagen).  All reactions were 
carried out in thin-wall 200 µl PCR tubes (Abgene) at a final volume of 50 µl using a 
heated lid at a constant temperature of 100°C.  The standard procedure used is a 
modified version of the GC-rich protocol provided by the manufacturer.  The addition 
of DMSO (Sigma) (which reduces primer secondary structure) and the use of a 68°C 
extension temperature yields a higher and more consistent PCR success rate. 
 
Reagent Volume (µl) 
dH2O 31.5 
KOD Reaction Buffer (10X) 5 
MgSO4 (25 mM) 2 
DMSO (100%) 2.5 
dNTP Mix (2 mM each) 5 
Template DNA (5 ng/µl) 1 
Oligonucleotide Primer 1 (15 µM) 1 
Oligonucleotide Primer 2 (15 µM) 1 
KOD HotStart DNA polymerase (1 n rxn-1) 1 
Total 50 
 
Table 2.2.  Typical PCR reaction.  5% DMSO (final) in the reaction aids reduction in primer and 
template secondary structure that can interfere with PCR.  The final concentration of each 
oligonucleotide is 0.2 mM. 
 
Step Temperature (oC) Time 
1 94 (initial heating) 2 min. 
2 94 (denaturation of primers) 15 secs. 
3 55 (annealing) 30 secs. 
4 68 (extension) 1 min. kb-1
5 (cycle to 2nd step 28 times) 
6 68 (final extension) 1 min. kb-1. 
7 4 (end of PCR program) 5 min. 
 
Table 2.3.  Typical thermocycler program for PCR reaction.  An initial 2 min melt ensures full 
priming in the first cycle.  In most cases 55oC was found to be sufficient regardless of primer Tm.  
The use of 29 cycles typically yielded approximately 1 µg/50 µl reaction. 
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All PCR products were purified using the QIAquick PCR Purification kit (Qiagen) 
according to the manufacturer’s instructions. DNA from each reaction was eluted in 50μl 
H2O. 
 
2.2.5 Restriction enzyme digestion reactions 
In all cases when double restriction enzyme digests were performed, buffer conditions 
compatible with both enzymes were chosen (according to the double digest table in the 
Roche catalogue).  All digests were carried out at 10U restriction enzyme/1μg target 
DNA at 37°C for two hours. Reactions were halted where possible by heating according 
to the manufacturer’s instructions (Roche). 
 
Reagent Volume (µl) 
dH2O 14 
Reaction Buffer (10X) 2 
BSA (20X) 1 
DNA (1 µg) 1 
Restriction enzyme 1 (10 u µl-1) 1 
Restriction enzyme 2 (10 u µl-1) 1 
Total 20 
 
Table 2.4.  Typical restriction enzyme digest for vector and PCR products.  BSA was used in 
accordance with the manufacturer’s instructions (Roche).  The reaction volume was chosen as the 
lowest volume without exceeding the final glycerol concentration of 5% in order to avoid enzyme 
star activity (non-specific DNA cleavage). 
 
Digested DNA products were purified by electrophoresis using a standard 1% agarose 
(Bio-Rad) gel.  Gels were stained with 0.5 μg ml-1 ethidium bromide (Bio-Rad) and 
visualized on a 258 nm UV-transilluminator.  The desired vector or PCR product was 
excised from the gel using a sterile scalpel blade and purified using the QIAquick Gel 
Extraction Kit (Qiagen).  Each reaction was eluted in 50 μl H2O. 
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2.2.6 Ligation reactions 
Ligation reactions were incubated for one hour at room temperature using T4 DNA 
ligase according to the manufacturer’s instructions (NEB). 
 
Reagent Volume (µl) 
dH2O 3 
Reaction Buffer (10X) 2 
Linearised vector (33 fmol) 8 
Digested PCR insert (100 fmol) 6 
T4 DNA ligase (400 u µl-1) 1 
Total 20 
 
Table 2.5.  Typical ligation reaction.  A ratio of 3:1 (PCR insert:vector) was used where possible. 
 
2.2.7 Transformations 
All transformations of bacterial cells were carried out according to the instructions 
supplied by the manufacturer of the competent cells (Invitrogen).  A typical 
transformation was performed as follows: 1 μl of DNA solution (at a stock concentration 
of 50 ng μl-1) was added to the appropriate competent cell aliquot (50 μl), incubated on 
ice for 10 minutes, heat-shocked at 42°C for 30 seconds, incubated on ice for 2 minutes, 
incubated at 37°C for 30 min. after the addition of 200 μl LB and plated on the 
appropriate media.  1 ng and 50 ng total DNA were used for cloning and expression 
vectors, respectively.  5 μl of the total ligation reaction mixture (Table 2.5) were used to 
transform competent cells.  All plates were incubated overnight at 37°C. 
 
2.2.8 Site-directed mutagenesis and DNA sequence verification 
All site-directed mutagenesis experiments were carried out using the QuikChange kit 
(Stratagene) according to the manufacturer’s instructions.  All mutagenic primers were 
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HPLC purified (Sigma) to remove compounds that might reduce the efficiency of site-
directed mutagenesis reactions.  1 μl of the mutated plasmid DNA was transformed and 
purified as above. 
 
Reagent Volume (µl) 
dH2O 40 
Reaction Buffer (10X) 5 
dNTP Mix 1 
Template DNA (10 ng) 1 
Oligonucleotide Primer 1 (15 µM) 1 
Oligonucleotide Primer 2 (15 µM) 1 
Pfu DNA Polymerase (2.5 u µl-1) 1 
Total 50 
 
Table 2.6.  Typical site-directed mutagenesis reaction.  Where possible primers were designed to 
conform to the manufacturer’s parameters: Tm 75-85oC, GC content 40-60%, length 25-45 bases, 
length of regions flanking the mutations 11-21 bases, G or C at the end of the primer. 
 
Step Temperature (oC) Time 
1 95 30 secs. 
2 95 30 secs. 
3 55 1 min. 
4 68 1 min. kb-1
5 (cycle to 2nd step 12 times) 
6 4 5 min. 
 
Table 2.7.  Typical thermocycler program for a QuikChange (Stratagene) reaction. 
 
All DNA clones and mutations were sequenced by Cogenics using standard fluorescent 
dideoxy terminator techniques to confirm construct identity.  Sequences were aligned and 
analyzed using SeqMan (DNASTAR Lasergene 8). 
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2.3 Protein purification techniques 
2.3.1 Protein concentration determination 
Protein concentration was determined directly by spectroscopic analysis using a Cary 50 
Bio (Varian) spectrophotometer.  A spectrum (200 nm to 350 nm) was recorded for each 
sample.  Concentration was determined according to: 
 
lcA ⋅⋅= 280280 ε  
 
where c is the molar concentration, A280 is the absorbance at 280 nm, ε280 is the molar 
extinction coefficient at 280 nm (calculated using the DNASTAR Protean software) and l 
is the path-length of the cuvette. 
 
2.3.2 Protein concentration and storage 
Protein concentration was carried out using Vivaspin ultrafiltration concentrators 
(VivaScience).  The capacity (ml) and membrane molecular weight cutoff (MWCO) 
varied depending upon sample volume and molecular weight.  The most commonly used 
concentrators were 20 ml Vivaspins of 3, 5, 10 or 30 kDa MWCO. Most samples were 
concentrated in Vivaspins by centrifugation at 4000g.  The time necessary for 
concentration varied greatly with initial sample volume, final concentration required, and 
the nature of the protein being analyzed.  In most cases, final protein preparations were 
snap frozen in 10-200 μl aliquots (in eppendorf tubes) in the appropriate buffer by 
immersion in liquid nitrogen and then stored at -80°C. 
 
55
2.3.3 SDS-PAGE 
All SDS-PAGE experiments were performed using precast Novex 1.0 mm Bis-Tris gels 
(Invitrogen) according to the manufacturer’s instructions.  Gels were run at 200 V for 38 
min. in an XCell SureLock mini-cell (Invitrogen) on a Bio-Rad PowerPac 300.  For each 
gel, broad range protein standard (Bio-Rad) molecular marker was used.  Each protein 
sample was mixed with NuPAGE 4x LDS sample buffer (Invitrogen) and NuPAGE 
sample reducing agent (Invitrogen) according to the manufacturer’s instructions and 
heated to 100°C for 10 min. prior to loading.  The typical final volume loaded was 
between 10 and 30 μl per well.  Gels were developed by staining with InstantBlue 
Coomassie stain (Expedeon) according to the manufacturer’s instructions.  Gels were 
imaged on a Kodak Digital Science Image Station 440CF using transmitted ambient light 
with a yellow (523 nm) high-pass filter. 
 
2.3.4 Protein expression 
All expression studies used either E. coli Rosetta 2 (DE3) pLysS or E. coli BL21 (DE3) 
competent cells (Novagen), which were transformed according to the manufacturer’s 
instructions.  One colony from an overnight plate was used to inoculate 2 ml of LB 
medium containing the appropriate antibiotics.  The culture was incubated for 8 hours at 
37°C and 1 ml was used to inoculate 250 ml of LB + antibiotics.  The 250 ml culture was 
grown overnight at 37°C and was subsequently used as a starter culture.  1L of LB + 
antibiotics was inoculated with 10 ml starter culture and grown to an optical density at 
600 nm of 0.4 at 37°C.  The temperature was then reduced to 30°C and when an optical 
density at 600 nm of 0.6-0.8 was achieved (mid-log phase) IPTG was added to a final 
concentration of 1 mM to induce protein expression.  At three and a half hours post 
induction cells were harvested by centrifugation at 6,000g for 10 min.  The pellet was 
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washed by re-suspension in phosphate-buffered saline (PBS) (Sigma) and re-harvested as 
before.  All cell pellets were stored in 50 ml Falcon tubes (Corning) at -20°C. 
 
2.3.5 Bacterial lysis 
All bacterial lysis was carried out at 4°C.  Bacterial pellets were fully resuspended in 10 ml 
g-1 (lysis buffer/pellet) according to the individual purification protocol and 
supplemented with 30 kU g-1 rLysozyme and 25 U ml-1 Benzonase (Novagen) to aid in 
lysis and reduce lysate viscosity.  Lysis buffer was augmented with one EDTA-free 
Protease Inhibitor Cocktail Tablet (Roche) 50 ml-1.  Cells were lysed by sonication 
(Branson Sonifier 450) on ice at 40% power with six bursts of ~20 secs. 60 ml-1 sonicate 
volume.  The lysate was clarified by centrifugation at 45,000g for one hour.  Aliquots of 
the whole sonicate, clarified lysate, and insoluble pellet (dissolved in ~10 M urea) were 
removed for SDS-PAGE analysis. 
 
2.3.6 GST-purification 
All proteins were expressed as 3C-protease cleavable GST-fusions and unless otherwise 
stated were purified as follows.  Cell pellets were resuspended and lysed (as above) in 
GST-lysis buffer (50 mM TrisCl pH 8.0, 300 mM NaCl, 0.5 mM tris-(carboxyethyl) 
phosphine (TCEP) (Pierce)).  The clarified lysate was applied to an appropriate amount 
of glutathione Sepharose 4B resin (typically 2-5 ml) (Amersham) pre-equilibrated in 
GST-lysis buffer.  The slurry was incubated overnight at 4°C with gentle mixing.  Resin 
was recovered by centrifugation at 500g for 5 min.  An aliquot was taken of the 
supernatant for SDS-PAGE analysis and the rest discarded.  The resin was diluted with 
an equal volume of lysis buffer and carefully removed into an empty 25 ml glass Econo-
column (Bio-Rad) pre-equilibrated in GST-lysis buffer and allowed to settle under 
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gravity.  The resin was washed with 50 column volumes (i.e. total resin volume = 1 
column volume) of wash buffer (50 mM TrisCl pH 8.0, 300 mM NaCl, 0.5 mM TCEP) 
under gravity flow. 
 
If an un-cleaved GST-fusion protein was required, the target protein was eluted at this 
stage using 3 x ½ column volumes of wash buffer supplemented with 10 mM reduced 
glutathione (pH 8.0).  Aliquots of each elution fraction were taken for SDS-PAGE 
analysis.  Alternatively if a 3C-cleaved target protein was required, the washed resin was 
equilibrated with 3C-cleavage buffer (20 mM TrisCl pH 8.0, 200 mM NaCl, 1 mM 
EDTA (Sigma), 0.5 mM TCEP) and diluted with 1 column volume to produce a 50% 
resin slurry.  Non-cleavable GST-tagged 3C protease, supplied by J. Lloyd and Dr. Jiejin 
Li (NIMR), was added to the resin according to their recommendations and the 50% 
slurry was incubated overnight with gentle mixing.  The target protein was eluted with 
3C-cleavage buffer in 3 x ½ column volume fractions.  Again, aliquots of each elution 
fraction were taken for SDS-PAGE analysis. 
 
2.3.7 Ion-exchange chromatography 
In the case of PknB purification, an ion-exchange step was required following 3C-
cleavage.  Following cleavage the NaCl concentration of the buffer was adjusted to 50 
mM by dilution of the protein sample in preparation for ion-exchange. The protein 
sample was applied to a Q-sepharose column (by cycling the column flow-through back 
through the column) equilibrated with 50 mM NaCl, 50 mM TrisCl pH 8.0.  Bound 
proteins were eluted using a NaCl gradient of 0-300 mM, 50 mM TrisCl pH 8.0. 
Fractions containing PknB were identified using SDS-PAGE, pooled and the protein was 
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concentrated (to 2-5 mg ml-1) using a Vivaspin centrifugal concentrator (10 kDa cutoff) 
and subjected to size-exclusion chromatography. 
 
2.3.8 Size-exclusion chromatography 
The eluent from the previous column was concentrated to 3-5 ml and loaded onto a pre-
packed HiLoad Superdex prep grade column (Amersham) using an AKTA Prime system.  
Either Superdex 75 or 200 (S75 or S200) was used depending on the molecular weight of 
the target protein.  The column was pre-equilibrated in gel filtration buffer (typically 10 
mM TrisCl pH 8.0, 50 mM NaCl) and run at 0.3 ml min-1 overnight collecting in 3 ml 
fractions.  Fractions containing the appropriate peaks were pooled, concentrated, and 
stored at -80°C. 
 
2.3.9 NMR sample preparation 
Recombinant uniformly 15N- and 13C-labelled full-length Rv1827 was expressed using the 
pGEX 6P1 vector system (GE Healthcare) in Rosetta 2(DE3) pLysS E. coli (Novagen), 
grown in minimal media.  1 L 15N-13C- minimal media contained Na2HPO4 (6 g), 
KH2PO4 (3 g), NaCl (0.5 g), MgSO4 (0.25 g), CaCl2 (0.015 g), FeSO4 (0.015 g), 
thiamine·HCl (1 g), D-biotin (0.1 g), 15NH4Cl (1 g) (99at.% 15N min. from GOSS 
Scientific Instruments Ltd.), D-glucose (2 g) (U-13C6, 99% from Cambridge Isotope 
Laboratories Inc.) and ampicillin (100 µg ml-1).  All minimal media was 0.2 µm filter-
sterilised and induced expression cultures (see above) were grown at 18°C overnight and 
harvested as above. 
 
NMR samples contained 0.75-1.0 mM uniformly 15N- and 13C-labelled Rv1827 (1-162) in 
90% H2O/10% 2H2O containing 20 mM sodium acetate pH 5.8 and 50 mM NaCl. 
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Phosphorylation of uniformly 15N- and 13C-labelled Rv1827 was carried out as previously 
described prior to dialysis into NMR buffer using Slide-A-Lyzer MINI Dialysis Units 
(Pierce) with a 3500 Da MWCO. 
 
2.4 Biochemical and biophysical techniques 
2.4.1 Phosphorylation studies 
Stoichiometric phosphorylation of full length Rv1827 (162 residues) at Thr 22 was 
achieved by diluting the protein to between 0.25 and 1.0 mM in 50 mM TrisCl pH 8.0, 
150 mM NaCl, 5 mM MgCl2, supplemented with ATP at twice the final Rv1827 molar 
concentration and adding PknB kinase domain (residues 1-279) to produce a final molar 
ratio of substrate:kinase of 250:1.  PknB kinase domain was purified using GST, ion 
exchange and size exclusion chromatography.  Stoichiometric phosphorylation of 
Rv1827 at Thr 22 was typically accomplished in 20 min. at room temperature.  
Phosphorylation of Rv1827 at Thr 21 by PknG was achieved under the same conditions 
in ~20 hours.  PknG was purified by GST and size exclusion chromatography.  For some 
applications removal of the kinase from the phosphorylated Rv1827 samples was 
necessary.  This was achieved by size-exclusion chromatography (outlined in section 
2.3.8). 
 
2.4.2 Limited proteolysis 
Sequencing grade modified trypsin (Promega) was used in all the limited proteolysis 
experiments at a ratio of target protein:trypsin of 500:1 (w/w) at room temperature. For 
SDS-PAGE analysis, aliquots of the reaction mixture were taken at defined time points 
(e.g. at 0, 1, 5, 10, 20 etc. mins after addition of trypsin) and immediately mixed with LDS 
60
sample loading buffer (Invitrogen) and NuPAGE® Sample Reducing Agent (Invitrogen) 
at 100oC for 2 min. to stop the reaction. 
 
2.4.3 Preparation of M. tuberculosis cell-free lysate and Pull-down assays 
M. tuberculosis cell-free extract (lysate) was prepared (by Debbie Hunt, NIMR) from M. 
tuberculosis H37Rv grown in 100 ml Dubos broth containing 0.05% Tween 80 (v/v) 
supplemented with 0.2% glycerol (v/v) and 4% Dubos medium albumin (v/v) in 1 L 
polycarbonate culture bottles (Nalgene) in a Bellco roll-in incubator (at 2 rpm) at 37°C. 
When cultures reached an optical density (λ=600 nm) of 0.8-1.0 bacteria were harvested 
by centrifugation (10000g, 20 min.). Cell pellets were washed with 20 ml 10 mM TrisCl 
pH 7.5 before resuspension in 1.5 ml 10 mM TrisCl pH 7.5 containing one EDTA-free 
protease inhibitor cocktail tablet (Roche) 50 ml-1. Bacteria were placed on ice and lysed in 
the presence of glass beads (150-212 μm, Sigma) in a Ribolyser (Hybaid) and placed on 
ice for 5 min.  Glass beads and intact bacteria were removed by centrifugation twice at 
13000g for 15 min. at 4°C.  Cell-free extracts were further filtered through a low binding 
Durapore 0.22 μm membrane filter (Ultrafree-MC, Millipore). Aliquots of 10 μl 
glutathione Sepharose 4B resin (Amersham) pre-equilibrated in 50 mM TrisCl pH 8.0, 
300 mM NaCl and 0.5 mM TCEP were saturated with gel filtration purified GST and 
GST-Rv1827 constructs. Unbound protein was removed by five cycles of centrifugation 
at ~500g for 3 min., aspiration of the supernatant and resuspension of the sedimented 
resin in 0.5 ml of the same buffer.  Each aliquot of saturated resin was mixed with 100 μl 
clarified M. tuberculosis cell-free lysate and incubated at 4oC for 3 hours with mixing. 
Unbound protein was removed as described. LDS sample loading buffer (Invitrogen) 
and NuPAGE® Sample Reducing Agent (Invitrogen) were added directly to the 
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recovered resin according to the manufacturer’s instructions. Protein content was 
analysed by SDS-PAGE. 
 
2.4.4 Dynamic light scattering 
Dynamic light scattering was carried out on a DynaPro-801 dynamic light scattering 
instrument (DynaPro). Protein samples were diluted according to the manufacturer’s 
instructions (usually 4-5 mg ml-1). Each sample was passed through a 0.22 μm filter and a 
minimum of fifty measurements were taken at 20°C. 
 
2.4.5 Multi-angle laser light scattering 
Samples of purified protein were applied at a flow rate of 0.5 ml min-1 to a Superdex 200 
(or 75) 10/300 GL column pre-equilibrated in 50 mM TrisCl pH 8.0, 300 mM NaCl 
mounted on a Jasco HPLC. A DAWN-HELEOS multi-angle laser light scattering 
detector (Wyatt Technology Corp., Santa Barbara, CA) recorded the scattered light 
intensity of the column eluent at sixteen angles. The protein concentration of the eluent 
was determined from refractive index change (dn/dc = 0.186) using an OPTILAB-rEX 
differential refractometer equipped with a Peltier temperature-regulated flow cell, 
maintained at 25oC (Wyatt Technology Corp., Santa Barbara, CA). The weight-averaged 
molecular weight of material contained in the chromatographic peaks was determined 
using ASTRA v5.1 (Wyatt Technology Corp., Santa Barbara, CA). 
 
2.4.6 Circular dichroism spectroscopy 
Rv1827 samples were diluted to 210 μg ml-1 with 50mM phosphate buffer (pH 6.85) for 
far-UV CD and to 3.75 mg ml-1 in the same buffer for near-UV CD.  Spectra were 
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acquired on a JASCO-J715 spectropolarimeter. Spectral collection of far-UV (260-190 
nm) and near-UV (250-320 nm) CD were carried out in 1 mm and 10 mm path-length 
quartz cuvettes, respectively.  Spectra were taken with a 100 nm min.-1 scan rate, 0.25 
secs. time constant and 2 nm spectral bandwidth.  Final spectra are the average of at least 
20 scans, and data analysis was carried out using Specpro (Dr. S. Martin, NIMR).  CD 
signal was measured in millidegrees and converted to Δєmrw according to: 
 
( )
lc
mrwS
mrw ⋅⋅
⋅=Δ
3290
ε  
 
where S is the CD signal in millidegrees, mrw is the mean residue weight of the protein, c 
is the protein concentration (mg ml-1) and l is the cell path length (cm) 
 
Thermal denaturations were carried out in a 2 mm path length quartz cuvet from 2-95°C 
(2°C min-1; 4 secs. time constant) and were monitored at 202 nm. 
 
2.4.7 Mass spectrometric techniques 
2.4.7.1 Electrospray mass spectrometry 
Mass spectrometry was utilised in this study primarily to verify the identity and chemical 
homogeneity of purified protein samples.  It was also used to determine the 
phosphorylation state of putative substrates for the kinases that have been investigated.  
Protein molecular weight was determined using a stand-alone syringe pump (Perkin 
Elmer, Foster City CA) coupled to a Platform electrospray mass spectrometer 
(Micromass, Manchester, UK).  Samples were desalted on-line using a 2 mm x 10 mm 
guard column (Upchurch Scientific, Oak Harbor WA) packed with 50 μm Poros RII 
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resin (Perseptive Biosystems, Framingham) inserted in place of the sample loop on a 
rheodyne 7125 valve.  Proteins were injected onto the column in 10% acetonitrile, 0.10% 
formic acid, washed with the same solvent and then step eluted into the mass 
spectrometer in 70% acetonitrile, 0.1% formic acid at a flow rate of 10 μl min.-1.  The 
mass spectrometer was calibrated using myoglobin and standard samples comprised of 
100-300 pmol protein at a minimum concentration of 1 μM. 
 
2.4.7.2 MALDI-TOF mass spectrometry 
For protein identification, bands were excised and subjected to tryptic in-gel digestion in 
accordance with a protocol supplied by Dr. S. Howell (NIMR).  Each band of interest 
was excised with a sterile scalpel and placed in a 0.5 ml tube.  SDS-PAGE buffer 
components and Coomassie stain were removed by two washes with extraction buffer 
(200 mM ammonium bicarbonate, 50% acetonitrile) for 30 min. at 37°C.  The gel sample 
was reduced with extraction buffer supplemented with 20 mM dithiothreitol (DTT) 
(Sigma) for 1 hour at 37°C.  The DTT was removed with three washes of extraction 
buffer for 30 min. at 37°C.  The cysteines in the gel sample were alkylated (in the dark) 
by extraction buffer supplemented with 5 mM iodoacetamide for 20 min. at room 
temperature.  The iodoacetamide was removed with three washes of 20 mM ammonium 
bicarbonate, 50% acetonitrile buffer for 30 min. at room temperature.  All buffer was 
removed and 0.5 ml of 100% acetonitrile was added to the gel sample and incubated for 
15 min. at room temperature.  The acetonitrile was removed and the gel sample was 
dried in a desiccator for 1 hour.  The fully desiccated gel sample was stored at room 
temperature until proteolytic digestion was performed.  Digestion was performed by 
adding 100 ng (in 50 μl of 5 mM ammonium bicarbonate) of modified sequencing-grade 
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trypsin (Promega) to the desiccated gel sample.  The digestion was performed at 37°C 
overnight.  MALDI-TOF analysis was performed using 0.3 μl of the tryptic digest.  
 
A Reflex III MALDI time-of-flight mass spectrometer (Bruker Daltonik GmbH, 
Bremen, Germany) equipped with a nitrogen laser and a Scout-384 probe was used to 
obtain positive ion mass spectra of digested protein with pulsed ion extraction in 
reflectron mode.  An accelerating voltage of 26 kV was used with detector bias gating set 
to 2 kV and a mass cut-off of m/z 650.  Thin layer matrix surfaces of α-cyano-4-
hydroxycinnamic acid mixed with nitrocellulose were prepared as described by 
Shevchenko et al., 1996.  A 0.3 μl aliquot of acidified digestion supernatant was deposited 
onto the thin layer and allowed to dry prior to rinsing with water.  Analysis of the 
resulting spectra was carried out by Mascot (Matrix Science Ltd.), which uses mass 
spectrometry data to identify proteins from primary sequence databases. 
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3 Nuclear magnetic resonance spectroscopy: materials and 
methodology 
3.1 Overview 
There are two techniques by which protein structures are routinely determined at atomic 
resolution: nuclear magnetic resonance (NMR) spectroscopy and x-ray crystallography.  
Structures solved by X-ray crystallography originate directly from measurements of the 
electron density in a crystal lattice, whereas NMR is an inherently indirect technique.  
NMR solution structures are modeled using data derived from experimentally determined 
chemical shifts.  Unlike X-ray crystallography, NMR spectroscopy can also be used to 
analyze time-dependent chemical phenomena such as reaction kinetics and 
intramolecular dynamics, and as such is a powerful technique for investigating the 
properties of proteins in solution. 
 
Both X-ray crystallography and NMR spectroscopy have their limitations.  X-ray 
crystallography is dependent on the generation of diffracting protein crystals, which is 
often rate limiting and not always possible for a given macromolecule.  Structure 
determination by NMR spectroscopy is limited primarily by the size of the 
macromolecule under investigation, as the complexity of NMR spectra increase 
dramatically with increased molecular weight, and the stability of samples over long 
periods of time at room temperature.  Structure determination by NMR spectroscopy can 
also be a lengthy procedure and it is difficult to eliminate human error in the analysis of 
NMR spectra.  Nonetheless, NMR solution structures make up a significant percentage 
of those deposited in the Protein Data Bank (~14% in March 2009). 
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3.2 Nuclear magnetic resonance spectroscopy 
3.2.1 Spectroscopy 
NMR spectra were acquired at 25oC on Varian Inova 800 and 600 and Bruker Avance 
700 and 600 MHz spectrometers, all equipped for 1H/15N/13C triple-resonance 
experiments.  The Bruker spectrometers were controlled by TOPSPIN software 
(http://www.bruker-biospin.com/topspin.html) and the Varian spectrometers by 
VNMR software (http://www.varian.com).  In most experiments water suppression was 
achieved using WATERGATE (Piotto et al., 1992).  NMR experiments and acquisition 
of the spectra that were used for the structural and hydrodynamic investigation of 
Rv1827 and the PknB-phosphorylated form were performed by Dr. Geoff Kelly 
(NIMR). 
 
1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra were acquired for 15N 
singly or 15N- and 13C-doubly isotopically labeled protein and used for various purposes 
such as evaluation of sample quality and consistency, titrations and assignment purposes, 
which resulted in the employment of various acquisition parameters (1024 x 64 to 2048 x 
1024 data points). 
 
Shown in Table 3.1 are the two (1H-15N HSQC) and three dimensional (all other) NMR 
experiments that were performed for backbone assignment, sidechain assignment and 
generation of distance restraints for Rv1827 and the PknB-phosphorylated form.  The 
buffer conditions and sample concentrations used in each experiment are described in 
section 2.3.9. 
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Experiment Purpose of experiment 
1H-15N HSQC General 
HNCACB 
CBCA(CO)NH 
HN(CA)CO 
HNCO 
HNCA 
Backbone assignment 
(H)C(CCO)NH 
H(CCCO)NH 
HCCH-TOCSY 
Sidechain assignment 
15N-edited NOESY 
13C-edited NOESY Distance restraints 
 
Table 3.1.  NMR spectroscopy experiments and the reasons for performing them. 
 
3.2.2 Spectral processing 
All NMR spectra were processed using nmrPipe (Delaglio et al., 1995).  Typically, the 
acquisition dimension was multiplied by a Gaussian window function and a 90o shifted 
sine-bell function in the indirect dimensions to enhance spectral apodisation (resolution).  
Polynomial solvent subtraction was used on the acquisition dimension and linear 
prediction was used on the indirect dimension to improve and increase the spectral 
resolution if required.  All dimensions were zero-filled to the next appropriate power of 
two. 
 
3.2.3 Spectral analysis and resonance assignment 
NMR spectra were analysed using CARA (Computer-Aided Resonance Assignment) 
version 1.5.5/NEASY (http://www.nmr.ch/).  1H, 15N and 13C resonance assignment of 
the backbone was achieved by analysis of HNCACB, CBCA(CO)NH, HN(CA)CO, 
HNCO and HNCA triple resonance experiments (Bax and Grzesiek, 1993 ) (Table 3.1 
and Figure 3.1 (top)).  Assignment of 1H, 15N and 13C sidechain resonances was  
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Figure 3.1.  Resonance assignment using HNCACB and HN(CA)CO spectra (A) and 1H-15N 
HSQC spectrum of Rv1827 pThr 22 coloured according to the results of the 2H exchange 
experiment (B).  Peaks that exchanged within 2 minutes are coloured green.  Peaks that 
exchanged within 17 hours are coloured orange and those that did not exchange within 17 hours 
are coloured red.  Peaks folded in the 15N-dimension are shown as hollow contours.  See Figure 6.2 
for annotated 1H-15N HSQC spectrum. 
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completed using (H)C(CCO)NH, H(CCCO)NH, three-dimensional HCCH-TOCSY and 
15N-edited and 13C-edited NOE spectra. 
 
3.3 Hydrodynamic analysis by NMR 
3.3.1 Relaxation experiments 
The dipolar nuclear magnetic spin relaxation of protonated heteronuclei (such as 15N) is 
mediated by the overall tumbling of the molecule in solution and by the internal motions 
of 15N-1H bond vectors.  Therefore by measurement of 15N relaxation parameters, such 
as the longitudinal or transverse relaxation rate constants and the steady state 1H-15N 
NOE, useful information can be gained about the intramolecular dynamics of a protein. 
 
15N T1, T2 and 1H-15N NOE enhancement relaxation experiments were performed at 600 
MHz (at 25oC), using standard acquisition methods (Kay et al., 1989).  Buffer conditions 
and sample concentrations are described in section 2.3.9.  Tau values used in the T1 and 
T2 relaxation experiments are shown in Table 9.2. 
 
3.3.2 Longitudinal and transverse relaxation 
The relaxation of an amide 15N nucleus at high field frequency is dominated by the 
dipolar interaction with the directly attached proton spin (Kay et al., 1989).  Longitudinal 
(spin-lattice or T1) and transverse (spin-spin or T2) relaxation experiments can be used to 
monitor the reorientation of amide 15N-1H bond vectors in the backbone of proteins 
over a wide range of timescales.  T1 relaxation values are sensitive to high frequency 15N-
1H bond vector motions (on the nano- to pico-second time scale) and T2 relaxation 
values are sensitive to slower dynamic processes. 
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 The 15N-1H bond vectors of residues in unstructured regions of proteins reorient rapidly 
in solution and have similar T1 and T2 relaxation times (Figure 3.2).  As proteins become 
larger, more structured and tumble more slowly in solution, their bond vectors reorient 
more slowly and their 15N T2 relaxation rate gets proportionally faster.  Unlike the T2 
mechanism, T1 relaxation is dependent on the transfer of the energy of excited nuclei to 
their surroundings (the lattice).  This transfer of energy (and thereby the rate of T1 
relaxation) will be most efficient if the 15N-1H bond vector reorients at the Larmor 
frequency.  If its motion is faster or slower, the nuclei will not be able to transfer energy 
to their surroundings as efficiently, resulting in a slower rate of T1 relaxation (Figure 3.2).  
Therefore, for a large macromolecule that is tumbling slowly in solution, the rate of T2 
relaxation of its amide 15N nuclei will be fast, and the rate of T1 relaxation will be slow.   
 
The ratio between the average T1 and T2 relaxation values for a given molecule can be 
used to determine its correlation time (τc).  This may be imagined as the time it takes for 
the molecule in solution to rotate through an angle of one radian.  In the context of a 
protein, which has one 15N-1H bond vector per residue (except for proline residues), 
global and local correlation times can also be estimated.  As the T2 relaxation of the 
amide 15N nuclei in well-folded globular proteins usually occurs 5 to 10 times more 
rapidly than their T1 relaxation, estimation of the correlation time is possible. 
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Figure 3.2.  Schematic representation of T1 (blue) and T2 (red) relaxation times as a function of 
correlation time (τc). 
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 3.3.3 The nuclear Overhauser effect 
The nuclear Overhauser effect (NOE) arises as a result of the fact that dipolar-coupled 
spins do not relax independently, and is one of the most important effects in NMR 
spectroscopy.  The NOE is characterized by the cross-relaxation rate constant, which is 
defined by the steady-state NOE enhancement.  The steady-state NOE experiment is 
most simply understood by using a dipolar-coupled two-spin (A, X) system as an 
example.  If the X spin system is irradiated by a weak radio frequency field (that does not 
disturb the A spin) for a period of time then the average populations across the 
transitions are equalized and the A spin magnetization evolves to a steady-state value.  
Under these conditions the X spins are said to be saturated.  The value of the 
longitudinal magnetization (population difference) for the A spin is altered by saturation 
of the X spins.  If the steady-state NOE enhancement is positive then the longitudinal 
magnetization across the A spin transitions are increased by reducing the longitudinal 
magnetization across the X spin transitions. 
 
To measure the value of the NOE enhancement a steady-state NOE difference 
experiment is performed in which two spectra are recorded.  In the first spectrum the X 
spin is saturated for a period of time sufficient to establish the NOE enhancement of the 
A spin.  Then a 90o pulse followed by a reverse INEPT sequence is applied and the free-
induction decay is recorded.  In the second spectrum the X spin is not saturated.  
Instead, a 90o pulse is applied to the system at equilibrium and the free-induction decay is 
recorded.  Thus the NOE enhancement is calculated as the fractional change in the 
intensity (I) of A on saturating X 
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dunsaturate
saturated
I
INOE =  
 
Typical NOE enhancement values of approximately 0.8 are expected for the 15N nuclei 
of large molecules with well defined tertiary structure tumbling slowly (on the nano-
second timescale) in solution and values significantly lower are expected for nuclei of 
small molecules tumbling rapidly (on the sub-nanomolar timescale) in solution. 
 
3.4 Dihedral angles and hydrogen bonds 
3.4.1 Dihedral angles 
Dihedral torsion angle (φ and ψ) restraints were calculated using the program TALOS 
(Cornilescu et al., 1999), which compares chemical shift assignments with a database of 
known protein assignments with known secondary structural elements.  The 
implementation of TALOS-derived dihedral angle restraints in structure calculations is 
described in more detail in section 6.2.1.  The dihedral angle restraints used in calculation 
of Rv1827 pThr 22 solution structures are listed in section 9.3. 
 
3.4.2 Hydrogen bonds 
Amide proton exchange was monitored by acquiring successive 15N-HSQC spectra 
following dissolution of lyophilized protein in 100% 2H2O containing 20 mM sodium 
acetate pH 5.8 and 50 mM NaCl.  The first 15N-HSQC spectrum was acquired 5 minutes 
after dissolution of the lyophilized protein and showed the presence of 79 backbone 
amide protons that had not yet exchanged (Figure 3.1).  After 17 hours only 49 backbone 
amide protons had not exchanged from which it was inferred that these amides were 
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engaged in hydrogen-bonds, confirmed by appropriate Hα-Hα correlations in the 13C-
edited NOE spectra.  The implementation of hydrogen bond restraints in structure 
calculations is discussed in more detail in section 6.2.2.  The hydrogen bond restraints 
used in calculation of Rv1827 pThr 22 solution structures are listed in section 9.4. 
 
3.5 Structure determination by NMR 
3.5.1 NOESY spectra 
All NOESY spectra were acquired, processed and analyzed as previously outlined.  
Distance constraint assignment was performed following analysis of three-dimensional 
1H-15N-NOESY-HSQC with a mixing time of 120 ms and mixing times of 100 and 120 
ms for  1H-13C-NOESY-HSQC spectra acquired in 100% 2H2O and  90% H2O/10% 
2H2O, respectively. 
 
The 1H-13C-NOESY-HSQC spectra were analyzed and annotated using an assigned 
HCCH-TOCSY peaklist as a template, effectively representing intra-residue NOEs from 
which all other observable inter-residue NOESY peaks were picked.  The 1H-15N-
NOESY-HSQC spectra were analyzed and annotated using an assigned H(CCCO)NH 
peaklist as a template, which was used to represent intra-residue NOEs, from which 
other observable inter-residue NOESY peaks were identified and analysed. 
 
The secondary structure of FHA domains is almost entirely composed of β-sheets, 
consequently NOESY spectral assignment began with identification of Hα-Hα NOEs that 
defined the register of β-sheet-forming residues.  From these short and medium range 
assignments, the appropriate hydrogen bonds were inferred from the amide proton 
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exchange data.  This procedure is described in more detail in section 6.2.2.  Long-range 
NOEs with unique assignment possibility were also identified at this stage. 
 
3.5.2 Distance calibration 
Distance calibration involves converting peak intensities or volumes into upper-distance 
limits between atoms.  As both peak intensity and volume are directly proportional to 
one another (assuming that the line-widths of all peaks are identical), either may be used 
for peak calibration. 
 
Peak intensities were directly measured in XEASY and converted into upper distance 
constraints using the awk script ‘distance_calibration.csh’ (section 9.2), which categorized 
peak intensities into strong/medium/weak, in accordance with known distances in 
secondary structural elements (Wuthrich, 1986).  Peak overlap was resolved on an 
individual basis usually through comparison of the equivalent regions of the 90% 
H2O/10% 2H2O and 100% 2H2O spectra.  Pseudoatom correction was added to all cases 
where there was chemical shift redundancy for stereo-pairs that were not stereo-
specifically assigned. 
 
3.5.3 ARIA 1.2 
ARIA 1.2 was used to calculate the structure of Rv1827 pThr 22 and the model of the 
unphosphorylated form (Linge et al., 2003).  Distance restraints from the 1H-15N-
NOESY-HSQC and 1H-13C-NOESY-HSQC were included for structure calculation.  
Also incorporated were hydrogen bond restraints (section 9.4) from the 2H exchange 
experiment and dihedral angles derived from TALOS (section 9.3).  Crystallography and 
NMR System (CNS) was used to perform simulated annealing combined with molecular 
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dynamics protocols (in torsion angle space for structural calculations and Cartesian space 
for water refinement) (Brunger et al., 1998).  The parameters used for the simulated 
annealing and water refinement protocols are shown in section 9.6. 
 
3.6 NMR titrations 
The NMR titration was performed by recording a 1H-15N HSQC spectrum after each 
addition of phosphopeptide.  The results of the phosphopeptide titration are discussed in 
section 5.4.5.  The concentrations of the phosphopeptide and Rv1827 throughout the 
titration are summarized in Table 3.2.  Spectra were recorded at 25oC using Rv1827 
dissolved in the buffer described in section 2.3.9.  The phosphopeptide was dissolved in 
20 mM sodium acetate (pH 5.8) and 50 mM NaCl.  The sequence of the phosphopeptide 
was: 
 
E-V-T-V-E-T-pT-S-V-F-R-A-D-[Y-K-K] 
 
In the above sequence, the phosphothreonine residue is denoted by pT and the C-
terminal Y-K-K tag was added to increase the solubility of the phosphopeptide and so 
that its concentration could be determined by UV spectrophotometry. 
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Titration 
number Peptide (µM) Rv1827 (µM)
molar equivalent 
(peptide:Rv1827) Total vol. (µl) 
0 0.0 251.0 0.00 500 
1 7.9 248.0 0.03 505 
2 23.4 244.0 0.10 515 
3 45.5 237.0 0.19 530 
4 72.9 228.0 0.32 550 
5 104.6 218.0 0.48 575 
6 145.0 206.0 0.70 610 
7 185.3 193.0 0.96 650 
8 249.1 173.0 1.44 725 
9 343.2 143.0 2.40 875 
10 422.4 120.0 3.52 1050 
 
Table 3.2.  NMR titration of pThr 22 peptide into unphosphorylated Rv1827. 
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4 A role for Rv1827 in the regulation of glutamate metabolism 
4.1 M. tuberculosis represents pathogencity on a global scale 
In 1993 the World Health Organisation (WHO) declared tuberculosis as a global 
emergency.  It is currently recognized as a worldwide pandemic with approximately 2 
billion people infected with M. tuberculosis, the causative agent of tuberculosis.  
Tuberculosis is also a leading killer among HIV-infected people with weakened immune 
systems: approximately 200,000 people living with HIV/AIDS die from tuberculosis 
every year.  With the emergence of multiply and extensively drug-resistant tuberculosis 
strains in all countries surveyed by the WHO, the identification of novel drug targets and 
therapies has never been more important. 
 
Tuberculosis in humans is a complex disease caused by bacterial populations located in 
discrete lesions, or micro-environments (Boshoff and Barry, 2005).  Some types of 
micro-environments are conducive to bacterial replication, whereas others restrict their 
growth without sterilising the infecting population.  Within pulmonary macrophages and 
human granulomas M. tuberculosis is exposed to a number of host-generated chemical 
stresses including diminished oxygen (hypoxia) and increased nitric oxide (NO) 
concentrations (Gomez and McKinney, 2004). 
 
4.2 Survival of M. tuberculosis within the human macrophage 
M. tuberculosis is able to respond to the microaerophilic environment of the human 
macrophage through the dosRST system (Sardiwal et al., 2005; Shiloh et al., 2008).  This is 
a classical two-component regulatory system comprising of a transmembrane sensor 
histidine kinase (DosS/T) and a response regulator (DosR).  In response to hypoxia and 
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environments with elevated NO, DosS/T undergoes autophosphorylation and hence 
activation.  In the activated state DosS phosphorylates an Asp residue of the response 
regulator DosR and in doing so causes a signal about the extracellular environment to be 
transmitted into the cell (Sousa et al., 2007). 
 
DosR/T are transcription factors that once activated induce the transcription of 
approximately 50 genes, known as the dormancy regulon (Shiloh et al., 2008).  The 
function of many of the transcribed genes remains unknown.  Those that have been 
characterized include an electron transporter (ferredoxin, fdxA) (Ricagno et al., 2007), a 
heat shock protein (α-crystallin, hspX or acr) (Hu et al., 2006), and an operon associated 
with nitrite and nitrate reduction (narK2X) (Shiloh et al., 2008; Sohaskey and Wayne, 
2003).  Research has shown that in vitro stimulation via hypoxia and NO initiates a 
metabolic shift within cultured bacilli to a state that recapitulates the latent phase of 
mycobacterial infection (Wayne and Sohaskey, 2001).  Understanding the nature and 
regulation of metabolic changes associated with the shift from actively replicating to 
dormant populations of M. tuberculosis may in turn lead to the identification of anti-
mycobacterial therapeutic targets. 
 
4.2.1 Survival-promoting adaptations of M. tuberculosis 
Adaptations resulting in such metabolic flexibility are thought to involve the M. 
tuberculosis core intermediary metabolism and specifically the tricarboxylic acid (TCA) 
cycle.  The TCA cycle is an essential biochemical pathway within cellular metabolism, 
yielding reducing equivalents for energy generation and biosynthetic reactions as well as 
precursors for lipids, amino acids and heme. 
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Many microorganisms use unique or alternative TCA cycle reactions that appear to be 
required to maintain TCA cycle functionality where expected enzyme reactions (as 
defined by the presence or absence of the corresponding genes or demonstrable 
enzymatic activity) are "missing” (Cordwell, 1999).  M. tuberculosis is no exception and 
lacks an α-ketoglutarate dehydrogenase (KDH) activity.   Ordinarily this would generate 
succinyl-CoA and consequently succinate from α-ketoglutarate (Tian et al., 2005a; Tian et 
al., 2005b). 
 
M. tuberculosis has substituted KDH activity for an α-ketoglutarate decarboxylase (KGD) 
activity that in concert with the succinic semi-aldehyde dehydrogenase capacity of 
Rv0234c/Rv1731 (GabD1/GabD2) can generate succinate oxidatively.  The literature on 
the biochemical pathways in the M. tuberculosis TCA cycle also suggests the ability to 
generate succinate reductively via the glyoxylate shunt.  Furthermore a functional γ-
aminobutyrate shunt may facilitate the inter-conversion of α-ketoglutarate and γ-
aminobutyrate with succinic semi-aldehyde and glutamate (Bott, 2007; O'Hare et al., 
2008).  Thus the M. tuberculosis TCA cycle appears to be able to operate in half cyclic 
modes, characteristic of organisms adapted to microaerophilic conditions, to generate 
necessary metabolic intermediates (Tian et al., 2005a). 
 
4.3 Rv1827 and phosphorylation-mediated metabolic regulation 
Rv1827 (known also as GarA (glycogen-accumulation regulator A) or CFP17) was 
originally identified as a M. tuberculosis culture filtrate protein (CFP) found as a 162 
residue (17.6 kDa) full length protein and an N-terminally truncated form comprising 
residues 31-162 (Weldingh et al., 1998).  Both forms were found to induce protective 
immunity in animal models (Weldingh and Andersen, 1999). 
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 Rv1827 is highly conserved across the actinomycetes which include the mycobacteria and 
corynebacteria, but a eukaryotic homologue is absent.  In C. glutamicum, phosphorylation 
of its Rv1827 homologue (OdhI) by PknG has been found to regulate intracellular 
glutamate levels (Bott, 2007; Niebisch et al., 2006; Schultz et al., 2007).  It was found that 
OdhI phosphorylation by PknG resulted in significantly less glutamate catabolism, and 
hence a high degree of glutamate accumulation within the cell.  Deletion of the PknG 
gene (ΔpknG) was found to be sufficient to cause the glutamate utilization defect, as was 
mutation of the PknG-phosphorylation site on OdhI when PknG was present (Niebisch 
et al., 2006).  However, a ΔpknG ΔodhI double deletion mutation abolished the glutamate 
utilization defect and glutamate appeared to be catabolised normally.  This suggested that 
kinase-mediated regulation of intracellular glutamate concentrations is exerted through 
regulation of OdhI activity.  Indeed, the activity of C. glutamicum 2-oxoglutarate 
dehydrogenase (OdhA) was later found to be regulated by phosphorylation of OdhI.  
OdhA catalyses the dehydrogenation of α-ketoglutarate and leads to the generation of 
succinate via a succinyl-CoA intermediate.  Binding of OdhI to OdhA inhibits the 
enzyme, and this inhibitory effect can be relieved through OdhI phosphorylation by 
PknG (Asakura et al., 2007; Schultz et al., 2007). 
 
Sequence alignments predict that Rv1827 harbors a C-terminal FHA domain and an N-
terminal extension of approximately 50 amino acids of no apparent predicted structure or 
function.  Full length Rv1827 was found to be the optimal substrate for PknB in 
mycobacterial cell-free extracts and both Rv1827 and OdhI were found to be 
phosphorylated by their respective PknG kinases in vivo (Niebisch et al., 2006; O'Hare et 
al., 2008; Villarino et al., 2005).  In each case, single phosphorylation sites were mapped 
to an N-terminal region of Rv1827.  PknB specifically phosphorylates Thr 22 and PknG 
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specifically phosphorylates Thr 21.  Phosphorylation of Rv1827 by PknB and PknG were 
found to be mutually exclusive events (England et al., 2008; Niebisch et al., 2006; O'Hare 
et al., 2008; Villarino et al., 2005).  Interestingly both phosphorylation sites conform to 
the Rv1827 preferred phospho-binding motif as determined by oriented peptide library 
screening (Yaffe and Smerdon, 2004).  Each phosphorylation site maintains a 
hydrophobic residue at the pThr + 3 position, suggesting a common mechanism by 
which signals from two different kinases can be transmitted through a common 
structural response of Rv1827. 
 
Rv1827 can be used as an in vitro substrate for PknD, PknE and PknF, although no 
functional significance has been attributed to these events (Villarino et al., 2005).  It has 
recently been reported that Rv1827 FHA domain binds to a phosphopeptide 
encompassing the PknB phosphorylation site of its own N-terminus, with an apparent kd 
of 0.385 (±0.003) µM (England et al., 2008).  This prompted the authors to suggest that 
N-terminal phosphorylation of Rv1827 induces an intramolecular interaction through 
tight recognition of the FHA domain for its phosphorylated N-terminus.   
 
In summary, it seems that OdhI is able to control glutamate metabolism in C. glutamicum 
and Rv1827 presumably functions in an analogous manner in M. tuberculosis.  An 
additional level of control is exerted by N-terminal phosphorylation of Rv1827/OdhI.  
However, it is unclear how Rv1827 or OdhI interact with their respective enzyme targets.  
This leads to the question of whether the interaction is dependent on the 
phosphorylation state of the enzymes or can Rv1827/OdhI interact with them phospho-
independently.  Moreover it is perplexing how phosphorylation of Rv1827 within its N-
terminal region abrogates these interactions.  As a first step towards addressing these 
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issues it was important to find out whether Rv1827 interacts only with KGD, or if it has 
multiple binding partners.   
 
4.4 Identification of Rv1827 binding partners by pull-down assays 
In an attempt to characterize Rv1827 binding partners in M. tuberculosis cell-free extracts, 
a GST-Rv1827 fusion protein construct was utilized to perform pull-down experiments.  
In these experiments Rv1827 was found to bind specifically and reproducibly to three 
high molecular weight proteins that were identified by MALDI-TOF mass spectrometry 
(Figure 4.1 left, lane 3) (S. L. Westcott, PhD Thesis 2004).  Two of these, Rv1248c (α-
ketoglutarate decarboxylase; KGD) and Rv2476c (NAD+-specific glutamate 
dehydrogenase 4; GDH-4) have recently been reported as inhibitory targets of Rv1827 
(Niebisch et al., 2006; O'Hare et al., 2008).  KGD has a mass of 134 kDa and GDH has a 
mass of 177 kDa.  The N-terminus of KGD is homologous to the acyltransferase 
domain of the E2 subunit of the α-ketoglutarate dehydrogenase complex, while the C-
terminus is homologous to the E1 subunit of the same complex.  Rv3859c (α-subunit 
(GltB) of the glutamate synthase complex, GS) was additionally identified as a novel 
binding partner (S. L. Westcott, PhD Thesis 2004).  This protein has a mass of 166 kDa.  
Intriguingly all three enzymes utilize α-ketoglutarate as substrate, placing Rv1827 activity 
squarely in the context of core metabolism, as hinted by the work in C. glutamicum.  
 
Additional pull-down assays were carried out using PknB-phosphorylated Rv1827, the 
minimal FHA domain (residues 55-149) and a mutant protein containing an Ala 
substitution of Ser 95 (S95A).  Ser 95 is a highly conserved FHA domain residue whose 
mutation is widely reported to abrogate pThr-motif binding.  Whilst interactions with all 
three enzymes are apparently unaffected by removal of the N-terminal 54-residues, they  
 84
14.4
21.5
31.0
45.0
66.2
97.4
116.25
200.0
G
ST
G
ST
-R
v1
82
71
-1
62
 W
T
G
ST
-R
v1
82
71
-1
62
  p
Th
r 2
2
M GS
T-
Rv
18
27
55
-1
49
  F
HA
G
ST
-R
v1
82
71
-1
62
  S
95
A
M
tb
 c
el
l-f
re
e 
ly
sa
te
G
ST
G
ST
-R
v1
82
71
-1
62
 W
T
G
ST
-R
v1
82
71
-1
62
  p
Th
r 2
2
M GS
T-
Rv
18
27
55
-1
49
  F
HA
G
ST
-R
v1
82
71
-1
62
  S
95
A
14.4
21.5
31.0
45.0
66.2
97.4
116.25
200.0
Figure 4.1.  Identification of Rv1827 binding partners.  left  Pull-down gel showing that Rv1827 wild-
type (WT) binds to three high molecular weight proteins (lane 3).  Phosphorylation of Rv1827 at Thr 
22 by PknB (pThr 22) abrogates Rv1827 interactions (lane 4).  The Rv1827 FHA domain is sufficient 
for binding to the high molecular weight proteins (lane 5).  Mutation of the conserved Rv1827 FHA 
domain Ser 95 to Ala (S95A) causes loss of interactions with GltB, reduces interactions with GDH and 
maintains interactions with KGD at wild-type levels.  right  Reference gel showing the purified GST-
fusion constructs used in the pull-down experiments.  Gel loading is at approximately the same level 
as in the pull-down experiments.  The location of the three metabolic enzymes is indicated with a red 
box. 
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Figure 4.2.  Schematic representation of possible phospho-dependent and phospho-independent 
Rv1827 FHA domain interactions.  (A)  The canonical phosphopepitde-binding surface is represented 
with a ‘notch’ in the FHA domain.  The phospho-dependent ligand is represented in black and blue, 
and phospho-independent binding partners are represented in red.  (B)  The S95A mutant can no 
longer bind phospho-dependently, but can still potentially use other FHA domain surfaces for 
phospho-independent interactions. 
A
B
86
are abolished by Thr 22 phosphorylation (Figure 4.1 left, lanes 5 and 4).  Thus Rv1827 
FHA domain alone is sufficient for binding its metabolic enzyme targets and 
phosphorylation of the N-terminal region completely blocks these interactions.  
Furthermore, the phospho-binding deficient S95A mutant eliminates interaction with 
GltB, whilst association with GDH is reduced and binding to KGD is unaffected (Figure 
4.1 left, lane 6).   The reduced ability of Rv1827 S95A to bind GDH and GltB is 
suggestive of classical pThr-dependent interactions, yet phosphorylation sites on KGD, 
GDH and GltB have not been found (Nott et al., 2009).  These experiments show that 
PknB-phosphorylation of Rv1827 regulates interactions of its FHA domain with three 
functionally related TCA cycle enzymes, and that association with at least two, and most 
likely all three, involves a phospho-independent FHA binding function.  This is 
represented in the bottom panel of Figure 4.2 showing that potential Rv1827 phospho-
independent binding surfaces may be distinct from the canonical pThr binding site or 
partially coincident with it. 
 
4.5 Rv1827 modulates glutamate and α-ketoglutamate metabolism and ammonia 
assimilation 
O'Hare and co-workers have recently tried to characterize the effect that Rv1827 has on 
KGD and GDH activity.  They used recombinantly expressed KGD and GDH in an in 
vitro coupled-assay reaction system that used ferricyanide reduction as the final readout 
for the activity of the metabolic enzymes.  In this way they made measurements of the 
activity of the enzymes in the presence of increasing concentrations of Rv1827.  Their in 
vitro ferricyanide reductase assays showed that Rv1827 acts as a potent inhibitor of each 
enzyme.  Recombinant KGD purified from E. coli was found to have a maximal 
ferricyanide reductase activity of 1.8 s-1 and a Km for α-ketoglutarate of 480 µM, which is 
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similar to that observed for the recombinant M. smegmatis homologue MSMEG_4699 (1.6 
s-1 and a Km for α-ketoglutarate of 540 µM).  Concentration-dependent inhibition of 
KGD was observed upon addition of Rv1827, but not PknB-phosphorylated Rv1827 
(O'Hare et al., 2008; Tian et al., 2005b). 
 
Interestingly Rv1827 was found to affect the affinity of GDH for its substrate and thus 
the reaction rates of both its anabolic and catabolic reactions.  Thus whether Rv1827 acts 
as an inhibitor or an activator in vivo depends on substrate concentration.  If it is assumed 
that α-ketoglutarate concentrations are similar to those estimated for E. coli (0.1-0.9 mM) 
and C. glutamicum (1 mM) and that the concentration of glutamate is below 600 mM, then 
Rv1827 would inhibit GDH activity and reduce the rate of the low-affinity route of 
ammonia assimilation from α-ketoglutarate (O'Hare et al., 2008).  Recent data show that 
Rv1827 is a strong activator of glutamate synthase (GS) activity in M. smegmatis and M. 
Bovis cell-free lysates (Nott et al., 2009).  The combined activity of the GS complex and 
glutamine synthetase (GlnA) forms the high-affinity pathway of ammonia assimilation 
from α-ketoglutarate. 
 
Since KGD, GDH and the GS complex all utilize α-ketoglutarate as a substrate, these 
combined data suggest that Rv1827 exerts control of carbon flux and nitrogen 
assimilation at an important branch of central metabolism.  Either α-ketoglutarate can be 
oxidized in the TCA cycle by KGD or be converted into glutamate.  This may be 
achieved either by GDH (under conditions of nitrogen abundance) or the combined 
activities of the GS complex and GlnA under conditions of nitrogen limitation.  In all 
cases, Rv1827 regulatory activity is lost upon its phosphorylation by PknG or PknB 
(Nott et al., 2009; O'Hare et al., 2008). 
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4.5.1 Interactions are dependent on Rv1827 phosphorylation status 
Regardless of the differential effects Rv1827 has on the three α-ketoglutarate utilizing 
enzymes, it is remarkable that a single phosphorylation event can regulate such complex 
core metabolic activity.  In order to understand the differences between Rv1827 and the 
PknB-phosphorylated form through biophysical and biochemical analytical methods it 
was necessary to be able to generate them both in large quantities and at high purity.  In 
this respect the stoichiometric phosphorylation Rv1827 at Thr 22 by PknB was extremely 
fortunate.  This meant that large quantities of Rv1827 pThr 22 could be generated and, 
under the appropriate reaction conditions, none of the unphosphorylated form of 
Rv1827 would be left in the sample.  Thus a batch of unphosphorylated Rv1827 could be 
split and half of it treated with PknB so that accurate comparisons could be made 
between the two forms. 
 
Figure 4.3 shows that upon phosphorylation by PknB the mass of Rv1827 increases from 
17629.82 ± 0.53 Da to 17710.46 ± 0.48 Da.  The increase in mass of 80.64 Da 
corresponds to the addition of one phosphate per molecule.  Importantly, none of the 
unphosphorylated species is present in the sample of Rv1827 pThr 22. 
 
4.6 Conclusions 
M. tuberculosis possesses a flexible core metabolism that appears to be able to function 
oxidatively or reductively depending on environmental pressures.  Furthermore, signaling 
through Ser/Thr protein kinases is able to direct carbon flux in the TCA cycle and 
pathways of nitrogen assimilation to meet cellular needs for energy and biosynthetic 
precursors.  The small FHA domain-containing protein Rv1827 differentially regulates  
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Figure 4.3.  Rv1827 is stoichiometrically phosphorylated on one residue by PknB.  Electro-spray mass 
spectra of Rv1827 (top, blue) and Rv1827 pThr 22 (bottom, red).  Upon phosphorylation by PknB the 
mass of Rv8127 increases from 17629.82 ± 0.53 to 17710.46 ± 0.48 Da.  An increase in mass of 80.64 Da 
is correlated with the addition of a single phosphate group per molecule. 
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the activities of three α-ketoglutarate utilizing metabolic enzymes.  The isolated FHA 
domain suffices for inhibition of KGD and GDH and activation of the GS complex.  
Interestingly, a mutation (Ser 95 to Ala) that has been widely used to demonstrate FHA 
domain exclusivity for interaction with phosphopeptides does not affect Rv1827 
interactions with at least one of its target enzymes.  This strongly suggests that the FHA 
domain possesses phospho-independent binding capability. 
 
Remarkably, phosphorylation of one of two adjacent threonines in the N-terminus of 
Rv1827 by PknG or PknB abrogates binding of the FHA domain to its metabolic targets.  
Phosphorylation by PknG (at Thr 21) and PknB (at Thr 22) are mutually exclusive 
events.  Therefore, phosphorylation of Rv1827 at either threonine induces a 
conformational change that renders the adjacent one inaccessible to the other kinase.  
Furthermore the observation that N-terminal phosphorylation disrupts Rv1827 FHA 
domain-mediated interactions with its target metabolic enzymes suggest that an intra-
molecular interaction is triggered that occludes the interaction surface. 
 
Rv1827 that is stiochiometrically phosphorylated at Thr 22 by PknB can be generated 
with high purity and at high yield. This permitted rigorous biochemical, biophysical and 
structural investigation of the differences of these two forms of Rv1827 with the aim of 
understanding the mechanism by which N-terminal phosphorylation controls modulation 
of carbon flux in the M. tuberculosis TCA cycle. 
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5 Phosphorylation-induced conformational change of Rv1827 
5.1 Overview 
In seeking a molecular explanation for the observation that N-terminal phosphorylation 
prevents Rv1827 FHA domain interactions with its metabolic target enzymes a 
biochemical, biophysical and hydrodynamic study was conducted on unphosphorylated 
Rv1827 and the PknB-phosphorylated form.  The experiments aimed to characterize the 
postulated phosphorylation-induced conformational change prior to structural analysis. 
 
5.2 Phosphorylation confers stability 
5.2.1 Limited proteolysis 
The first method that was used investigate structural stability was limited tryptic 
proteolysis.  Trypsin is a protease that can cleave the peptide backbone of proteins C-
terminal of Arg or Lys residues.  Historically, it has been used as a means of identifying 
domain boundaries in proteins as it cannot cleave the peptide backbone in regions that 
are engaged in well defined secondary or tertiary structure.  It therefore targets flexible 
regions.  Following limited typtic proteolysis, cleavage sites can be identified from the 
masses of regions resistant to cleavage or by N-terminal sequencing by Edman 
degradation. 
 
Simulated tryptic proteolysis of Rv1827 performed using the online ExPASY 
PeptideCutter tool (http://www.expasy.org/tools/peptidecutter/) identified 12 possible 
cleavage sites from the amino acid sequence.  9 sites lie within the predicted FHA 
domain (residues 55-149) and are likely to be protected from tryptic cleavage as a result 
of the tight, ordered packing of residues typically found in FHA domains.  One lies at the 
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extreme C-terminus of the FHA domain (Lys 151) and two potential tryptic sites are N-
terminal of the FHA domain at Lys 10 and Arg 26.   
 
When subjected to limited trypsin proteolysis unphosphorylated Rv1827 is efficiently 
cleaved at Arg 26, which is four/five residues C-terminal of the PknB/G 
phosphorylation sites (Figure 5.1, left).  As expected the FHA domain is resistant to 
cleavage by trypsin.  For Rv1827 pThr 22 the Arg 26 tryptic site is almost completely 
protected, indicating that upon phosphorylation a conformational change occurs in this 
region of the molecule and results in its stabilization.  (Figure 5.1, right).  However, even 
in the PknB-phosphorylated form, trypsin is able to cleave after Lys 151.  This site lies 
two residues downstream of the last residue in the most C-terminal β-strand of the FHA 
domain. 
 
Interestingly, when Rv1827 pThr 21 (phosphorylated by PknG) is subjected to limited 
trypsin proteolysis the Arg 26 tryptic site is protected, albeit to a lesser degree than for 
Rv1827 pThr 22 (Figure 5.1, middle).  A possible explanation for this difference may be 
that in the pThr 21 form Arg 26 is effectively shifted away from the site of phosphate 
binding by approximately 3.4 Å (the distance between peptide bonds in a polypeptide 
chain), leaving it slightly less restrained and consequently more accessible to trypsin 
proteolysis.  Cleavage at Lys 151 is observed in Rv1827 pThr 21 at a similar efficiency as 
in Rv1827 pThr 22, demonstrating that differential N-terminal phosphorylation has no 
effect of the conformation of the protein C-terminal of the FHA domain. 
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Figure 5.1.  Limited tryptic proteolysis of unphosphorylated and PknG- and PknB-phosphorylated 
Rv1827.  Molecular weight markers (M) are displayed in kDa.  Unphosphorylated Rv1827 is cleaved by 
trypsin at Arg 26 (determined by mass spectrometry) within approximately 10 min.  The rate of trypsin 
cleavage at Arg 26 is reduced in the PknG-phosphorylated form (Rv1827 pThr 21), and when Rv1827 is 
phosphorylated by PnkB (Rv1827 pThr 22), Arg 26 is protected from tryptic proteolysis.  The limited 
tryptic cleavage profiles of PknG and PknB can be seen as higher molecular weight bands on the gel. 
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 5.2.2 Circular dichroism 
Another way of probing the stability of a protein is through thermal (or chemical) 
denaturation of the secondary structure.  This process can be followed using circular 
dichroism (CD) spectroscopy.  Amino acids have a chiral centre about their respective Cα 
atoms (except Gly) that differentially transmits left- and right-circularly polarized light if 
the amino acid is in a region of β-strand, α-helix or random coil.  Therefore the heating-
induced transition between the folded protein (with secondary structure) and unfolded 
polypeptide chain can yield information about the thermal stability of the protein. 
 
By following the CD thermal unfolding profiles at 202 nm it was found that PknB-
phosphorylation of Rv1827 at Thr 22 confers a significant increase in thermal stability 
compared with the unmodified form (Figure 5.2 A).  Whereas unphosphorylated Rv1827 
was found to be completely unfolded at 60oC, Rv1827 pThr 22 had to be heated to 80oC 
before the secondary structure was completely denatured.  Thus phosphorylation of the 
N-terminal region affects stability across the entire protein.  A likely explanation for this 
is that the N-terminal region interacts tightly with the FHA domain, as recently suggested 
by England and co-workers (England et al., 2008). 
 
Rv1827 produces a far-UV CD spectrum characteristic of a protein rich in β-strands.  
However, comparison of the far-UV CD spectra of Rv1827 and Rv1827 pThr 22 shows 
that phosphorylation induces a small but significant change in CD signal at 
approximately 202 nm (Figure 5.2 B, left).  This shift in signal may be correlated with the 
formation and stabilization of a short region of secondary structure with α-helical 
propensity that is not present in the unmodified protein.   However, as peaks in the near- 
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Figure 5.2.  Biophysical comparison of Rv1827 and Rv1827 pThr 22.  (A)  Thermal denaturation of 
Rv1827 (red lines) and Rv1827 pThr 22 (black lines) measured using circular dichroism (CD) at 202 
nm.  Whereas unphosphorylated Rv1827 is completely denatured by 60oC, Rv1827 maintains some 
secondary structure up to 80oC at which temperature it is completely denatured.  (B)  left  Far-UV CD 
spectra of Rv1827 (red) and Rv1827 pThr 22 (black) at room temperature (solid lines) and at 88oC 
(dashed lines).  The coincidence of the spectra of the two forms of Rv1827 at 88oC indicates that 
measurements were taken on samples of the same concentration.  right  Near-UV CD spectra of 
Rv1827 and Rv1827 pThr 22.  The coincidence of peaks in the spectra of the respective samples 
indicates that residues contributing to the near-UV CD spectra (Phe at 261 nm; Tyr at 275 and 282nm) 
were unaffected by phosphorylation-induced conformational change 
A
B C
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UV CD spectra are coincidental for both phosphorylated and unphosphorylated forms 
of Rv1827 we concluded that residues contributing to the near-UV CD spectra (Phe at 
261 nm; Tyr at 275 and 282nm) were unaffected by phosphorylation-induced 
conformational change (Figure 5.2 B, right). 
 
5.3 Phosphorylation induces a conformation compaction 
In order to understand the stabilizing effect that phosphorylation confers on Rv1827 in 
more detail, hydrodynamic parameters of the unphosphorylated and PknB-
phosphorylated forms were measured.  It was initially hypothesized that N-terminal 
phosphorylation would induce ‘head to tail’ dimerisation whereby the phospho-threonine 
of one molecule would bind to the FHA domain of another, as seen for the Chk2 FHA 
domain.  This mode of FHA binding has been shown to play important roles in the 
activation of kinases possessing FHA domains.  In this model dimerisation through FHA 
domain-mediated interactions brings the kinase domains into close proximity promoting 
auto-phosphorylation in trans. 
 
5.3.1 Multi-angle laser light scattering 
Multi-angle laser light scattering (MALLS) is a technique that provides a direct measure 
of absolute molecular mass by coupling size exclusion chromatography eluents directly to 
static light-scattering and concentration detectors.  Since the signal from light-scattering 
detectors is directly proportional to the molecular mass of the protein times the 
concentration (mg ml-1), combining this signal with that from a concentration detector 
(refractive index or absorbance), determination of the molecular mass of each peak 
eluting from the size exclusion chromatography column is possible.  
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The mean weight-averaged molecular weight of Rv1827 and Rv1827 pThr 22 were 
determined by size exclusion chromatography coupled to MALLS to be 17700 g mol-1 
(±1%) and 17500 g mol-1 (±1%), respectively (Figure 5.3 A).  Therefore both Rv1827 
and Rv1827 pThr 22 (which have formula masses of 17629 and 17709 Da, respectively) 
are monomeric in solution and phosphorylation does not promote Chk2-like 
dimerisation.  Interestingly, the chromatographic peak of Rv1827 pThr 22 is retarded by 
approximately thirty seconds compared with the unphosphorylated protein, suggesting 
that phosphorylation induces a conformational compaction.  However, it cannot be 
discounted that the addition of a phosphate group caused Rv1827 pThr 22 to interact 
with the matrix of the chromatography column, thus retarding its retention time. 
 
5.3.2 Dynamic light scattering 
The second hydrodynamic technique that was employed was dynamic light scattering 
(DLS).  This technique can show whether a protein sample is homogeneous or 
heterogeneous by measuring its polydispersion.  Both Rv1827 and Rv1827 pThr 22 were 
found to be monodisperse in solution, indicating their respective purity and 
homogeneity.  DLS can also be used to measure the hydrodynamic radius of a protein 
and thereby its translational diffusion coefficient (DT).  The hydrodynamic radius of a 
protein is effectively a measure of the distance along its longest axis, and is therefore 
related to how quickly it can diffuse through the solution.  A small, globular protein will 
have a small effective hydrodynamic radius and therefore a high rate of diffusion.  
Conversely a large or elongated protein will have a high effective hydrodynamic radius 
and will be able to diffuse less quickly through the solution. 
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Figure 5.3.  Hydrodynamic analysis of Rv1827 and Rv1827 pThr 22.  (A)  Comparison of the 
chromatograms (measured at 280 nm) of Rv1827 (blue) and Rv1827 pThr 22 (red) by size-
exclusion chromatography coupled to multi-angle laser light scattering (SEC-MALLS).  The 
weight-average molecular weight of material in the chromatographic peaks of the respective forms 
of Rv1827 are shown as square dots.  The differential refractive index (dashed lines) and scatter at 
90o (solid lines) closely coincide for each sample, indicating their respective homogeneity.  The 
mean weight-average molecular weight of Rv1827 and Rv1827 pThr 22 were determined to be 
17700 g mol-1 (± 1%) and 17500 g mol-1 (± 1%), respectively, indicating that both unphosphorylated 
and phosphorylated forms are monomeric in solution.  (B)  Comparison of the translational 
diffusion coefficients (DT) of Rv1827 and Rv1827 pThr 22, obtained by dynamic light scattering 
(DLS).  Both samples were at 250 µM.  Upon phosphorylation, the DT of Rv1827 increased from 
7.90 x 10-7 cm-1 sec-1 to 8.4 x 10-7 cm-1 sec-1 implying that phosphorylation induces an intramolecular 
conformational compaction of the molecule. 
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Comparison of the translational diffusion coefficients of the two forms of Rv1827 shows 
a small but significant increase for Rv1827 pThr 22 (8.4 x 10-7 cm-1 sec-1) compared with 
the unphosphorylated form (7.90 x 10-7 cm-1 sec-1) (Figure 5.3 B). Again this implies that 
phosphorylation induces an intramolecular conformational compaction of the molecule.  
It was therefore reasoned that upon phosphorylation of Rv1827 at Thr 22 by PknB (and 
by inference Thr 21 phosphorylation by PknG) an intramolecular association is 
promoted whereby residues of the N-terminus become tightly associated with the FHA 
domain conferring proteolytic protection, increased thermal stability, and a more 
compact global conformation 
 
5.4 NMR-based hydrodynamic analysis of unphosphorylated and phosphorylated 
Rv1827 
Knowing that both the unphosphorylated and PknB-phosphorylated states of Rv1827 
were monomeric and monodisperse in solution meant that NMR could be used to 
further investigate their respective hydrodynamic properties.  Whereas the techniques 
described in the previous section are informative and relatively labor unintensive, they 
are inherently of low resolution.  They could not provide unambiguous explanations for 
the differences in biochemical or biophysical properties that phosphorylation induced in 
Rv1827.  However, NMR can be used to analyze the hydrodynamic properties of a 
protein at atomic resolution and therefore address these questions directly. 
 
5.4.1 1H-15N HSQC assignment and shift-mapping 
Backbone amide resonance assignment was initially used as a means of determining 
regions of the molecule over which changes to the local chemical environment were 
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induced following phosphorylation.  Assignment of the respective 1H-15N HSQC spectra 
of Rv1827 and Rv1827 pThr 22 was achieved as described in section 3.2.3 and are shown 
in Figure 5.4 and Figure 5.5.  Both forms of Rv1827 yielded well dispersed 1H-15N HSQC 
spectra, so their assignment was relatively straight forward. 
 
The Rv1827 pThr 22 1H-15N HSQC spectrum contained 195 peaks in total from the 167 
residues in the protein construct, which has 5 more residues than the gene sequence.  
The 5 extra residues (Gly-Pro-Leu-Gly-Ser) are present at the N-terminus of the protein 
and are a consequence of the GST purification protocol (outlined in section 2.3.6).  The 
construct contains 10 proline residues, including the residual N-terminal tag which was 
left following 3C-cleavage.  Out of a possible 157 assignments for backbone amide 
resonances 156 were unambiguously made.  3 (out of a possible 5) Gln sidechain pairs 
and 6 (out of a possible 8) Asn sidechain pairs were assigned.  Arg HNε and His HNδ 
were folded in the 15N-dimension, and are represented as hollow contours in the 1H-15N 
HSQC spectra.  8 out of a possible 9 Arg HNε resonances were assigned and both of the 
His HNδ were assigned.  3 peaks in the Rv1827 pThr 22 1H-15N HSQC spectrum were 
unassigned. 
 
From the 1H-15N HSQC spectrum of unphosphorylated Rv1827, 155 out of a possible 
157 backbone amide resonances were assigned.  However, no sidechain amide group 
resonance assignments were possible as 15N-NOESY spectra were not analyzed for the 
unphosphorylated from of Rv1827. 
 
Analysis of chemical shift perturbations upon phosphorylation of Rv1827 was used an 
initial method of identifying regions of the molecule in which conformational changes  
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Figure 5.4.  1H-15N HSQC spectrum of Rv1827.  The spectrum was acquired at 600 MHz at 25oC in 
20 mM sodium acetate (pH 5.8), 50 mM NaCl and 10% 2H2O.  Peaks folded in the 15N-dimension 
are shown as hollow contours.  The inset at the lower right of the panel corresponds to the 
crowded region in the center of the spectrum.  Unassigned peaks are not annotated. 
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Figure 5.5.  1H-15N HSQC spectrum Rv1827 pThr 22.  The spectrum was acquired at 600 MHz at 
25oC in 20 mM sodium acetate (pH 5.8), 50 mM NaCl and 10% 2H2O.  Peaks folded in the 15N-
dimension are shown as hollow contours.  Assigned δ-NH2 (asparagine) and ε-NH2 (glutamine) 
pairs are linked with horizontal bars.  The inset at the lower right of the panel corresponds to the 
crowded region in the center of the spectrum.  pThr 22 is highlighted with a red ellipse.  
Unassigned peaks are not annotated. 
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were induced.  Figure 5.6 (top panel) shows 1H-15N chemical shift perturbations induced 
in Rv1827 following phosphorylation of Thr 22, and was calculated according to: 
 
( ) (( ))21521 6NH δδδ Δ+Δ=Δ       Equation 5.1 
 
where Δδ is the combined chemical shift perturbation and 1H and 15N are the proton and 
nitrogen chemical shifts in parts per million (ppm) for the backbone amide of each 
residue. 
 
It is clear that significant perturbations are induced over four regions (Figure 5.6, top 
panel).  The chemical environment of residues between Thr 21 and Leu 33 are 
significantly perturbed following phosphorylation, implying that an extended change in 
conformation occurs over this region.  The greatest chemical shift difference is found at 
pThr 22 and may be attributed to a combination of binding-induced ordering and the 
proximity of the phosphate group to the backbone amide, significantly down-shifting 
both 1H and 15N resonances. 
 
The chemical shift perturbations of three other short regions (centered on Ser 95, Asn 
117 and Lys 141, respectively) were hypothesized to correspond to the phospho-binding 
surface.  In common with other functional FHA domains this is formed by three loops 
each connecting two anti-parallel β-strands, as shown in Figure 1.4.  Interestingly Arg 81 
does not show a large chemical shift perturbation upon phosphorylation, although it is 
predicted to be critical for phosphate binding.  This may be explained by the fact that in 
available FHA-phosphopeptide structures it is the Arg 81 NH2 groups at the end of the 
side chain that contact the phosphate.  The backbone amide makes only structural  
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Figure 5.6.  1H-15N HSQC spectrum shift mapping of Rv1827 and Rv1827 pThr 22.  (A)  Chemical shift 
perturbation profile of Rv1827 upon its phosphorylation by PknB.  Chemical shift perturbation values 
were calculated according to Equation 5.1.  (B)  Overlaid 1H-15N HSQC spectra of Rv1827 (blue) and 
selected residues of Rv1827 pThr 22 (red).  The change in chemical shift of residues that is induced by 
phosphorylation is indicated with arrows. 
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 contacts with the FHA domain and is therefore a significant distance from the site of 
phosphate binding.  This also supports the idea that FHA domains have a pre-formed 
phospho-interaction surface and do not employ an induced-fit mode of binding. 
 
Figure (Figure 5.6 B) shows the 1H-15N HSQC spectrum of Rv1827 (blue) with a 
selection of residues most perturbed by phosphorylation annotated and their new 
positions superimposed (red).  Threonine 22 is shown to shift by the greatest amount, 
closely followed by Arg 96, which in other FHA-phosphopeptide structures makes direct 
contact with the phosphate group with its backbone amide. 
 
5.4.2 1H-15N relaxation experiments 
The protein backbone dynamics of unphosphorylated and PknB-phosphorylated Rv1827 
were investigated using 15N relaxation measurements.  T1, T2 and 1H-15N-NOE relaxation 
experiments were performed as each reports on internal molecular mobility by different 
mechanisms.  The principles behind the respective relaxation experiments are outlined in 
section 3.3.1. 
 
5.4.3 Backbone dynamics of Rv1827 pThr 22 
The T1, T2, and 1H-15N-NOE relaxation profiles for Rv1827 pThr 22 and Rv1827 are 
shown in Figure 5.7 and display interesting similarities and differences for these two 
forms of the protein.  In each relaxation profile, missing residues correspond to prolines, 
overlapped peaks or peaks with extremely weak intensity. 
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The FHA domain is defined in the T2 and 1H-15N-NOE relaxation profiles of Rv1827 
pThr 22 as being formed by residues 55-149 [agreeing with the 2H exchange data 
described in section 3.4.2 and Figure 3.1].  Over this region of the protein backbone the 
average T2 relaxation time was found to be 68.00 ± 10.14 ms for Rv1827 pThr 22 (Table 
5.1).  The average 1H-15N-NOE enhancement value was found to be 0.73 ± 0.10.  A T2 
relaxation time of ~68 ms and 1H-15N-NOE enhancement of ~0.73 characterizes what 
may be thought of as the rigid core of the molecule.  T2 relaxation times and 1H-15N-
NOE enhancements of this order are observed for residues 22-25 in addition to within 
the FHA domain.  Therefore upon phosphorylation by PknB, pThr 22 and several 
residues C-terminal to it associate intramolecularly with the FHA domain and become as 
rigidly ordered as the core of the molecule.  This results in an increase in thermal stability 
as discussed in section 5.2.2 and shown in Figure 5.1, B. 
 
 T1 (ms) T2 (ms) 1H-15N NOE 
Rv1827 845.16 ± 53.15 65.06 ± 10.55 0.74 ± 0.10 
Rv1827 pThr22 888.27 ± 66.32 68.00 ± 10.14 0.73 ± 0.10 
 
Table 5.1.  Summary of backbone dynamics of Rv1827 and Rv1827 pThr 22 across FHA domains 
residues (55-149). 
 
This trend is also observed by T1 relaxation, although the data are more variable and the 
FHA domain is apparently less well defined.  It is possible that anisotropy of the protein 
structure contributes to the observed T1 variability.  The N-terminal 19 residues and 
residues C-terminal of Lys 151 show extremely high internal motion.  From this it is 
concluded that the extreme N- and C-terminal residues are completely unrestrained.  
This explains the ability of trypsin to cleave the peptide backbone of Rv1827 C-terminal 
of Lys 151. 
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Figure 5.7.  T1, T2 and NOE relaxation values (acquired at 600 MHz), and T1/T2 ratios for Rv1827 
(right) and Rv1827 pThr 22 (left). 
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Figure 5.8.  T1 and T2 decays for Val 24 (square dots) and Ala 39 (round dots) in Rv1827 pThr 22. 
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An interesting feature of Rv1827 pThr 22 is the peak of T2 relaxation time centered 
about Gly 40, which on both the N- and C-terminal sides falls back to that of the core 
values.  This suggests that between the site of phosphorylation and the N-terminus of the 
FHA domain there exists a ‘linker’ of increasing and then decreasing internal mobility.  
This pattern is mirrored in the 1H-15N-NOE relaxation profile, but is less well defined by 
T1 across that region.  Examples of the raw T1 and T2 relaxation data for Ala 39 (linker 
region) and Val 24 (core region) are shown in Figure 5.8. 
 
5.4.4 Backbone dynamics of unphosphorylated Rv1827 
As in the PknB-phosphorylated form, the FHA domain is clearly defined by T2 relaxation 
and 1H-15N-NOE enhancement measurements (Figure 5.7).  The average T2 relaxation 
time and 1H-15N-NOE value over residues 55-149 are 65.06 ± 10.55 ms and 0.74 ± 0.10, 
respectively (Table 5.1).  These are highly similar to those observed for Rv1827 pThr 22 
and it is concluded therefore that phosphorylation of Rv1827 by PknB does not change 
the average backbone dynamics of the FHA domain.  Comparison of the T1 relaxation 
profiles for the phosphorylated and unphosphorylated forms of the protein over the 
region N-terminal to the FHA domain highlights a significant difference in internal 
mobility at the T1 timescale.  In the unphosphorylated form, the N-terminus of the 
protein exhibits high internal mobility in the N-terminal 50 residues leading to recovery 
of the longitudinal magnetization of the backbone amide bond vectors significantly more 
quickly than that of the core. 
 
Despite the fast internal motion seen in T1 relaxation, a trough in the T2 relaxation 
centered on Ala 27 (mirrored by dipolar-coupled cross-relaxation processes in the same 
region) suggests that the mobility of this region is nonetheless partially constrained.  A 
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combination of transient structural propensity centered on Ala 27 and conformational 
exchange in which this region is associated with and dissociated from the FHA domain is 
proposed to explain the dynamic properties of the N-terminus of unphosphorylated 
Rv1827. 
 
The T1/T2 ratios (per residue) for the unphosphorylated and PknB-phosphorylated 
forms of Rv1827 are shown in Figure 5.7 (D).  The average T1/T2 ratios for the FHA 
domains (residues 55-149) of the phosphorylated and unphosphorylated forms are very 
similar, as are the extreme N- and C-termini (Table 5.2).  This suggests that 
phosphorylation has no significant effect on the apparent mobilities of these regions.  
However, phosphorylation substantially decreases the internal mobility of residues 20-33 
(Figure 5.7, D).  Average T1/T2 ratios over this region increase from 5.62 ± 1.27 to 9.75 
± 4.57 upon phosphorylation, implying that a change in conformation is induced that 
extends significantly further than those most commonly observed for FHA-
phosphopeptide interactions.  It seems that under the conditions of intra-molecular 
phosphopeptide binding a novel FHA-binding mode may be operational.  Residues up to 
pThr + 10 may contribute to the overall affinity of the intramolecular interaction. 
 
 Average region-specific T1/T2 ratios 
 FHA domain (residues 55-149) Residues 20-33 
Termini (residues 
1-19 and 150-162) 
Rv1827 13.51 ± 1.96 5.62 ± 1.27 2.32 ± 1.16 
Rv1827 pThr22 13.40 ± 2.27 9.75 ± 4.57 2.26 ± 1.27 
 
Table 5.2.  Comparison of the average region-specific T1/T2 ratios for Rv1827 and Rv1827 pThr 22. 
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5.4.5 Unphosphorylated Rv1827 can exist in a ‘pre-bound’ conformation 
To investigate the possibility that the dynamic behavior of the N-terminal residues is the 
product of transient ordering within an otherwise unrestrained region, pThr 22 
phosphopeptide was titrated against non-phospho Rv1827 and 1H-15N chemical shift 
perturbations were monitored by NMR.  Upon phosphopeptide addition the chemical 
shifts of residues involved in phosphate binding recapitulate those of the Rv1827 pThr 
22 form.  However, residues 21-30 move to new locations in the 1H-15N-HSQC 
spectrum distinct from those in either the un-modified or modified protein spectra 
(Figure 5.9).  This suggests that phosphopeptide interactions with the FHA domain 
induce changes in the chemical environment of these residues, presumably by 
displacement.  It is therefore proposed that, rather than acting to tether a disordered N-
terminal region, Thr 22-phosphorylation appears to stabilise a pre-existing but low 
occupancy association of residues 21-30 with the FHA domain (Figure 5.9).   This 
explains a small but consistent decrease in apparent affinity observed for binding of pThr 
22 and pThr 21 phosphopeptides to full-length un-phosphorylated Rv1827 as compared 
to the N-terminally truncated FHA domain alone (Nott et al., 2009).  It additionally 
provides a rationale for the increased KGD and GDH inhibition also apparent in 
enzyme assays following deletion of residues 1-54 (Nott et al., 2009). 
 
5.5 Conclusions 
A combination of biochemical, biophysical and hydrodynamic analyses have shown that, 
upon phosphorylation by PknB at Thr 22, Rv1827 undergoes a novel intra-molecular 
conformational compaction.  This yields significant proteolytic protection at a site four 
(or in the case of PknG-phosphorylation five) residues C-terminal of the  
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Figure 5.9.  Unphosphorylated Rv1827 can exist in a ‘pre-bound’ conformation.  top  Comparison 
of an equivalent region of the 1H-15N HSQCs of Rv1827 (blue, left) and Rv1827 after addition of 2.5 
molar equivalents of pThr 22 peptide (green, right).  Resonances of F25, R26 and A27 in the 
unphosphorylated (blue filled circles) and pThr 22 (red filled circles) forms are labeled.  The new 
resonances of F25 and R26 upon addition of phosphopeptide are indicated with arrows.  Addition 
of phosphopeptide displaces A27 to a new, unknown location.  bottom  Cartoon representing 
Rv1827 in the unphosphorylated, pThr 22 and pThr 22-peptide bound conformations (blue, red 
and green with pink, respectively). 
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phosphorylation site.  The resultant intramolecular binding substantially increases the 
thermal stability of the molecule.  It appears also that a small region of α-helix is 
stabilized as evidenced by the change in CD signal at ~202 nm. 
 
NMR chemical shift perturbation mapping suggests that the phosphate binding site is 
formed by the residues most highly conserved in other studied FHA domains, namely 
Arg 81, Ser 95, Asn 117 and Lys 141.  T1, T2 and 1H-15N NOE relaxation measurements 
show that regions of high mobility are apparent at the extreme N- and C-termini and the 
34-54 region, while residues around pThr 22 display dynamic behavior identical to that of 
the core FHA domain.  Remarkably, restricted (though still significant) internal motion is 
also observed for the N-terminal region in the non-phosphorylated form. 
 
We conclude that interactions in the 'prebound' form resemble those observed in the 
final 'closed' conformation, and contribute to the overall stability of intra-molecular 
binding in the phosphorylated protein (Figure 5.10).  Through these conformational 
effects, the phosphorylated N-terminal region appears to function as a molecular 'off' 
switch enabling robust competition for FHA domain interactions with target enzymes as 
shown in Figure 4.1.  This suggests that the surface used by the FHA domain to interact 
with its metabolic targets may be partially coincidental with the extended surface used for 
intramolecular phosphate binding. 
 
The next chapter will describe the methodology that was used for solving the solution 
structure of Rv1827 pThr 22 and present a description of the final ensemble of 
structures. 
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Figure 5.10.  Model of conformation exchange upon phosphorylation.  In the unphosphorylated 
state, Rv1827 appears to conformationally exchange between a ‘pre-bound’ form in which the N-
terminus is associated with the FHA domain and an ‘un-bound’ form in which the N-terminus is 
unrestrained.  When Rv1827 is phosphorylated by either PknG or PknB, a tight intramolecular 
association of the N-terminus with the FHA domain is induced.  This intramolecular association 
abrogates interactions of the FHA domain with its metabolic binding partners. 
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6 Solution structure of Rv1827 pThr 22 
6.1 Overview 
In order to understand the effect of phosphorylation of Rv1827 at the molecular level, 
the solution structure of Rv1827 pThr 22 was solved by NMR spectroscopy and a model 
of the unphosphorylated form was generated for comparison.  A combination of manual 
and automatic procedures were employed for the structure determination of Rv1827 
pThr 22.  Manual structure calculations were performed using constraints derived from 
1H-13C- and 1H-15N-NOESY spectra, hydrogen bonds that were inferred from 2H-
exchange experiments and backbone torsion angle restraints derived from TALOS 
(Torsion Angle Likelihood Obtained from Shift and sequence similarity).  ARIA 1.2 was 
used for automatic structure calculation using unassigned peak lists, chemical shift 
assignments and hydrogen bond information defined in the manual calculations.  1H-15N 
relaxation data were additionally used in a final step of structure refinement.  The quality 
of calculated structures was checked using PROCHECK-NMR and assessed manually 
against known structures of other FHA domains. 
 
6.2 Structure determination methodology 
6.2.1 Prediction of secondary structure 
The initial structural characterization of Rv1827 pThr 22 began with prediction of the 
secondary structure.  NMR was used to predict secondary structure as the chemical shift 
of backbone atoms is sensitive to the torsion angles either side of the Cα atom.  For each 
amino acid the torsion angle between the backbone amide (NH) and the Cα atom is the 
phi (Φ) angle and the torsion angle between the Cα atom and the backbone carbonyl 
(CO) is the psi (Ψ) angle.  Residues in regions of α-helical secondary structure have 
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characteristically different Φ and Ψ torsion angles to residues in parallel and anti-parallel 
β-sheets.  For example, the Cα chemical shifts of residues in α-helices have typically up-
field shifted resonances compared to random coil values and those in β-sheets have 
typically down-field shifted resonances. 
 
The secondary structure of a protein can be predicted by trying to match the backbone 
chemical shifts of amino acid triplets against those of known secondary structure.  The 
program TALOS does this by trying to find statistically significant matches in a database 
of ~24000 triplets.  If significant matches are found, TALOS predicts the Φ and Ψ 
torsion angles of the amino acid at the centre of each amino acid triplet. 
 
TALOS incorporates the assignments of 15N(1H), 1H(15N), 13Cα, 13Cβ, 1Hα and 13C(O) 
chemical shifts of each amino acid for secondary structural prediction.  Consequently 
greater coverage of assignment results in more accurate predictions.  Table 6.1 shows a 
comparison of the proportion of complete backbone assignments (of 15N(1H), 1H(15N), 
13Cα, 1H α and 13C(O)) of unphosphorylated Rv1827 and the PknB-phosphorylated form.  
These assignments were obtained as described in section 3.2.3.  The highest proportion 
of assignment was made over the most ordered regions of the two forms of Rv1827. 
 
  Rv1827 Rv1827 pThr 22 
 Total atoms Number unassigned 
% 
assignment 
Number 
unassigned 
% 
assignment 
Full length (-4-162) 843 119 85.9 45 94.7 
Residues 20-149 
(structure) 656 61 90.7 13 98.0 
Core residues  
(20-25, 55-149) 510 34 93.3 7 98.6 
 
Table 6.1.  Backbone assignment of Rv1827 and Rv1827 pThr 22.  Backbone atoms are defined as 
15N(1H), 1H(15N), 13Cα, 1Hα and 13C(O). 
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Figure 6.1.  Secondary structural prediction of Rv1827 pThr 22 by the program TALOS.  top  
Residues for which significant matches of Phi (orange) and Psi (red) torsion angles were made 
using TALOS.  bottom  Secondary structure predicted by Phi and Psi torsion angles.  Regions of 
β-strands are shown in blue and regions of α-helix/turns are shown in green.  The FHA domain of 
Rv1827 is largely predicted to consist of β-strands. 
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Figure 6.1 (A) shows the TALOS predictions of Φ and Ψ torsion angles of Rv1827 pThr 
22 for residues for which at least nine matches were found.  Figure 6.1 (B) shows the 
secondary structural predictions for matched residues, and have been catagorised into 
predicted β-strands and α-helices.  Residues 55 to 145 were predicted to predominantly 
form β-strands.  The short stretches of predicted α-helices were hypothesized to form 
loops between β-strands.  Interestingly, a short region of β-strand is predicted between 
pThr 22 and Val 24, suggesting that residues around the phosphorylation site form an 
extended conformation similar to those seen in other FHA-phosphopeptide complexes 
(Byeon et al., 2005; Li et al., 2004).  A residue at the pThr + 8 (Leu 30) is predicted to 
reside in a region of α-helix, although statistically significant matches were not found for 
residues N- and C-terminal to it.  In support of the 15N relaxation data discussed in 
section 5.4.3, no secondary structure was predicted for the termini of the protein or the 
region between Leu 30 and the Ser 55 due to the high internal mobility of these regions. 
 
For the structural calculations presented in the following sections TALOS-derived Φ and 
Ψ torsion angle restraints were incorporated with a TALOS error of 10o and a TALOS 
factor of 2.  It was decided that TALOS predictions for pThr 22, Ser 23 and Val 24 
should not be included in calculations as the presence of the phosphate group on pThr 
22 could potentially cause chemical shift perturbations of the backbone atoms of these 
residues not related to secondary structure.  Another motivation for not including these 
residues was that modified residues are not represented in the TALOS database of amino 
acid triplets. 
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6.2.2 Hydrogen bond restraints 
The introduction of hydrogen bond restraints to structure calculations can be useful.  
They help to define the secondary structure of the protein at an early stage in the 
calculations so that possible ambiguity in other restraints does not become a limiting or 
biasing factor in structure refinement.  Hydrogen bond restraints were included in all but 
fully automatic structure calculations.  37 hydrogen bonds were inferred from a 
combination of a 2H exchange experiment and 1Hα-1Hα NOEs identified in 1H-13C-
NOESY spectra.  The results of the 2H exchange experiment are represented in Figure 
6.2, which shows the Rv1827 pThr 22 1H-15N-HSQC spectrum coloured according to 
how quickly backbone amide protons exchanged with 2H from the solution upon 
dissolution of the lyophilized protein in 100% 2H2O.  Amide protons that exchanged 
within 2 min. are coloured green and those that exchanged between 2min. and 17 hours 
are coloured orange.  Those that had not exchanged after 17 hours in 100% 2H2O are 
coloured red and were assumed to be engaged in long-lived hydrogen bonds. 
 
In the context of a secondary structure composed mostly of anti-parallel β-strands the 
unambiguous identification of inter-strand 1Hα-1Hα NOEs was used to define the register 
of β-strands in the β-sheets.  From these data, candidate inter-strand hydrogen bonds 
were inferred.  If a non-exchanging amide proton was identified from the 2H exchange 
experiment along with the corresponding unambiguous reciprocal 1Hα-1Hα NOE 
relationship for the 1Hα of the same residue, a hydrogen bond restraint between that 
amide group and the backbone carbonyl of the adjacent residue of the adjacent strand 
was included in calculations.  In order to maintain the co-linearity of the hydrogen bonds 
the distance between the carbonyl oxygen and the amide proton was set to 2.1 ± 0.5 Å  
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Figure 6.2.  Annotated 1H-15N HSQC spectrum of Rv1827 pThr 22 coloured according to the results of 
the 2H exchange experiment.  Peaks that exchanged within 2 minutes are coloured green.  Peaks that 
exchanged within 17 hours are coloured orange and those that did not exchange within 17 hours are 
coloured red.  Peaks folded in the 15N-dimension are shown as hollow contours.  Assigned δ-NH2 
(asparagine) and ε-NH2 (glutamine) pairs are linked with horizontal bars.  The inset at the lower right 
of the spectrum corresponds to the crowded regions in the center.  pThr 22 is highlighted with a red 
ellipse.  Unassigned peaks are not annotated. 
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and the distance between the carbonyl oxygen and the amide nitrogen was set to 3.0 ± 
0.5 Å.  Consequently 74 hydrogen bond restraints for 37 hydrogen bonds between β-
strands were included in total.  Two hydrogen bond restraints of the same distance were 
included between the Hε and Nε of Arg 81 and the carbonyl of Val 94 as a hydrogen 
bond at this position has been observed in all FHA-phosphopeptide complex crystal 
structures solved to date. 
 
Three hydrogen bond restraints were included between the phosphorus atom of pThr 22 
and the hydroxyl group of Ser 95, the backbone amide of Arg 96 and the terminal NH2 
group of Arg 81.  These are three conserved FHA domain-phosphopeptide hydrogen 
bonds and are shown in detail in Figure 1.5 for the Rad53 FHA1-phosphopeptide 
complex crystal structure.  The phosphorus atom was chosen instead of its individual 
phosphate oxygens so as not to influence the sidechain dihedral angles of the pThr 
residue in structure calculations.  The distance between the phosphorus atom and the 
respective hydrogen bonding protons was set as 3.1 ± 0.5 Å.  The distance between the 
hydroxyl oxygen of Ser 95 and the phosphorus atom was set as 4.0 ± 0.5 Å, as were the 
distances between the nitrogen of the Arg 96 backbone amide and the nitrogen of the 
Arg 81 terminal NH2 group. 
 
In the available crystal structures of FHA domain-phosphopeptide complexes these three 
FHA domain residues engage in conserved hydrogen bonds with the oxygen atoms of 
the phosphate group in the pThr ligand.  However, as no stereochemical information was 
obtainable about the phosphate oxygens in pThr 22, hydrogen bond restraints between 
the phosphorus atom and FHA domain residues were included instead.  This left free 
rotation around the chi2 and chi3 bonds of pThr 22. 
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6.2.3 Resonance assignment of Rv1827 pThr 22 
Through analysis of the various triple resonance spectra outlined in sections 3.2.3 and 
3.5.1, the assignment of Rv1827 pThr 22 backbone and side chain resonances was 
achieved.  In total, Rv1827 pThr 22 contains 1962 potentially assignable atoms.  
Assignment of several subsets of atoms such as the sidechain NH2 groups of Arg 
residues, Lys NH3+ groups and in many cases the hydroxyl protons of Ser and Thr 
residues, assignment was not possible.  Additionally, the protons of methylene groups 
were not stereo-specifically assigned in any cases.  If it was not possible to stereo-
specifically assign the resonances of sidechain proton pairs due to spectral resolution (or 
overlapping resonances), the same 13C and 1H chemical shifts were assigned to each (in a 
form of pseudoatom correction). 
 
Shown in Table 6.2 is the proportion of assignments made for different regions of 
Rv1827 pThr 22 across all assignable atoms.  No pseudoatom groups are included so the 
total number of atoms is non-redundant. 
 
 Rv1827 pThr 22 
 Total atoms unassigned % assignment 
Full length 
(-4-162) 1962 318 83.8 
Residues 20-149 
(structure) 1553 188 87.9 
Core residues 
(20-25, 55-149) 1242 155 87.5 
 
Table 6.2.  Non-redundant assignment statistics for Rv1827 pThr 22. 
 
6.2.4 Automatic versus manual structure determination 
For all the ensembles of structures presented in the following sections the N-terminal 19 
residues and the C-terminal 12 residues of Rv1827 pThr 22 have been omitted for clarity.  
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Figure 6.3 (A) shows the scheme with which the ensembles of structures in this section 
are coloured. 
 
Initial solution structure calculations of Rv1827 pThr 22 were performed automatically 
using ARIA 1.2 (Linge et al., 2003).  These calculations incorporated the complete set of 
resonance assignments for Rv1827 pThr 22, TALOS-derived Φ and Ψ torsion angle 
restraints and complete peak lists from the 1H-15N-NOESY spectrum (recorded in 10% 
2H2O) and 1H-13C-NOESY spectra (one recorded in 10% and the other recorded in 
100% 2H2O).  Distance calibration of peak intensities for the respective spectra was 
carried out as described in section 3.5.2.  Figure 6.3 (B) shows the 20 lowest energy 
structures calculated automatically out of 50 water-refined structures.  A poor degree of 
convergence is observed for the FHA domain (residues 55-149, black).  The 35 residues 
N-terminal to it are un-converged and appear bunched up against the N-terminal end of 
the domain with no discernable secondary or tertiary structure.  The number of 
unambiguous and ambiguous restraints (categorized by type and distance) used in these 
calculations are shown in Table 6.3. 
 
  intra. seq. med. long Total 
unambiguous 1227 656 218 696 2797 
ambiguous 369 248 142 501 1260 automatic 
all 1596 904 360 1197 4057 
       
manual all 1039 69 73 893 2074 
       
unambiguous 1190 610 218 824 2842 
ambiguous 416 267 154 554 1391 
automatic 
and 
manual all 1606 877 372 1378 4233 
 
Table 6.3.  Comparison of the number of unambiguous and ambiguous restraints incorporated in 
structure calculations automatically and manually when used in isolation (top and middle) and 
combined (bottom).  intra. (intra-residue), seq. (sequential, i → i+1), med. (medium, ≤ i → i+4) 
and long (≥ i → i+5). 
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For comparison, Figure 6.3 (C) shows the 20 lowest energy structures calculated from 
manually derived NOE distance restraints (summarized in Table 6.3), hydrogen bond 
restraints and TALOS-derived Φ and Ψ torsion angle restraints.  Again, residues 
comprising the FHA domain are poorly converged.  The region N-terminal to the FHA 
domain is now distributed over a greater area as a result of the addition of hydrogen 
bonds constraining the phosphorus atom of pThr 22 to Ser 95, Arg 96 and Arg 81.  
However, no discernable secondary or tertiary structure is present around the site of 
phosphorylation.   
 
Significantly higher convergence over the FHA domain was achieved by combining the 
distance restraints manually-derived from the NOESY spectra, hydrogen bonds and 
TALOS-derived Φ and Ψ torsion angles with complete resonance assignments and 
unassigned peak lists (Figure 6.3, D).  A higher degree of convergence was also observed 
for pThr 22, Ser 23 and Val 24.  Under these circumstances the residues between the 
phosphorylation site and the FHA domain were more constrained as they were 
effectively ‘tethered’ at the N- and C-terminal ends.  Despite low convergence, residues 
in this linking region followed a path predominantly across one face of the FHA domain 
by doubling back over the phosphorylation site.  The Φ and Ψ torsion angle restraints 
for Leu 30 are partly responsible for this U-turn in direction along with an intense and 
overlapped 1H-13C NOESY peak between Ala 27 and Arg 97 that was assigned 
unambiguously (yet erroneously) by ARIA. 
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Figure 6.3.  Manual versus automatic structure calculation of Rv1827 pThr 22.  (A)  Schematic 
showing the colouring used in the images below.  The extreme N- (1-19) and C-terminal (150-162) 
residues (grey) have not been included in the structure pictures for clarity.  (B)  Ensemble of 
Rv1827 solution structures calculated automatically by ARIA 1.2.  (C)  Ensemble of Rv1827 
structures calculated using manually-derived distance restraints and hydrogen bonds.  (D)  
Ensemble of Rv1827 structures calculated using both manually-derived and automatic procedures. 
A
B
C
D
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 6.3 Structural refinement  
6.3.1 Identification of unambiguous NOESY-derived distance restraints 
An iterative process of structure calculation and manual evaluation of distance restraints 
derived from NOESY peak lists facilitated refinement of Rv1827 pThr 22 solution 
structures.  A set of manually assigned unambiguous NOESY-derived restraints was 
iteratively used in structure calculations incorporating full NOESY peak lists to 
automatically extract more NOESY-derived restraints that were then evaluated manually 
for ambiguity.  If judged unambiguous these new restraints were added to the initial list 
of restraints and the process was repeated until convergence was reached in which no 
more NOESY peaks could be unambiguously assigned as distance restraints (Table 6.4). 
 
  Intra. seq. med. long Total 
unambiguous 1156 561 216 844 2777 
ambiguous 444 286 157 657 1544 
refined 
automatic 
and manual all 1600 846 373 1501 4320 
 
Table 6.4.  Comparison of the proportion of the total ambiguous and unambiguous distance 
restraints of different types derived from NOESY spectra.  intra. (intra-residue), seq. (sequential, i 
→ i+1), med. (medium, ≤ i → i+4) and long (≥ i → i+5). 
 
Application of this iterative procedure revealed the ensemble of 20 lowest energy 
structures shown in Figure 6.4.  A high degree of convergence is evident across the FHA 
domain and in the pThr 22 to +3 position.  Significant convergence is also present in the 
linker region, and shows it following a narrow path across one face of the FHA domain.  
Such high convergence in what is demonstrably a region of high internal mobility was 
reasoned to be an inappropriate in silico over-interpretation.  The implications of this are 
discussed in detail in the next section. 
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Figure 6.4.  Ensemble of solution structures of Rv1827 pThr 22 calculated using the final set of 
distance restraints and automatic procedures.  top  Schematic showing the colouring of the 
ensemble of structures (same as in Figure 6.3).  bottom  Ensemble of Rv1827 pThr 22 solution 
structures, showing a high degree of convergence across the FHA domain (black) and the linker 
region (orange). 
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 6.3.2 Restraint evaluation and thresholding using 15N relaxation profiles 
NMR-based relaxation measurements give a powerful insight into the internal molecular 
motion of the protein backbone.  As discussed in section 5.4.3 and shown in Figure 5.7, 
the T2 and 1H-15N NOE relaxation profiles of Rv1827 pThr 22 show that the site of 
phosphorylation binds to the FHA domain and becomes as relatively inflexible as it.  
However, the N- and C-termini are highly mobile and the linker region (residues 25-54) 
has a peak of internal mobility centered on Gly 40.  As the extreme termini have 
apparently no intrinsic structure, correlated with the identification of no medium- to 
long-range NOEs, they were not incorporated into further calculations. 
 
Dealing with the linker region presented an interesting challenge.  It was reasoned that 
distance restraints for residues with a long T2 relaxation time (in excess of 150 ms, 
corresponding to 1H-15N-NOE enhancement values lower than 0.3) ought to be treated 
in the same way as the termini, and discarded.  This corresponded to the 12 most highly 
mobile residues of the linker region (residues 35-46).  As with the termini of the protein 
only intra-residue and sequential NOEs were identified in this region. 
 
The explanation for the over-interpretation of data in automatic structure calculation 
procedures (resulting in the ensembles shown in Figure 6.4) lies in the nature of NOESY 
experiments.  The cross-relaxation of dipolar-coupled spins becomes less efficient with 
increased distance between the spin systems according to r-6.  NOEs of atoms in highly 
mobile regions of a molecule arise as a result of the cross-relaxation of dipolar-coupled 
spins that are constitutively close in space, but without containing structural information.  
These are observed predominately as intra-residue and sequential NOEs which, as these 
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spin systems are necessarily close in space, produce intense resonances due to a high 
degree of conformational averaging.  In distance calibration of the spectra, these in turn 
are attributed the tightest distance restraints in structure calculations.  So far so good: 
intra-residue NOEs have no long-range structural significance and so will not bias 
structure calculations.  Not quite.  What about the overlap in resonances in highly mobile 
regions?  Here, the chemical shifts of atoms approach their random coil values and the 
resonances of subgroups of atoms of residues of the same type are consequently 
considerably more overlapped than in ordered regions of the molecule.  This poses a 
problem.  Overlapped intra-residue and sequential NOEs can be equally well interpreted 
in automatic structure calculation as highly weighted medium- and long-range structural 
constraints between residues of the same or similar types. 
 
If these peaks are removed from peak lists, yet the chemical shifts of atoms they 
correspond to remain in the assignments table, automatic assignment and structure 
calculation will continually try to find new assignments for them.  If the peaks remain in 
the peak lists and the atoms are removed from the chemical shift table, they may be 
assigned incorrectly to other atoms. 
 
Both the peaks and the corresponding atom chemical shifts must be omitted from 
automatic structure calculations in order to mitigate the potentially misleading effects of 
automatic erroneous assignment of these types of resonances.  Conceptually this is 
simple to understand, but practically untenable due to the possibility of human error in 
the evaluation of NOESY spectra that may contain thousands of peaks.  In other words 
asking a person to completely assign a NOESY spectrum and then selectively remove 
resonances that have been judged by another empirical method to be too highly mobile 
to be relevant for structure calculations is very error prone. 
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 Another way to deal with this issue is evaluation at the restraint level, not the peak and 
chemical shift lists level.  In an idealized situation, NOESY spectra used for structure 
calculation would not contain overlapped resonances and consequently each atom of a 
molecule would have a unique chemical shift.  If this were the case, automatic resonance 
assignment and structure calculation could unambiguously derive a set of non-violating 
restraints to describe the molecule.  Therefore in an ideal world there would be 
equivalence between the peak lists plus the chemical shifts and the set of restraints that 
satisfy them. 
 
As Rv1827 pThr 22 has been demonstrated to exhibit high internal mobility at the 
termini and in the region between ~Leu 30 and Ser 55, automatic in silico procedures for 
structure calculation encountered many of the problems outlined above.  Therefore at 
the stage where more unambiguous restraint information could not be extracted from the 
respective NOESY spectra, NOE-derived distance restraints were manually evaluated in 
light of the relaxation data described previously, and subsequent calculations were carried 
out in the absence of peak lists.  By this method a molecular model of the protein that 
satisfied all the available empirical data could be generated without at every step 
reintroducing ambiguity and bias from the mobile regions of the molecule. 
 
Several unambiguous medium- and long-range NOEs were identified for residues 27-34 
and 48-54.  These two regions lie at the N- and C-terminal ends of the linker.  The T2 
and 1H-15N NOE relaxation characteristics over these regions appear to be neither as 
ordered as the core of the molecule, nor as disordered as the center of the linker or the 
termini.  Interestingly, the amino acid sequences of these regions are highly conserved in 
Rv1827 homologues in the actinomycetes.  We reasoned therefore that identifying local 
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secondary structure in these regions would aid our understanding of how to incorporate 
information about them into subsequent structural refinement.  The strategy that was 
employed involved characterizing intra-regional distance restraints defining secondary 
structure and then long-range distance restraints between the respective regions and the 
FHA domain.  These regions are represented in cyan in Figure 6.5. 
 
Residues between Ala 27 and Asp 34 were characterized to form a region approximating 
a short stretch of helix.  Unambiguous i → i+4 NOEs were identified between Phe 29 
and Leu 33 and suggested that a canonical α-helix was present.  However, i → i+6 NOEs 
between Arg 26 and Ala 32 and i → i+7 NOEs between Arg 26 and Leu 33 made it clear 
that this region did not form an α-helix, but a region with less well defined helical 
propensity.  This region will now be referred to as H1.  These findings agreed with the 
nature of the TALOS Φ and Ψ torsion angle predictions for Leu 30, which is at the 
centre of this region.  Despite the high sequence conservation for the 7 residues 
immediately N-terminal to the FHA domain, no intra-regional NOE relationships were 
identified that stabilized any discernable secondary structure in this region.   
 
Next, distance restraints between H1 and residues on the FHA domain were evaluated 
for ambiguity.  A set of 16 unambiguous distance restraints were identified that 
orientated H1 with respect to the FHA domain.  Several FHA domain residues were 
identified that made multiple contacts with H1.  NOE relationships between Gln 138 
and Ala 27, Phe 29 and Leu 33 suggested that this residue was important not only for the 
H1-FHA interaction, but also for stabilizing intra-regional interactions within H1 itself.  
Long-range NOEs between Ala 27 and Lys 141 and also Glu 32 and Arg 143 suggested 
that basic residues on the FHA domain were also important for maintaining the H1-FHA  
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Figure 6.5.  Restraint thresholding of Rv1827 pThr 22 solution structure calculations using T2 and 
NOE relaxation profiles.  (A)  Schematic showing the regions of Rv1827 in which different 
thresholding procedures were employed (red: no distance restraints, cyan: intra-regional distance 
restraints, black: all distance restraints).  (B)  Ensemble of solution structures from Figure 6.4, 
coloured according to the schematic in (A).  (C)  Rv1827 pThr 22 T2 (left) and NOE (right) relaxation 
profiles coloured according to the schematic in (A).  (D)  Ensemble of Rv1827 pThr 22 solution 
structures produced by applying the distance restraint thresholding procedure, coloured according to 
(A).  By being un/less-restrained, residues in the linker region explore more conformational space, 
reflecting their high internal mobility. 
133
domain association.  NOEs between the aromatic ring of Phe 29 and the 1Hβ protons of 
Asn 117 were also unambiguously assigned.  This is an interesting observation as Asn 
117 is one of the most highly conserved FHA domain residues, and annotated as a 
residue critical for phosphopeptide-binding.  In the available structures of FHA domains 
in complex with phosphopeptide ligands Asn 117 is engaged in hydrogen bonds with the 
pThr +2 or +3 residue.  However, in the intramolecularly bound form of Rv1827 pThr 
22, Asn 117 makes contacts with the aromatic ring of the pThr + 7 residue as well as side 
chain interactions with Val 24 and Phe 25. 
 
At the C-terminal end of the linker region NOE relationships were identified between 
residues 51 to 54 and residues 148 and 149, which form the C-terminal end of the final β-
strand of the FHA domain.  However, identification of these long-range NOEs is 
unsurprising since Ser 55 is the first residue of the N-terminal β-strand of the FHA 
domain, and is adjacent and anti-parallel with Thr 148 and Gly 149.  Therefore the C-
terminal end of the linker is necessarily close in space to these residues of the FHA 
domain and the NOE relationships appeared to be of no structural significance. 
 
After removal of all ambiguous distance restraints and the restraints involving regions 
coloured red in Figure 6.5 (A, B and C), the final proportions of distance restraints used 
to calculate the final ensembles of Rv1827 pThr 22 structures are summarized in Table 
6.5.  Removal of restraints according to the scheme in Figure 6.5 (C) yielded the 
ensemble of structures shown Figure 6.5 (D).  Both sets of ensembles in Figure 6.5 are 
coloured with the same scheme to highlight the effect of completely removing restraints 
involving residues 35-46 on the convergence of the linker. 
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  intra seq. med. long Total 
Final 
restraints 659 385 179 775 1998 
 
Table 6.5.  Summary of final NOE-derived distance restraints for Rv1827 pThr 22 after restraint 
thresholding.  intra. (intra-residue), seq. (sequential, i → i+1), med. (medium, ≤ i → i+4) and long 
(≥ i → i+5). 
 
6.4 Rv1827 pThr 22 solution structure evaluation 
Statistical analyses of the ensemble of the 20 lowest energy solution structures of Rv1827 
pThr 22 are described in section 9.8, Table 9.1 and Figure 9.1 of the appendix section.  
Presented in this section is a more qualitative analysis, focused on a molecular model of 
Rv1827 pThr 22 that satisfies all the available empirical data.  As discussed in sections 
5.4.3 and 5.4.4, T1, T2 and 1H-15N NOE relaxation profiles have provided significant 
insight into the internal molecular mobility of the unphosphorylated and PknB-
phosphorylated forms of Rv1827.  Additionally they have provided a rational basis on 
which to selectively manipulate NOESY-derived distance restraints (section 6.3.2) so that 
the calculated ensembles of conformations reflect both core structure and highly 
dynamic regions of the molecule.  However, as non-standard methodology was 
employed, careful evaluation of the molecular model must follow. 
 
6.4.1 Qualitative analysis and structure validation 
A caveat of x-ray crystallography as an experimental technique for describing molecular 
structure is that a crystal structure does not display dynamic information about the 
molecule, and necessarily so.  A high resolution crystal structure therefore represents a 
snap-shot in time of the molecule under investigation.  On the other hand NMR is 
amenable to the study of protein dynamics at atomic resolution, but a problem is still 
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encountered when viewing an ensemble of solution structures one molecule at a time. 
One molecule from an ensemble of solution structures contains no intrinsic information 
about the other molecules of the ensemble.  This is especially problematic when a protein 
is known to have high internal mobility in specific regions.  In this case it is important to 
keep in mind that any one molecule is unrepresentative of the conformational space 
capable of being explored by its highly dynamic regions.  Therefore viewing ensembles of 
solution structures can be far more informative in giving the viewer a description of the 
regions with high and low internal motility.  This description derives from the level of 
convergence of regions of the molecules in an ensemble.  In ensembles of solution 
structures a higher degree of convergence is correlated with higher proportions of non-
violating, unambiguous distance restraints used in calculations.  It follows that higher 
convergence effectively represents there being an increasingly restricted set of 
conformations capable of satisfying the set of distance restraints.  Conversely, the fewer 
the restraints there are, the greater the conformational space capable of being explored in 
simulated annealing calculations. 
 
Both of these effects have been incorporated into the calculation of solution structure 
ensembles of Rv1827 pThr 22.  A high degree of convergence is observed for the FHA 
domain (residues 55-149) and the pThr 22 to + 3 region (residues 22-25).  The pairwise 
r.m.s. deviation from the mean structure calculated among the 20 lowest energy 
structures out of 50 refined structures over these core regions for backbone atoms is 0.64 
± 0.09 Å.  However, necessarily poor convergence is present in the linker region 
(residues 26-54).  As discussed in sections 5.4.3 and 6.3.2 the peak of internal mobility of 
the linker is centered on Gly 40, with the T2 relaxation profile clearly showing that 
internal mobility decreases on either side back to core levels over approximately 13 
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residues (Figure 5.7, B and Figure 6.5, B).  Consequently this trend ought to be 
recapitulated in the ensemble of structures representing Rv1827 pThr 22. 
 
Figure 6.6 (A, left) shows the pairwise r.m.s. deviation from the mean structure calculated 
among the 100 lowest energy structures out of 500 refined structures for backbone 
atoms.  By increasing the number of structures generated, a greater amount of 
conformational space can be sampled by the linker region in the ensemble.  However, in 
doing this the pairwise r.m.s. deviation from the mean structure over core regions is 
driven down to potentially unrealistic accuracy (0.33 ± 0.20 Å for residues 22-25 and 55-
149).  Nevertheless, the highest pairwise r.m.s. deviation from the mean structure for the 
linker region is centered approximately on Gly 40, recapitulating the T2 relaxation profile.  
Figure 6.6 (A, right) shows the ensemble of Rv1827 pThr 22 solution structures coloured 
according to the pairwise r.m.s. deviation from the mean structure.  Colour ranges of 
≤0.1 Å r.m.s. deviation (minimum, blue) and ≥7.5 Å r.m.s. deviation (maximum, red) 
were used to colour the residues of the molecules in the ensemble. 
 
An easier way to understand the colour mapping is that the most highly converged 
residue on the core is blue and residues with a pairwise r.m.s. deviation from the mean 
structure equal to or greater than the 5 most highly disordered residues of the linker are 
in red.  Intermediate levels of convergence are colour-graded in a rainbow spectrum 
(from blue, turquoise, green, yellow and orange to red.  Figure 6.6 (B, left and C, left) 
show the T2 and 1H-15N NOE relaxation profiles of Rv1827 pThr 22 coloured according 
to the same scheme as the pairwise r.m.s. deviation from the mean structure.  Residues 
with T2 relaxation rate constants ≤48 ms are blue and those ≥230 ms are red.  Residues 
with 1H-15N NOE enhancements ≤0.05 are the reddest and those ≥0.85 are the bluest.   
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Figure 6.6.  Qualitative evaluation of the Rv1827 pThr 22 ensemble of 20 lowest energy structures.  
Structures are the same as those in Figure 6.5 (D).  (A)  r.m.s. deviation calculated over backbone 
atoms for the ensemble of solution structures (left) and the ensemble of structures coloured according 
to the r.m.s. deviation (≤ 0.1 Å blue, ≥ 7.5 Å red) (right).  (B)  T2 relaxation profile of Rv1827 pThr 22 
and the ensemble of structures coloured according to T2 relaxation (≤ 45 ms blue, ≥ 230 ms red).  (C)  
NOE relaxation profile of Rv1827 pThr 22 and the ensemble of structures coloured according to NOE 
enhancement (≤ 0.05 blue, ≥ 0.85 red). 
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Again, the colours have been transposed onto the structures to the right of the respective 
relaxation profiles.  This makes it easier to see how well the pairwise r.m.s. deviation 
from the mean structure of the ensemble reflects the relaxation data. 
 
The FHA domain and the N-terminal phosphorylation site clearly show the highest 
convergence (blue) and the centre of the linker region clearly shows the lowest 
convergence (red).  When coloured according to the relaxation data, the increased 
internal mobility of the H1 region with respect to the core is highlighted (by cyan to 
yellow colouring), although not absolutely reflected by the pairwise r.m.s. deviation from 
the mean structure, where it is more blue.  This difference highlights the difficulty of 
generating a molecular model that satisfies all facets of the empirical information about a 
biological molecule. 
 
6.4.2 Qualitative description of the solution structure of Rv1827 pThr 22 
The FHA domain of Rv1827 is formed by residues 55-149.  They adopt a classical FHA 
domain fold comprising a compact 11-stranded β-sandwich topology.  This is shown in 
Figure 6.7.  Residues forming β-strands are coloured red in the ribbons representation in 
the top panel and are shown in red cartoon form in the middle panel.  No α-helical 
insertions are present in the loops between β-strands.  Therefore the short regions of 
TALOS-predicted α-helix within the FHA domain correspond to tight turns between the 
β-strands. 
 
The location and orientation of the most highly conserved N-terminal residues are well 
defined by a total of 65 long-range NOEs.  Overall, residues 21-33 adopt an extended 
conformation encompassing a short region of helical propensity (H1, blue).  This region  
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Figure 6.7.  Rv1827 pThr 22 final solution structures.  top  ribbons representation of Rv1827 pThr 22.  
β-strands are coloured red and loops between strands of the FHA domain are coloured white.  The H1 
region is coloured blue and pThr 22 is shown as sticks.  bottom  Cartoon and transparent surface 
representation of a representative structure of Rv1827 pThr 22.  β-strands are shown as red arrows and 
the H1 region as a blue cylinder.  Shown as sticks are pThr 22, Arg 81 and Ser 95. 
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follows a path across the FHA surface distinct from that previously observed in FHA-
phosphopeptide complex structures.  This difference is highlighted in Figure 6.8, which 
shows a comparison between the Rv1827 FHA domain interaction with its 
phosphorylated N-terminus and the Chk2-phosphopeptide complex (Li et al., 2002).  
The phosphorylated N-terminus of Rv1827 is orientated almost orthogonal with respect 
to the β-sandwich faces of the FHA domain compared to the phosphopeptide-FHA 
domain interaction in Chk2, which is approximately parallel.  It is difficult to predict 
whether the isolated Rv1827 FHA domain would bind a phosphopeptide inter-
molecularly in the same orientation as intra-molecularly.  It may be that association of the 
H1 region with a specific auxiliary surface on the FHA domain plays a significant part in 
orientating the extended conformation C-terminal to the phosphorylation site.  
Nevertheless, when phosphorylated by PknB the conserved residues of the N-terminus 
ultimately direct the subsequent ensemble of linker conformations along one side of the 
FHA β-sandwich. 
 
As previously mentioned, FHA domain selectivity for the residue pThr + 3 is a theme 
that has emerged from both the identification of in vivo phosphopeptide binding partners 
and in vitro phosphopeptide library screens.  Rv1827 is an interesting case in that two 
adjacent N-terminal threonines are specifically phosphorylated by two different kinases.  
When either threonine is phosphorylated, the pThr + 3 residue conforms to the 
preferred Rv1827 FHA domain selectivity criterion.  If Thr 21 is phosphorylated by 
PknG, Val 24 is the pThr + 3 residue and if Thr 22 is phosphorylated by PknB, Phe 25 is 
the pThr + 3 residue.  Both are relatively large, hydrophobic amino acids and it seems 
plausible that the binding orientation of the N-terminus would look extremely similar in 
either case.  Indeed this may explain the increased ability of trypsin to cleave Arg 26  
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Rv1827 Chk2
Arg 117
Ser 140
Asn 166Asn 117
Arg 81Ser 95
Figure 6.8.  Comparison of the phosphopeptide-binding orientations of Rv1827 and Chk2.  The FHA 
domains of Rv1827 and Chk2 are shown in cartoon representation with white loops connecting red β-
strands.  The respective phosphopeptide ligands are coloured cyan.  FHA domain residues important 
for phosphopeptide binding are shown as sticks, as is the pThr residue of the ligands.  Chk2 FHA 
domain binds phosphopeptides approximately parallel with the planarity of the β-sheets, whereas 
Rv1827 FHA domain binds its intramolecular phosphopeptide ligand almost orthogonal to the 
planarity of the β-sheets. 
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when Rv1827 is phosphorylated at Thr 21, by shifting the register of the extended 
conformation such that Arg 26 is less well constrained. 
 
6.5 A model of the ‘pre-bound’ conformation of unphosphorylated Rv1827 
It was suggested in section 5.4.1  that in the unphosphorylated state, the region of high 
sequence conservation within the N-terminus of Rv1827 associates with the FHA 
domain.  The occupancy of this ‘pre-bound’ state has yet to be characterized, but it is 
clear that the exchange regime between the completely unbound and pre-bound 
conformations does not substantially impede the high affinity association of the FHA 
domain with its target enzymes.  It was further proposed that conformations in the 
unphosphorylated, pre-bound state resemble those in the phosphorylated form, whereby 
interactions between H1 and the FHA domain stabilize the pThr 22 interaction with the 
phosphate binding site (Figure 5.10).  From this it seemed reasonable to imagine that the 
conformation of the H1 region in both the unphosphorylated pre-bound and 
phosphorylated forms of Rv1827 might be very similar. 
 
Based on this assumption, a model of the unphosphorylated, pre-bound conformation of 
Rv1827 was generated in order to help visualize this form of the protein.  For these 
calculations, distance restraints were based on those used to calculate the structures of 
Rv1827 pThr 22 presented in the previous sections.  However, all restraints were 
removed for residues N-terminal of Arg 26 (NOE-derived distance restraints and pThr-
FHA domain hydrogen bonds).  Additionally no statistically significant TALOS 
predictions were made for residues N-terminal of the FHA domain, supporting the lack 
of defined secondary structure.  The intra-regional restraints for the H1 region (shown as 
cyan in Figure 6.5 and described in section 6.3.2) were unchanged, as were the long-range  
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Figure 6.9.  Qualitative evaluation of the model of the ‘pre-bound’ form of unphosphorylated Rv1827.  
(A)  r.m.s. deviation calculated over backbone atoms for the ensemble of solution structures (left) and 
the ensemble of structures coloured according to the r.m.s. deviation (≤ 0.1 Å blue, ≥ 7.5 Å red) 
(right).  (B)  T2 relaxation profile of Rv1827 pThr 22 and the ensemble of structures coloured 
according to T2 relaxation (≤ 45 ms blue, ≥ 230 ms red).  (C)  NOE relaxation profile of Rv1827 pThr 
22 and the ensemble of structures coloured according to NOE enhancement (≤ 0.05 blue, ≥ 0.85 red). 
A
B
C
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distance restraints between H1 and the FHA domain.  The model generated is shown in 
Figure 6.9, and is coloured according to the same scheme and is in the same format as 
Figure 6.6.  The structures of the pre-bound form of unphosphorylated Rv1827 are 
aligned over residues 55-149 only.  This necessarily produced greater divergence in the 
H1 region and illustrates its weaker association with the FHA domain than in the 
phosphorylated form of the protein. 
 
As with the solution structures of Rv1827 pThr 22, colouring the ensemble of models of 
unphosphorylated Rv1827 according to the pairwise r.m.s. deviation from the mean 
molecule, T2 and 1H-15N NOE relaxation profiles, the differential internal mobility over 
various regions is easier to appreciate.  The FHA domain has extremely low internal 
mobility, and the peak of internal mobility of the linker region is centered on Gly 40.  
The H1 region adopts approximately the same intra-regional conformation as in the 
phosphorylated state.  This leads to an interesting hypothesis about the mechanism of 
phosphorylation of Rv1827 by PknB. 
 
We know that PknB activation loop phosphorylation is required for full kinase activity, 
and that the FHA domain of Rv1827 needs to bind to the phosphorylated activation 
loop to be phosphorylated N-terminally (Villarino et al., 2005).  The approximate 
distance between the activation loop phosphorylation sites and the catalytic site of the 
kinase domain is somewhere between 15-25 Å.  It is not possible to know for sure as the 
electron density in the crystal structures of PknB kinase domain is very poor in this 
region, suggesting high internal mobility.  This order of distance is remarkably similar to 
distances between the site of phosphate binding on the FHA domain and the location of 
Thr 22 in the unphosphorylated but pre-bound model of Rv1827.  It is suggested 
therefore that as the FHA domain docks onto the phosphorylated activation loop of the 
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PknB kinase domain, the H1 region effectively increases the local concentration of the 
phosphorylation target site (Thr 22) at the kinase domain catalytic site.  This would lead 
to more efficient phosphorylation of Thr 22 by PknB.  If the N-terminal 54 residues of 
Rv1287 were totally unrestrained in the unphosphorylated form, the FHA domain might 
be able to bind and dissociate from the PknB activation loop before the phosphorylation 
target site had found its way into the catalytic site of the kinase.  Under these 
circumstances, it is imagined that N-terminal phosphorylation of Rv1287 would be 
significantly less efficient. 
 
So, as well as providing extra stability once N-terminal phosphorylation has been 
achieved, it may be that latent association of the H1 region with the FHA domain may 
also promote efficient PknB-mediated phosphorylation. 
 
6.6 Conclusions 
The solution structure of Rv1827 pThr 22 demonstrates that N-terminal phosphorylation 
induces a novel intramolecular conformational compaction in Rv1827 whereby the N-
terminal phosphorylation site binds back to surface associated with canonical FHA-
phosphopeptide interactions.  The N- and C-terminal β-strands of the FHA domain run 
anti-parallel to each other such that the domain boundary is on the opposite side of the 
FHA domain from the phosphate-binding surface.  This means that in order for pThr 22 
to associate with the residues that hydrogen bond to the phosphate group (Arg 81, Ser 95 
and Arg 96), the linker region is directed across one of the β-sheets of the domain.  This 
results in an orientation of intramolecular phophopeptide binding that is almost 
orthogonal to that usually observed in FHA domain-phosphopeptide complexes. 
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Furthermore, interactions between the H1 region and the FHA domain help to stabilize 
the intramolecular association and go some way towards explaining the biochemical and 
biophysical observations outlined in chapter 3.  The N-terminal region of high sequence 
conservation forms an extended conformation that makes contacts with the FHA 
domain as far as the pThr + 11 position.  Thus upon phosphorylation the stabilization of 
Arg 26 (the pThr + 4 position) may explain its resistance to tryptic proteolysis and the 
stabilization of the H1 region may explain the small increase in CD signal at 202 nm that 
suggested the induction of a small region of helix. 
 
It is apparent that there are many caveats and pitfalls when calculating the solution 
structures of a molecule that contains regions of demonstrably high internal mobility, as 
evidenced in this case by 1H-15N-relaxation measurements.  Relying solely on automatic 
structure calculation procedures produced ensembles of structures that did not accurately 
reflect their internal mobility.  It was therefore deemed appropriate to apply restraint 
thresholding procedures manually such that the final ensemble of solution structures 
satisfied all of the available empirical data. 
 
The initial aim of this work was to understand the mechanism by which N-terminal 
phosphorylation of Rv1827 abrogates interactions of its FHA domain with its target 
metabolic enzymes.  The solution structure of the phosphorylated form and the model of 
the unphosphorylated form cannot achieve this, but importantly they can provide a 
rational for further investigation and experimentation.  The identification of the surfaces 
on the FHA domain of Rv1827 that are used to interact with the metabolic enzymes will 
be explored in the next chapter. 
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7 Identification of Rv1827 intermolecular interaction surfaces 
7.1 Overview 
Chapter 4 began with the identification of Rv1827 interaction partners in M. tuberculosis 
cell-free extracts and the observation that phosphorylation of Rv1827 at Thr 22 by PknB 
abrogated these interactions.  It was subsequently found that in its unphosphorylated 
form, Rv1827 is a potent inhibitor of the enzymes KGD and GDH, and it is an activator 
of the GS complex (Chapter 5) (Nott et al., 2009).  The phosphorylation state of Rv1827 
therefore has a significant impact on core biochemical processes surrounding α-
ketoglutarate metabolism and nitrogen assimilation in M. tuberculosis and the closely 
related actinomycetes. 
 
In order to understand the conformational changes that Rv8127 undergoes following N-
terminal phosphorylation, a detailed biochemical, biophysical, hydrodynamic and 
structural investigation of the unphosphorylated and phosphorylated forms of the 
protein was performed.  However, despite having several novel and interesting features, 
the solution structures could not fully explain how in the unphosphorylated state the 
FHA domain of Rv1827 interacts with the metabolic enzymes.  To address this issue a 
rationally designed mutagenic study on Rv1827 was performed, guided by the solution 
structures of Rv1827 pThr 22 and the unphosphorylated model. 
 
7.2 Rational design of Rv1827 mutants 
Knowing that conformational changes associated with N-terminal phosphorylation 
abrogated Rv1827 interactions with its metabolic targets, it was hypothesized that the 
surface used by the FHA domain to bind intermolecularly must in some way be changed 
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or occluded by the intramolecular association of the phosphorylation site (pThr 21 or 22) 
and the FHA domain. 
 
The crystal and solution structures of other FHA domains both free and in complex with 
their respective phosphopeptide ligands show that few, it any, conformational changes 
are associated with intermolecular FHA domain interactions.  Thus FHA domains appear 
not to change conformation upon ligand binding.  It was therefore reasoned that a 
mutational analysis focused on surfaces of the Rv1827 FHA domain that were occluded 
through the intramolecular association of the phosphorylated N-terminus would be more 
fruitful in identifying intermolecular interaction surfaces.  From the solution structures of 
Rv1827 pThr 22 we saw that two partially overlapping surfaces were occluded by 
intramolecular binding. 
 
The first of these is the canonical FHA-phosphopeptide interaction surface, which is 
formed by the loops joining β-strands β3/β4, β4/β5, β6/β7 and β10/β11.  These loops 
contain the conserved residues required for FHA-phosphopeptide interactions (Arg 81, 
Ser 95, Leu 116, Asn 117 and Lys 141).  The second surface comprises residues from β7, 
β10 and β11 and forms a positively charged cleft within which the linker and H1 regions 
reside (Figure 7.1, A).  Residues from this FHA surface were observed to make contacts 
with, and help to stabilize, the H1 region in the N-terminally phosphorylated form of 
Rv1827.  The most significant contributions to this stabilization were made by the FHA 
domain residues Lys 141, Arg 143 and Gln 138 (see section 6.3.2 for more details).  Thus 
as well as being required for intramolecular phosphopeptide interactions, Lys 141 also 
forms part of this secondary intramolecular interaction surface. 
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Figure 7.1.  Rational design of Rv1827 mutants.  All structures in this figure are of the same ensemble 
(as in Figure 6.7) and are in the same relative orientation.  (A)  Surface charge of Rv1827 pThr 22 FHA 
domain (blue: positive, red: negative) with the N-terminal region shown in ribbons representation (H1 
region is light blue).  (B)  Rv1827 FHA domain surface (white) with the location of the conserved van 
Doren surface highlighted in pink.  (C)  The location of residues targeted in site directed 
mutatgenesis (stick and ball representation with cyan surface) shown relative to the N-terminal 
phosphorylation site (pThr 22 shown in lines representation), the H1 region (blue) and the linker 
region both in cartoon representation.  The location of residues targeted in for mutagenesis largely 
coincide with the predicted van Doren surface. 
A B
C
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The FHA domain region formed by β7, β10 and β11 was identified by bioinformatics as 
a conserved surface (the van Doren surface) and potentially therefore is of conserved 
function (see section 1.5.4 and Figure 7.1, B).  This and its stabilizing contacts with the 
H1 region made it an attractive target for mutagenesis and hinted at a possible 
mechanism by which N-terminal phosphorylation abrogated intermolecular interactions.  
Could it be that in Rv1827, the van Doren surface is employed for intermolecular 
interactions and that N-terminal phosphorylation induces stabilization of the H1 region 
such that this surface is occluded? 
 
Based on the net positive charge of the β-sheet that is occluded by H1 in the solution 
structures of Rv1827 pThr 22, it was possible that electrostatic interactions were involved 
in the Rv1827 FHA-enzyme interactions, so we targeted charged residues of this region.  
We created mutant Rv1827 constructs that contained individual Lys 141 and Arg 143 
substitutions for Glu (K141E and R143E), and a double mutant that contained both 
mutations (K141E/R143E).  We also created a mutation of Gln 138 to Arg (Q138R) in 
order to investigate whether adding a basically charged residue to the region would have 
any effect on intermolecular interactions.  The design of mutagenic primers and the site-
directed mutagenesis reactions were performed by Lasse Stach (NIMR). 
 
We saw previously that mutation of the conserved Rv1827 FHA domain phosphate-
binding Ser 95 to Ala (S95A) mutation reduced interactions with GDH and eliminated 
interactions with the β-subunit (GltB) of the GS complex (see section 4.4).  We 
wondered if mutation of another conserved residue would have the same effect.  We 
therefore mutated Asn 117 to Ala (N117A), which has been demonstrated in other FHA 
domains to significantly reduce their ability to bind to phosphopeptides.  The locations 
of all the residues mutated are shown in Figure 7.1 (C). 
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 7.3 Identification of intermolecular Rv1827 interaction surfaces 
In an attempt to characterize the effects that the Rv1827 FHA domain mutations had on 
its intermolecular interactions with KGD, GDH and GltB (the β-subunit of the GS 
complex) we performed GST-fusion pull-down assays.  These experiments took the 
same form as those described previously (in section 4.4), and the results are shown in 
Figure 7.2 and summarized in Table 7.1.  All of the Rv1827-fusion constructs used in the 
pull down assays contained the full length form of Rv1827 (162 residues), which was N-
terminally fused to GST. 
 
 Wild type K141E R143E 
K141E/ 
R143E Q138R N117A S95A 
GDH + - - - + + - 
GltB (GS) + - + - + - - 
KGD + - - - + - + 
 
Table 7.1.  Summary of mutant Rv1827 interactions with KGD, GltB (GS complex) and GDH. 
 
7.4 Effects of mutation of conserved FHA domain residues 
As seen previously, wild-type, unphosphorylated Rv1827 bound to KGD, GDH and 
GltB (Figure 4.1 and Figure 7.2).  The S95A mutant associated strongly with KGD but 
showed reduced binding to GDH and eliminated interactions with GltB.  The N117A 
mutation caused interactions with both KGD and GltB to be lost, but association with 
GDH was maintained at approximately wild-type levels.  It seems therefore that two  
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Figure 7.2.  Identification of intramolecular and intermolecular Rv1827 interaction surfaces.  Pull-
down assays with WT Rv1827 and the six indicated mutants of Rv1827. 
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conserved FHA domain residues that are essential for phosphopeptide interactions are 
independently required for two different phospho-independent interactions.  In Rv1827, 
Ser 95 is required for association with GltB and GDH (but not KGD) and Asn 117 is 
required for association with KGD and GltB (but not GDH). 
 
7.5 Effects of mutation of non-conserved FHA domain residues 
Interestingly, a differential pattern of intermolecular interactions was also observed for 
the other Rv1827 mutants.  In the case of the K141E and K141E/R143E double 
mutants, the interactions with all three of the metabolic enzymes were virtually 
eliminated.  However, the R143E mutation maintained interaction with GltB at wild type 
levels but lost the ability to bind to KGD and GDH.  Therefore Arg 143 is required for 
Rv1827 interactions with KGD and GDH (but not GltB) and Lys 141 is required for 
effective interactions with all three metabolic targets. 
 
The Q138R mutant maintained interactions with all of the enzymes and, in addition, an 
interacting protein of ~145 kDa was observed on the pull down gel (Figure 7.2).  As yet, 
identification of this high molecular weight protein has not been attempted.  It would 
appear that changing the surface charge of the FHA domain at the region associated with 
H1-FHA interactions significantly alters the ability of Rv1827 to interact with its three 
metabolic targets.  Decreasing the positive charge of this area reduces intermolecular 
interactions and substituting a negatively charged residue for a positively charged one 
promotes interactions.  In the case of the Rv1827 FHA domain, mutational analysis of 
the conserved van Doren surface has, for the first time, demonstrated that this region 
forms a functional protein-protein interaction surface. 
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7.6 Biophysical and kinetic analysis of Rv1827 mutants 
To investigate whether the Rv8127 mutants maintained their differential modulatory 
activity as well as binding to their metabolic targets, a subset of them were tested in both 
surface plasmon resonance (SPR) experiments (by Dr. Jiejin Li at NIMR) and enzyme 
activity assays (by Dr. Helen O’Hare at Leicester University).  The double mutant 
containing both K141E/R143E substitutions was not used in these experiments as 
mutation of Lys 141 was shown by the pull down assays to severely restrict interactions 
with all three enzymes.  Similarly the Q138R mutant was not used as it did not 
significantly change the interaction pattern with the enzymes compared to the wild type 
Rv1827 protein.  In these experiments, recombinant KGD and GDH (supplied by Dr. 
Helen O’Hare) were used and the activity of the GS complex was tested in M. smegmatis 
cell free lysate.  The results of these assays were normalized to the unphosphorylated 
Rv1827 wild type values and are shown in Figure 7.3 (A), and summarized in Table 7.2. 
 
 Wild type K141E R143E N117A S95A 
GDH + - - + - 
GltB (GS) + - + - - 
KGD + - - - + 
 
Table 7.2.  Combined summary of the effects on enzyme activity (KGD, GltB (GS complex) and 
GDH) and SPR binding (to KGD and GDH) of the different Rv1827 FHA domain mutants. 
 
 
The relative SPR binding results largely recapitulate the trend observed in the pull down 
assays.  Both Lys 141 and Arg 143 are required for association with KGD and GDH,  
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Figure 7.3.  Confirmation of intramolecular and intermolecular Rv1827 interaction surfaces.  top  
The “relative activity” of Rv1827 and its mutants at 4 µM on KGD (blue), GDH (green), and GS 
(red), normalised to that of the WT protein. Full titrations are shown in (Nott et al., 2009).  lower  
Relative SPR binding to immobilised KGD and GDH. Values are the mean of three independent 
measurements and error bars represent the SEM. 
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and Rv1827 interactions with KGD and GDH are relatively insensitive to mutation of 
Ser 95 and Asn 117, respectively.  The Rv1827 K141E mutation is not effective against 
any of the three enzymes, again demonstrating that it is required for functional 
intermolecular FHA domain interactions.  Reflecting the trend seen in the pull down 
assay, the activity of the GS complex, GDH and KGD are insensitive to mutation of Arg 
143, Asn 117 and Ser 95, respectively. 
 
7.7 Conclusions 
These results confirm that the Rv1827 FHA domain surface involved in regulatory intra-
molecular interactions is coincident with that employed in the formation of each of the 
enzyme complexes.  The inter-molecular binding events appear to be specific since 
Rv1827 interactions with KGD, GDH and GS are sensitive to different combinations of 
three of the four Rv1827 mutations.  However, each pairwise interaction is relatively 
insensitive to mutation at one of the positions (S95A, N117A or R143E), and only 
K141E has a significant effect on binding to all three enzymes.  The differential effects 
on binding/inhibition/activation of S95A, N117A and R143E preclude the possibility 
that these mutations are merely acting to either stabilise the ‘pre-bound’ conformation or 
globally disrupt FHA folding, since inter-molecular interactions with all three enzymes 
would be impeded in both scenarios. 
 
Therefore the apparently complex pattern of mutational effects evident in Figure 7.3 are 
interpreted in terms of a core FHA binding surface that is subtly tailored to 
accommodate three structurally diverse enzyme targets in a location that is responsive to 
regulatory Rv1827 phosphorylation (Figure 7.4).  These results reveal a clear biological 
role for phospho-independent interactions in FHA domain function that may  
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Figure 7.4.  Rv1827 FHA domain uses three partially overlapping surfaces to bind intermolecularly.  
The effects on binding and enzyme inhibition or activation represented as three distinct but 
substantially overlapping subregions of the FHA surface. KGD, GDH, and GS each use three of the 
four mutated positions to specifically bind to Rv1827.  Lys 141 within the basic FHA region is the only 
residue whose mutation affects all three interactions. 
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nonetheless involve residues integral to the canonical pThr binding surface.  
Consequently, it is now suggested that abrogation of interactions through mutation of 
highly conserved pThr-binding residues cannot necessarily be taken as prima facie 
evidence for phosphorylation-dependent FHA binding in the absence of supporting data. 
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8 Discussion 
8.1 Rv1827 is a novel FHA domain-containing protein  
Modular signaling architectures have evolved to direct varied biological activities through 
combinatorial linkage of multiple domains with specific function within a single molecule 
(Pawson, 2007).  Many such examples are now known and FHA domains themselves are 
found in a variety of modular signaling molecules where their apparent phospho-binding 
function is complemented by other interaction domains and/or enzymatic activities (Li et 
al., 2002; Oliver et al., 2006; Zhang and Durocher, 2008). 
 
In contrast to such multidomain systems, Rv1827 is a small protein that comprises only a 
single FHA domain and a seemingly unstructured N-terminal tail region.  It nonetheless 
acts as an activator or inhibitor to regulate three core metabolic enzymes.  These 
differential modulatory effects are summarized in Figure 8.1, where dashed lines 
represent Rv1827-mediated inhibition of KGD- and GDH-catalyzed reactions (blue and 
green, respectively) and the bold red line represents activation of GS complex activity.  
Rv1827 is conserved only across the actinomycetes and, in spite of its deceptively simple 
architecture, plays an important role in determining carbon flux and nitrogen 
assimilation. 
 
In chapters 4 and 5 we saw that the phosphorylation of a single site in the N-terminus of 
Rv1827 abrogates its interactions with its metabolic targets and is associated with 
substantial changes in its biophysical properties.  Whereas unphosphorylated Rv1827 is 
readily cleaved by trypsin at Arg 26, phosphorylation of Thr 21 (by PknG) and Thr 22 
(by PknB) lend significant protection to this tryptic site.  Additionally, PknB-mediated 
phosphorylation confers significant thermal stability to Rv1827, increasing the  
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Figure 8.1.  Summary of Rv1827 activity on glutamate metabolism and nitrogen assimilation in M . 
tuberculosis.  The three enzymes regulated by Rv1827 lie at the crossroads of the TCA cycle. KGD 
(blue) decarboxylates α-ketoglutarate.  GDH (green) and GS (red)/GlnA (glutamine synthetase, 
orange) function in the low- and high-affinity pathways of ammonia assimilation, respectively.  
Inhibition of KGD and GDH (dashed lines) by Rv1827 and its activation of GS (bold red lines) alter 
the flux of α-ketoglutarate towards glutamate synthesis. 
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temperature at which its secondary structure is completely denatured from 60 to 80oC.  It 
was found that this increase in stability is brought about by intramolecular association of 
the N-terminal phosphorylation site with the FHA domain, contrasting the initial 
hypothesis that phosphorylation would induce Chk2-like dimerisation (Li et al., 2002). 
 
We then investigated the internal mobility and backbone dynamics of unphosphorylated 
Rv1827 and the conformationally more compact PknB-phosphorylated form using NMR 
relaxation measurements.  When phosphorylated by PknB, the N-terminal pThr 22 site 
binds back to the FHA domain and becomes highly ordered.  Thus the phospho-
dependent intramolecular association confers stability across both the phosphorylation 
site and the FHA domain.  Remarkably the 1H-15N relaxation measurements showed that 
the N-terminal region in unphosphorylated Rv1827 was not as unstructured as we had 
previously thought.  It fact, it adopts a ‘pre-bound’ conformation, in which there is 
transient association of residues centered around Ala 27 with those on the FHA domain 
surface.  This surprising result suggested that phosphorylation of Thr 21 (by PknG) or 
Thr 22 (by PknB) acted to stabilize a pre-existing intramolecular interaction of the N-
terminus with the FHA domain.  To understand the nature of the intramolecular 
association of the N-terminal region with the FHA domain, a detailed structural analysis 
using NMR spectroscopy was subsequently performed. 
 
Rv1827 and the PknB-phosphorylated form were ideally suited to hydrodynamic and 
structural characterization by NMR spectroscopy due to their relatively small size.  Both 
forms were highly soluble and stable for long periods of time at room temperature.  It 
was also fortunate that homogeneous, mono-disperse samples of each species could be 
readily generated.  However, the calculation of solution structures of Rv1827 pThr 22 
and models of the unphosphorylated form presented several challenges.  The significant 
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proportion of disordered/transiently structured residues (~ 40%) meant that standard 
methodology failed to produce ensembles of structures that reflected the high internal 
mobility of the region between the N-terminal phosphorylation site and the FHA 
domain.  To address this issue, the T2 relaxation and NOE enhancement hydrodynamic 
data were employed to threshold the distance restraints over different regions of the 
molecule.  The implementation of this strategy is discussed in detail in section 6.3.2.  The 
quality of ensembles of solution structures was then assessed by comparing the average 
pairwise r.m.s. deviation (for backbone atoms) from the average molecule to the T2 
relaxation profiles of Rv1827 and the PknB-phosphorylated form. 
 
The final ensembles of Rv1827 pThr 22 solution structures and models of the 
unphosphorylated form have several interesting and novel structural features.  Whereas 
the core Rv1827 FHA domain topology is highly similar to those of other FHA domains 
(an 11 β-stranded twisted β-sandwich), its mode of phosphopeptide binding is 
significantly different.  In the majority of FHA domain-phosphopeptide complex 
structures solved to date, the phosphopeptide runs along the binding surface parallel to 
the planarity of the β-sheets.  However, despite using the conserved Arg 81 and Ser 95 to 
co-ordinate the phosphate of pThr 22, the direction of the ensuing peptide chain is 
skewed towards and over one of the Rv1827 FHA domain β-sheets.  A possible 
explanation for this may be that the contacts between the H1 region and surface formed 
by β7 and the top portions of β10 and β11 act to extend the canonical phospho-
dependent interaction surface into a partially overlapping secondary interaction surface.  
Thus the intramolecular interaction that is induced upon PknB-mediated 
phosphorylation is stabilized by both phospho-dependent and phospho-independent 
FHA domain binding activity. 
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Remarkably, it appears that the conserved van Doren surface (comprising β7 and the top 
portions of β10 and β11) has multiple functionalities in Rv1827.  Not only is it employed 
for phospho-independent modulatory interactions of unphosphorylated Rv1827 with its 
metabolic targets, but is conversely used to stabilize its own kinase-sponsored occlusion.  
It may even promote efficient PknB-mediated phosphorylation by localizing the kinase 
target region close to the catalytic site upon interaction of the FHA domain with the 
phosphorylated activation loop.  Furthermore, the H1 region could act like an entropic 
spring to effectively absorb or dampen the shift in intramolecular phosphopeptide 
binding register when either Thr 21 or Thr 22 is phosphorylated.  Thus virtually identical 
structural, and therefore functional, responses could be elicited by the signaling activity 
of either PknG or PknB through phosphorylation of Rv1827. 
 
8.2 A mechanistic insight into the regulation of metabolism 
We have derived a molecular description of the mechanism by which Rv1827 activity 
within core metabolism is regulated through phosphorylation-mediated signaling.  
Rv1827 is a focal point for signaling cross-talk serving as a substrate for at least two 
STPKs; PknB, an essential regulator of cell morphology (Fernandez et al., 2006; Kang et 
al., 2005), and PknG, a virulence factor contributing to M. tuberculosis survival in mice and 
infected macrophages (Cowley et al., 2004; Walburger et al., 2004).  Integration of 
multiple signaling inputs is made possible through a common structural response to 
PknB or PknG activity that sponsors a regulatory intramolecular interaction between the 
Rv1827 FHA domain and pThr motifs at its N-terminus.  In doing so, intramolecular 
binding results in occlusion of the FHA domain surfaces used for intermolecular 
interactions (Figure 8.2).  Thus phosphorylation-mediated signaling is coupled to core 
metabolic activity through an Rv1827 intramolecular “off-switch”. 
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Figure 8.2.  Model of the regulation of target enzymes by Rv1827.  Rv1827 adopts multiple 
conformations in the “open” form.  Pre-binding of the N-terminal linker is highly stabilized in the 
“closed”, inactive conformation by phosphorylation by PknB (this study) or PknG (O'Hare et al., 
2008), disrupting the formation of the enzyme complex.  Return to the “open” structure may then 
arise through action of the MTB Ser/Thr phosphatase, PstP. 
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Intra-molecular association has been observed previously in modular SH2 and SH3 
domain-containing proteins such as Src-family kinases (Boggon and Eck, 2004), Crk 
(Kobashigawa et al., 2007; Rosen et al., 1995) and Itk (Andreotti et al., 1997) but such a 
mechanism has not been previously described for any FHA domain protein.  
Furthermore, in Src, Crk and Itk, intra-molecular binding mainly acts to control 
accessibility of pTyr (SH2) or PxxP (SH3) motif interaction surfaces on the SH2 or SH3 
domains, thereby modulating kinase targeting and activity. 
 
In contrast, it has been shown here how intra-molecular binding can simultaneously 
modulate FHA domain interactions with both canonical pThr-motif ligands and, more 
significantly, multiple non-phosphorylated partners, substantially expanding the known 
repertoire of FHA domain activities and regulatory mechanisms. 
 
Rv1827 is a potent inhibitor/activator of its metabolic targets and uses partially 
overlapping binding surfaces on its FHA domain to exert such control.  Both conserved 
FHA domain residues and those from a bioinformatically predicted conserved surface 
are employed for intermolecular Rv1827 binding events.  Furthermore these interactions 
do not require the prior phosphorylation of the Rv1827 binding partners.  This 
demonstrates that as well as being specific for pThr-containing ligands within the context 
of phosphorylation-mediated signaling, FHA domains can also possess the capability of 
engaging in phospho-independent protein-protein interactions. 
 
When investigating the activity of KGD in the presence of Rv1827, O’Hare and 
colleagues found that an Rv1827 concentration of 53 nM gave half maximal KGD 
enzymatic activity when then the enzyme was at 57 nM.  This suggested an apparent 
affinity for the inhibitory interaction in the mid- to high-nanomolar range, although due 
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to assay sensitivities the authors found it difficult to accurately determine the affinities of 
the interactions (O'Hare et al., 2008).  The authors also found that the inhibition was 
apparently non-competitive for α-ketoglutarate.  This is suggestive of an allosteric 
mechanism of inhibition, as Rv1827 reduced the maximal rate of the chemical reaction 
(Vmax) without changing the apparent binding affinity of the catalyst for the substrate.  
Conversely O’Hare and colleagues found that Rv1827 appeared to competitively inhibit 
GDH by lowing its affinity for its substrate.   
 
It is tempting to speculate about the reasons why two different kinases signal through the 
same substrate to alter metabolic flux.  It may be that M. tuberculosis has evolved similar 
metabolic responses to different environmental factors or stimuli (Figure 8.3).  
Explanations may lie with the possibility that PknG and PknB use different mechanisms 
for phosphorylation of Rv1827.  From the available data is seems reasonable to infer that 
in the absence of kinase activity, and if its cytosolic concentration approaches or exceeds 
that of its interaction partners, Rv1827 will most likely be complexed with the three 
metabolic enzymes.  The function of kinase signaling in this context is metabolic 
disinhibition/disactivation through Rv1827 phosphorylation.  Therefore, the efficiency 
of the kinases will depend on their ability to phosphorylate Rv1827 in different 
preformed metabolic complexes (KGD-Rv1827, GDH-Rv1827 and GS-Rv1827). 
 
We know that binding of the FHA domain of Rv1827 to the phosphorylated activation 
loop of PknB is required for efficient phosphorylation of Rv1827 at Thr 22.  The FHA 
domain-PknB activation loop interaction is mediated by the canonical phospho-binding 
FHA surface.  Therefore if the phospho-binding surface is partially or completely 
occluded when Rv1827 is bound to GDH or the GS complex (remember that interaction  
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Figure 8.3.  Phosphorylation signaling-mediated metabolic regulation.  The activity of PknG, PknB, 
and PstP controls carbon flux and nitrogen assimilation through regulation of the phosphorylation 
state of Rv1827. 
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with KGD was insensitive to the S95A mutation), then presumably the efficiency of 
phosphorylation of Rv1827 by PknB will be greatly reduced.  Conversely, PknB-mediated 
phosphorylation of Rv1827 in complex with KGD may be less attenuated as the 
phospho-binding surface of the FHA domain may be more exposed and can bind more 
readily to the PknB activation loop. 
 
As PknG does not contain phosphorylation sites in its activation loop it seems that it 
may employ a different mechanism.  Phosphorylation of the N-terminal region of PknG 
does not affect its efficiency of phosphorylating a peptide representing its Rv1827 target 
site, but does increase the efficiency with which PknG can phosphorylate full length 
Rv1827 (O'Hare et al., 2008).  However, the N-terminal phosphorylation sites of PknG 
that promote Rv1827 phosphorylation are significantly further from the kinase active site 
than those used by PknB for efficient kinase-substrate docking.  Similarly the PknA 
phosphorylation sites at the C-terminal end of PknG are a significant distance from the 
catalytic site (Fiuza et al., 2008; O'Hare et al., 2008; Scherr et al., 2007).  In this way the 
PknG target site in the N-terminal region of Rv1827 may take longer to find its way into 
the active site of the kinase after kinase-substrate docking.  Thus dependence on the 
accessibility of the Rv1827 phospho-binding surface when it is complexed with the 
different metabolic enzymes may prove to be a mechanism by which these two kinases 
subtly differ in their regulatory functions.  Elucidation of the mechanisms by which 
PknG and PknB regulate disinhibition/disactivation of metabolic processes through 
phosphorylation of enzyme-complexed Rv1827 is a natural next step in understanding 
the phosphorylation signaling mechanisms of M. tuberculosis.  However, equally important 
is identification of the stimuli that initially activate the kinases. 
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8.3 Future perspectives 
It has been shown here how phosphorylation signaling can bring about changes in M. 
tuberculosis core metabolic processes, but we still know relatively little about the functional 
significance of such changes for survival of the organism.  Outstanding areas of research 
include identification of the signals that bring about the change of dormant populations 
of mycobacteria to actively replicating populations.  Recent advances in the 
implementation of chemostatic systems are beginning to address this issue.  Here, 
mycobacteria can be cultured under tightly controlled conditions that simulate those in 
specific host environments, such as the human macrophage.  Their responses to defined 
changes in environmental conditions can then be measured by proteome wide mass 
spectrometry (Rao et al., 2008; Shui et al., 2009), transcriptomics and metabolomics 
(Halouska et al., 2007). 
 
Further characterization at the structural level of the inhibition of KGD and GDH by 
Rv1827 and the mechanism of its activation of the GS complex might provide useful 
hypotheses or predictions regarding metabolic changes associated with dormant/actively 
replicating transitions.  As the three metabolic enzymes with which Rv1827 interacts are 
likely to form extremely large, highly symmetric multi-protein complexes, cryo-electron 
microscopy may be a useful tool for this task. 
 
Currently, little is known about the functionality of other Ser/Thr protein kinase 
networks in M. tuberculosis, although we have become aware that characterization of the 
phospho-proteome by mass spectrometry has recently commenced and, surprisingly, the 
GroEl chaperone has been found to be a substrate of the M. tuberculosis Ser/Thr protein 
kinases.  Such research may in turn lead to testable hypotheses regarding the activity of 
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other FHA domain-containing proteins, their cognate kinases and interaction partners.  
If Rv1827 is a representative example of their mechanistic and functional diversity, this 
will hopefully increase our understanding of the properties of signaling networks in M. 
tuberculosis and lead to the identification of novel therapeutic targets. 
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9 Appendix 
9.1 Sequence alignment of Rv1827 across the actinomycetes 
Residues in this alignment are colored according to type. 
                          25                       50    
                          .                        .  
M. tuberculosis MTDMNPDIEKDQTSDEVTVETTSVFRADFLSELDAPAQAGTESAVSGVEG 50 
M. leprae   MTDMDSGRQEDQTSDEVTVETTSVFRADFLNELDAPAQAGAESVVSGVEG 50 
M. marinum   MTDMDAARDRDQTSDEVTVETTSVFRADFLNELDAPTQSGTESSVSGVEG 50 
M. ulcerans   MTDMDAARDRDQTSDEVTVETTSVFRADFLNELDAPTQSGTESSVSGVEG 50 
M. abscessus   ---MVTDNDKDDTSGEVTAETTSVFRADFATELEAPAQAGAD--VSGVEG 45 
M. smegmatis   MTDKDSNLGADQ-SEDVTVETTSVFRADFLNELDAPAAAGTEGAVSGVEG 49 
C. amycolatum   ---MTS----NSGQPEASVETTSVFRADLLKEMES--SSNTDSTVSGVEG 41 
C. glutamicum   ---MSD----NNGTPEPQVETTSVFRADLLKEMESS--TGTAPASTGAEN 41 
C. efficiens   ---MSD----NTGTPEPQVETTSVFRADLLKEMSG---AGSAPAATGADN 40 
C. diphtheriae   ---MSD----NTGAPDVQVETTSVFRADLLKEMESG--AGAATASGSDVT 41 
            :    :  .*********: .*:..   :.:     .    
 
                          75                       100    
                          .                        .   
M. tuberculosis LPPGSALLVVKRGPNAGSRFLLDQAITSAGRHPDSDIFLDDVTVSRRHAE 100 
M. leprae   LLAGSALLVVKRGPNAGSRFLLDQAITSAGRHPDSDIFLDDVTVSRRHAE 100 
M. marinum   LPAGSALLVVKRGPNAGSRFLLDQPITSAGRHPDSDIFLDDVTVSRRHAE 100 
M. ulcerans   LPAGSALLVVKRGPNAGSRFLLDQPITSAGRHPDSDIFLDDVTVSRRHAE 100 
M. abscessus   LPAGSALLVVKRGPNAGSRFLLDQATTSAGRHPDSDIFLDDVTVSRRHAE 95 
M. smegmatis   LPSGSALLVVKRGPNAGSRFLLDQPTTSAGRHPDSDIFLDDVTVSRRHAE 99 
C. amycolatum   LPAGSALLVVKRGPNAGSRFLLDQAVTTAGRHPDSDIFLDDVTVSRRHAE 91 
C. glutamicum   LPAGSALLVVKRGPNAGARFLLDQPTTTAGRHPESDIFLDDVTVSRRHAE 91 
C. efficiens   LPAGSALLVVKRGPNAGARFLLDQPTTTAGRHPESDIFLDDVTVSRRHAE 90 
C. diphtheriae   PPAGAGMLVVKRGPNAGARFLLDRPTTTAGRHPESDIFLDDVTVSRRHAE 91 
    .*:.:**********:*****:. *:*****:**************** 
 
                          125                      150     
                          .                        . 
M. tuberculosis FRLENNEFNVVDVGSLNGTYVNREPVDSAVLANGDEVQIGKFRLVFLTGP 
M. leprae   FRLEGNEFHVVDVGSLNGTYVNREPVDSAVLANGDEVQIGKFRLVFLIGS 
M. marinum   FRLEGNEFSVVDVGSLNGTYVNREPVDSAVLANGDEVQIGKFRLVFLTGP 
M. ulcerans   FRLEGNEFSVVDVGSLNGTYVNRGPVDSAVLANGDEVQIGKFRLVFLTGP 
M. abscessus   FRLDSAEFQVVDVGSLNGTYVNREPVDSAVLANGDEVQIGKFRLVFLTGP 
M. smegmatis   FRLEGGEFQVVDVGSLNGTYVNREPVDSAVLANGDEVQIGKFRLVFLTGP 
C. amycolatum   FRKNGDSYEVVDVGSLNGTYVNREPKNSAVLANGDEVQVGKFRLVFLIGN 
C. glutamicum   FRINEGEFEVVDVGSLNGTYVNREPRNAQVMQTGDEIQIGKFRLVFLAGP 
C. efficiens   FRINEGEFEVVDVGSLNGTYVNREPRNSQVLQTGDEIQIGKFRLVFLAGP 
C. diphtheriae   FRRQDGSFEVVDVGSLNGTYVNREPRNSEVLSSGDEVQIGKFRLVFIEGP 
  ** :  .: ************** * :: *: .***:*:*******: *  
 
           160 
           . 
M. tuberculosis KQGEDDGSTGGP 162 
M. leprae   KQDDDTGRTAGK 162 
M. marinum   KQGDDDGGTGGQ 162 
M. ulcerans   KQGDDDGGTGGQ 162 
M. abscessus   KSAGDDSASGGQ 157 
M. smegmatis   KS-DDSGSNA-- 158 
C. amycolatum   ------------ 141 
C. glutamicum   AE---------- 143 
C. efficiens   AA---------- 142 
C. diphtheriae   RA---------- 143 
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 9.2 NMR NOESY spectra distance calibration (distance_calibration.csh) 
The following awk script was used to calibrate the three NOESY spectra used for 
structure calculations of Rv1827 pThr 22. 
 
 
 
grep -B1 "# #" 080819_C13_D2O_NOESY_FINAL_VOL.peaks | grep -v "\-\-" > C13_NOE_D2O_peaks.peaks 
grep U C13_NOE_D2O_peaks.peaks | cut -dU -f2 | cut -d" " -f11 > 1Cd.txt 
# 
grep "# #" C13_NOE_D2O_peaks.peaks > 2Cd.txt 
# 
paste 2Cd.txt 1Cd.txt > 3Cd.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
#------------------------------------------------------------------------------------------------------------#!/bin/csh -f  
awk ' 
BEGIN {n=0;} 
{$1=="#";} 
{ if ($1=="#" && $7 <7.5e+3) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 3.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >=7.5e+3 && $7 <=2.5e+4) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 1.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >2.5e+4) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 0.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
 
       n++; 
} ' 3Cd.txt > 13C_finalnoe_D2O.tbl 
#------------------------------------------------------------------------------------------------------------#rm 1Cd.txt 2Cd.txt 3Cd.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
# 
# 
#------------------------------------------------------------------------------------------------------------ 
grep -B1 "# #" 080819_C13_H2O_NOESY_FINAL_VOL.peaks | grep -v "\-\-" > C13_NOE_H2O_peaks.peaks 
grep U C13_NOE_H2O_peaks.peaks | cut -dU -f2 | cut -d" " -f11 > 1Ch.txt 
# 
grep "# #" C13_NOE_H2O_peaks.peaks > 2Ch.txt 
# 
paste 2Ch.txt 1Ch.txt > 3Ch.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
#------------------------------------------------------------------------------------------------------------ 
#!/bin/csh -f  
awk ' 
BEGIN {n=0;} 
{$1=="#";} 
{ if ($1=="#" && $7 <7.5e+4) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 3.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >=7.5e+4 && $7 <=3.0e+5) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 3.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >3.0e+5) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 3.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
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       n++; 
} ' 3Ch.txt > 13C_finalnoe_H2O.tbl 
#------------------------------------------------------------------------------------------------------------ 
#rm 1Ch.txt 2Ch.txt 3Ch.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
#------------------------------------------------------------------------------------------------------------ 
grep -B1 "# #" 080819_N15_NOESY_FINAL_VOL.peaks | grep -v "\-\-" > 15N_NOE_peaks.peaks 
grep U 15N_NOE_peaks.peaks | cut -dU -f2 | cut -d" " -f11 > 1N.txt 
# 
grep "# #" 15N_NOE_peaks.peaks > 2N.txt 
# 
paste 2N.txt 1N.txt > 3N.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
#------------------------------------------------------------------------------------------------------------ 
#!/bin/csh -f  
awk ' 
BEGIN {n=0;} 
{$1=="#";} 
{ if ($1=="#" && $7 <1.0e+5) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 3.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >=1.0e+5 && $7 <=4.0e+5) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 1.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
else 
 if ($1=="#" && $7 >4.0e+5) 
{printf("assign (segid \"    \" and resid %5s and name %5s) (segid \"    \" and resid %5s and name %5s) 2.3 0.5 0.7  ! 
%5s\n",$3, $4, $5, $6, $7)} 
 
       n++; 
} ' 3N.txt > 15N_finalnoe.tbl 
#------------------------------------------------------------------------------------------------------------ 
rm 1N.txt 2N.txt 3N.txt 
#------------------------------------------------------------------------------------------------------------ 
# 
#------------------------------------------------------------------------------------------------------------ 
cat 13C_finalnoe_H2O.tbl 15N_finalnoe.tbl 13C_finalnoe_D2O.tbl > UNAMBIG_ASSI_080819_three_TEST.tbl 
# 
#rm 13C_finalnoe_D2O.tbl 13C_finalnoe_H2O.tbl 15N_finalnoe.tbl 
# 
#rm C13_NOE_D2O_peaks.peaks C13_NOE_H2O_peaks.peaks 15N_NOE_peaks.peaks 
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 9.3 Dihedral angle restraints for Rv1827 pThr 22 
 
Amino acid numbering is +5 with respect to the Rv1827 gene numbering due to the 
addition of 5 residues at the N-terminus of the protein from the pGEX 6P1 expression 
vector. 
 
 
VARS   RESID RESNAME PHI PSI DPHI DPSI DIST COUNT CLASS 
FORMAT %4d %s %8.3f %8.3f %8.3f %8.3f %8.3f %2d %s 
 
  35 L  -86.440  -13.930   27.810   27.360    5.750  9 Good 
  60 S -136.330  153.710   25.310   14.120   21.780 10 Good 
  61 A -143.290  144.640    8.460   12.340   17.370 10 Good 
  62 L -134.290  140.590   13.240   15.920   15.900 10 Good 
  63 L -123.730  135.040   17.720   11.260   14.100 10 Good 
  64 V -117.430  137.850   13.560   12.840   12.140 10 Good 
  65 V  -75.170  127.460   12.540    8.520   15.330 10 Good 
  70 N  -80.240   -9.250   23.540   24.790   31.950  9 Good 
  72 G   98.240  -18.230    8.330    9.430   21.190 10 Good 
  74 R -128.640  148.990   21.260   14.070   17.980 10 Good 
  75 F -123.790  121.950   12.280   13.200   11.020 10 Good 
  76 L -101.270  125.710   17.780   16.960   11.230 10 Good 
  79 Q -113.620  160.270   34.980   15.880   15.500 10 Good 
  82 T -107.820  141.210   12.120   15.350   20.210 10 Good 
  83 S -100.510  141.250   17.900    7.070   19.020 10 Good 
  84 A -131.560  147.070   17.350   19.950   27.970 10 Good 
  86 R -114.290  135.860   30.420   15.200   23.270  9 Good 
  87 H  -92.440  128.330   22.630   16.490   57.900 10 Good 
  93 F  -97.150  120.310    9.840    7.440   29.450 10 Good 
  94 L -100.600  117.310   12.440   22.410   28.800 10 Good 
  99 V -100.880  123.100   21.030   27.160   34.860 10 Good 
 104 A -135.800  151.660   20.250   14.430   24.190 10 Good 
 105 E -132.500  146.690   14.460   16.390   16.370 10 Good 
 109 E -118.040  127.030   23.490    8.160   15.810  9 Good 
 110 N   52.540   43.070    3.380    5.300   19.630  9 Good 
 111 N   64.620   18.370    5.770    7.700   14.700 10 Good 
 112 E -107.370  143.670   15.520   12.290   21.740 10 Good 
 113 F -122.260  136.910   18.060    9.570   14.150  9 Good 
 114 N -123.740  150.250   19.770   17.730   17.920 10 Good 
 115 V -132.040  141.280   12.320   11.090   17.730 10 Good 
 116 V -116.320  132.720    6.910    9.360   18.470 10 Good 
 117 D  -83.780  143.460   12.240   14.400   21.860  9 Good 
 120 S  -80.120  139.930   19.940   16.850   66.410  9 Good 
 121 L  -56.920  -32.680    7.720   11.070   53.360 10 Good 
 122 N  -94.530   -2.620   19.400   16.900   39.350 10 Good 
 124 T  -79.530  134.470   15.000   12.530   21.870 10 Good 
 125 Y -114.200  136.340   13.670   15.390   16.150 10 Good 
 126 V -116.860  124.330   17.240    8.340   16.340 10 Good 
 130 P  -64.910  144.370    9.130   10.440   37.520 10 Good 
 131 V -106.720  165.250   22.740    7.040   34.700  9 Good 
 133 S -122.510  147.930   21.590   27.970   14.520  9 Good 
 137 A -125.910  152.180   25.810   15.290   17.220 10 Good 
 139 G   96.860  -12.220    6.700    8.400   22.730 10 Good 
 141 E -124.760  138.010   14.740   11.830   16.700 10 Good 
 142 V -124.450  120.970   11.720   10.840   13.270 10 Good 
 143 Q -112.730  123.470    8.510   11.380   15.210 10 Good 
 144 I -117.040  115.950   12.420   12.630   21.550 10 Good 
 150 V -123.660  127.860    8.540    8.480   13.270 10 Good 
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 9.4 Hydrogen bond restraints for Rv1827 pThr 22 
 
Amino acid numbering is +5 with respect to the Rv1827 gene numbering due to the 
addition of 5 residues at the N-terminus of the protein from the pGEX 6P1 expression 
vector. 
 
 
 
assign (resid 100 and name HG ) (resid 27 and name P) 3.1 0.5 0.5 
assign (resid 100 and name OG ) (resid 27 and name P) 4.0 0.5 0.5 
assign (resid 86 and name HE ) (resid 99 and name O) 2.1 0.5 0.5 
assign (resid 86 and name NE ) (resid 99 and name O) 3.0 0.5 0.5 
assign (resid 86 and name QH2 ) (resid 27 and name P) 3.1 0.5 0.5 
assign (resid 86 and name NH2 ) (resid 27 and name P) 4.0 0.5 0.5 
assign (resid 101 and name HN ) (resid 27 and name P) 3.1 0.5 0.5 
assign (resid 101 and name N ) (resid 27 and name P) 4.0 0.5 0.5 
assign (resid 61 and name O ) (resid 77 and name HN) 2.1 0.5 0.5 
assign (resid 61 and name O ) (resid 77 and name N) 3.0 0.5 0.5 
assign (resid 75 and name O ) (resid 63 and name HN) 2.1 0.5 0.5 
assign (resid 75 and name O ) (resid 63 and name N) 3.0 0.5 0.5 
assign (resid 63 and name O ) (resid 75 and name HN) 2.1 0.5 0.5 
assign (resid 63 and name O ) (resid 75 and name N) 3.0 0.5 0.5 
assign (resid 73 and name O ) (resid 65 and name HN) 2.1 0.5 0.5 
assign (resid 73 and name O ) (resid 65 and name N) 3.0 0.5 0.5 
assign (resid 65 and name O ) (resid 73 and name HN) 2.1 0.5 0.5 
assign (resid 65 and name O ) (resid 73 and name N) 3.0 0.5 0.5 
assign (resid 152 and name O ) (resid 62 and name HN) 2.1 0.5 0.5 
assign (resid 152 and name O ) (resid 62 and name N) 3.0 0.5 0.5 
assign (resid 62 and name O ) (resid 152 and name HN) 2.1 0.5 0.5 
assign (resid 62 and name O ) (resid 152 and name N) 3.0 0.5 0.5 
assign (resid 150 and name O ) (resid 64 and name HN) 2.1 0.5 0.5 
assign (resid 150 and name O ) (resid 64 and name N) 3.0 0.5 0.5 
assign (resid 64 and name O ) (resid 150 and name HN) 2.1 0.5 0.5 
assign (resid 64 and name O ) (resid 150 and name N) 3.0 0.5 0.5 
assign (resid 148 and name O ) (resid 66 and name HN) 2.1 0.5 0.5 
assign (resid 148 and name O ) (resid 66 and name N) 3.0 0.5 0.5 
assign (resid 151 and name O ) (resid 139 and name HN) 2.1 0.5 0.5 
assign (resid 151 and name O ) (resid 139 and name N) 3.0 0.5 0.5 
assign (resid 140 and name O ) (resid 151 and name HN) 2.1 0.5 0.5 
assign (resid 140 and name O ) (resid 151 and name N) 3.0 0.5 0.5 
assign (resid 149 and name O ) (resid 142 and name HN) 2.1 0.5 0.5 
assign (resid 149 and name O ) (resid 142 and name N) 3.0 0.5 0.5 
assign (resid 142 and name O ) (resid 149 and name HN) 2.1 0.5 0.5 
assign (resid 142 and name O ) (resid 149 and name N) 3.0 0.5 0.5 
assign (resid 147 and name O ) (resid 144 and name HN) 2.1 0.5 0.5 
assign (resid 147 and name O ) (resid 144 and name N) 3.0 0.5 0.5 
assign (resid 141 and name O ) (resid 127 and name HN) 2.1 0.5 0.5 
assign (resid 141 and name O ) (resid 127 and name N) 3.0 0.5 0.5 
assign (resid 125 and name O ) (resid 143 and name HN) 2.1 0.5 0.5 
assign (resid 125 and name O ) (resid 143 and name N) 3.0 0.5 0.5 
assign (resid 143 and name O ) (resid 125 and name HN) 2.1 0.5 0.5 
assign (resid 143 and name O ) (resid 125 and name N) 3.0 0.5 0.5 
assign (resid 123 and name O ) (resid 145 and name HN) 2.1 0.5 0.5 
assign (resid 123 and name O ) (resid 145 and name N) 3.0 0.5 0.5 
assign (resid 134 and name O ) (resid 115 and name HN) 2.1 0.5 0.5 
assign (resid 134 and name O ) (resid 115 and name N) 3.0 0.5 0.5 
assign (resid 115 and name O ) (resid 134 and name HN) 2.1 0.5 0.5 
assign (resid 115 and name O ) (resid 134 and name N) 3.0 0.5 0.5 
assign (resid 132 and name O ) (resid 117 and name HN) 2.1 0.5 0.5 
assign (resid 132 and name O ) (resid 117 and name N) 3.0 0.5 0.5 
assign (resid 109 and name O ) (resid 112 and name HN) 2.1 0.5 0.5 
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assign (resid 109 and name O ) (resid 112 and name N) 3.0 0.5 0.5 
assign (resid 112 and name O ) (resid 109 and name HN) 2.1 0.5 0.5 
assign (resid 112 and name O ) (resid 109 and name N) 3.0 0.5 0.5 
assign (resid 107 and name O ) (resid 114 and name HN) 2.1 0.5 0.5 
assign (resid 107 and name O ) (resid 114 and name N) 3.0 0.5 0.5 
assign (resid 114 and name O ) (resid 107 and name HN) 2.1 0.5 0.5 
assign (resid 114 and name O ) (resid 107 and name N) 3.0 0.5 0.5 
assign (resid 105 and name O ) (resid 116 and name HN) 2.1 0.5 0.5 
assign (resid 105 and name O ) (resid 116 and name N) 3.0 0.5 0.5 
assign (resid 116 and name O ) (resid 105 and name HN) 2.1 0.5 0.5 
assign (resid 116 and name O ) (resid 105 and name N) 3.0 0.5 0.5 
assign (resid 103 and name O ) (resid 118 and name HN) 2.1 0.5 0.5 
assign (resid 103 and name O ) (resid 118 and name N) 3.0 0.5 0.5 
assign (resid 80 and name O ) (resid 108 and name HN) 2.1 0.5 0.5 
assign (resid 80 and name O ) (resid 108 and name N) 3.0 0.5 0.5 
assign (resid 106 and name O ) (resid 82 and name HN) 2.1 0.5 0.5 
assign (resid 106 and name O ) (resid 82 and name N) 3.0 0.5 0.5 
assign (resid 82 and name O ) (resid 106 and name HN) 2.1 0.5 0.5 
assign (resid 82 and name O ) (resid 106 and name N) 3.0 0.5 0.5 
assign (resid 104 and name O ) (resid 84 and name HN) 2.1 0.5 0.5 
assign (resid 104 and name O ) (resid 84 and name N) 3.0 0.5 0.5 
assign (resid 84 and name O ) (resid 104 and name HN) 2.1 0.5 0.5 
assign (resid 84 and name O ) (resid 104 and name N) 3.0 0.5 0.5 
assign (resid 83 and name O ) (resid 92 and name HN) 2.1 0.5 0.5 
assign (resid 83 and name O ) (resid 92 and name N) 3.0 0.5 0.5 
assign (resid 92 and name O ) (resid 85 and name HN) 2.1 0.5 0.5 
assign (resid 92 and name O ) (resid 85 and name N) 3.0 0.5 0.5 
assign (resid 85 and name O ) (resid 94 and name HN) 2.1 0.5 0.5 
assign (resid 85 and name O ) (resid 94 and name N) 3.0 0.5 0.5 
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 9.5 ARIA 1.2 new.html 
 
ARIA 1.2 run setup script for structure calculation in the absence of peaklists. 
 
 
<html> 
<head> 
<title>ARIA - start</title> 
</head> 
<body bgcolor=#ffffff> 
<h2>Parameters for the start:</h2> 
<BR> 
<h4><!-- ARIA --> 
ARIA_DIR=/dms/prog/bin/aria1.2<BR> 
ASPECTRUM_1=15N<BR> 
CSI_ERROR=30.0<BR> 
HBOND_FILE=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE/H_BONDS_080727.tbl<BR> 
HET1_1=1<BR> 
HET1_2=1<BR> 
HET1_3=N<BR> 
HET1_4=N<BR> 
HET1_5=N<BR> 
HET2_1=N<BR> 
HET2_2=N<BR> 
HET2_3=N<BR> 
HET2_4=N<BR> 
HET2_5=N<BR> 
PPMDHET1_1=0.5<BR> 
PPMDPRO1_1=0.07<BR> 
PPMDPRO2_1=0.05<BR> 
PRO1_1=3<BR> 
PRO1_2=2<BR> 
PRO1_3=N<BR> 
PRO1_4=N<BR> 
PRO1_5=N<BR> 
PRO2_1=2<BR> 
PRO2_2=3<BR> 
PRO2_3=N<BR> 
PRO2_4=N<BR> 
PRO2_5=N<BR> 
PROJECT_DIR=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE<BR> 
RUN_NUMBER=557<BR> 
SEQ_PDB_FILE=/dms/home/tnott/ARIA/RV1827p22.seq<BR> 
TALOS_ERROR=10.0<BR> 
TALOS_FACTOR=2.0<BR> 
TALOS_FILE=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE/geoff_pred2.tab<BR> 
UNAMBIG_TBL=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE/UNAMBIG_run232_D_40_51_no_OR.tbl
<BR> 
WHICH_PEAKS_1=all<BR> 
WHICH_PEAKS_2=all<BR> 
WHICH_PEAKS_3=all<BR> 
WHICH_PEAKS_4=all<BR> 
WHICH_PEAKS_5=all<BR> 
WHICH_SETUP=XEASY<BR> 
XPEAKS_1=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE/null.peaks<BR> 
XPROT_1=/dms/home/tnott/ARIA/FHA_PHT_LOOP_NOE/080912_RV1827_MASTER.prot<BR> 
submit_save=Save updated parameters<BR> 
</h4><!-- ARIA --> 
</body> 
</html> 
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 9.6 ARIA 1.2 simulated annealing (SA) and water refinement protocols from 
run.cns 
 
{================= SA protocol ===================} 
{* type of molecular dynamics *} 
{+ choice: "torsion" "Cartesian" +} 
{===>} md_type="torsion";  
{* initial seed for random number generator *} 
{* change to get different initial velocities *} 
{===>} iniseed=89764443;  
{* initial temperature for TAD *} 
{===>} tadinit_t=20000;  
{* initial temperature for TAD and Cartesian dynamics *} 
{===>} carinit_t=2000;  
{* final temperature after first cooling step *} 
{===>} final1_t=1000;  
{* finale temperature after second cooling step *} 
{===>} final2_t=50;  
{* Cartesian time step *} 
{===>} timestep=0.003;  
{* factor for timestep and number of steps in TAD *} 
{===>} tadfactor=9;  
{* initial number of MD steps *} 
{===>} initiosteps=20000;  
{* number of MD steps for refinement *} 
{===>} refinesteps=8000;  
{* number of MD steps during first cooling stage *} 
{===>} cool1_steps=10000;  
{* number of MD steps during second cooling stage *} 
{===>} cool2_steps=8000;  
{* first iteration for Cartesian refinement (after TAD) *} 
{===>} cart_firstit=0; 
 
{* Sort structures accordingly to total energy or sum of restraints energies? *} 
{+ choice: "totener" "restener" +} 
{===>} filesort="totener"; 
 
{================= final water refinement  ===================} 
{* Do you want water refinement for the last iteration? *} 
{+ choice: "yes" "no" +} 
{===>} firstwater="yes";  
{* Which solvent do you want to use? *} 
{+ choice: "water" "dmso" +} 
{===>} solvent="water";  
{* number of structures for the water refinement *} 
{* refine the n best structures regarding energy  *} 
{===>} waterrefine=50; 
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 9.7 Molmol macro for aligning Rv1827 pThr 22 and unphosphorylated ensembles 
 
 
Molmol macro for aligning Rv1827 pThr 22 ensemble of 50 structures: 
 
 
InitAll yes 
ReadListPdb ./file.nam  
CalcBond 1 0 1  
SelectMol 'mol.num=50'  
FirstMol 'mol.num=2' 
SelectMol ''  
SelectBond 'bb and res.num=26..153'  
DefPropAtom 'displayed' 'selected'  
DefPropBond 'displayed' 'selected'  
DefPropDist 'displayed' 'selected'  
DefPropPrim 'displayed' 'selected'  
DefPropMol 'displayed' 'selected'  
SelectAtom 'bb and res.num=26..30,60..153'  
Fit to_first 'selected' 
 
 
 
 
 
Molmol macro for aligning unphosphorylated Rv1827 ensemble of 50 structures: 
 
 
InitAll yes 
ReadListPdb ./file.nam  
CalcBond 1 0 1  
SelectMol 'mol.num=50'  
FirstMol 'mol.num=2' 
SelectMol ''  
SelectBond 'bb and res.num=26..153'  
DefPropAtom 'displayed' 'selected'  
DefPropBond 'displayed' 'selected'  
DefPropDist 'displayed' 'selected'  
DefPropPrim 'displayed' 'selected'  
DefPropMol 'displayed' 'selected'  
SelectAtom 'bb and res.num=60..153'  
Fit to_first 'selected' 
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 9.8 Statistical analysis of Rv1827 pThr 22 
PROCHECK-NMR was used to evaluate torsion angles of the final ensemble of 
structure of Rv1827 pThr 22, and the Ramachandran plot of Φ and Ψ torsion angles is 
shown in Figure 9.1.  A summary of the statistical analysis for the final ensemble of 
lowest energy structures of Rv1827 pThr 22 are shown in Table 9.1.   
 
 
 
 
 Rv1827 pThr 22 
NMR distance and dihedral constraints  
 Distance constraints  
  Total NOE 1998 
  Intra-residue 659 
  Inter-residue  
   Sequential (|i-j|=1) 385 
   Medium-range (|i-j| ≥ 2 ≤ 4) 179 
   Long-range (|i-j| ≥ 5) 775 
  Hydrogen bonds 82 
 Total dihedral angle restraints 100 
  φ  50 
  ψ  50 
     
Structure statistics   
 Violations (mean and s.d.)  
  Distance constraints (>0.5) (Ǻ) 1.778 ± 1.114 
  Dihedral angle constraints (>5) (deg) 0.389 ± 0.502 
 Deviations from idealized geometry  
  Bond lengths (Ǻ) 0.0058 ± 0.0001 
  Bond angles (deg) 0.7309 ± 0.0198 
  Impropers (deg) 2.0702 ± 0.0911 
 Average pairwise r.m.s.d. (Ǻ)a  
  Backbone 0.640 ± 0.090 
  Heavy  1.370 ± 0.130 
 r.m.s.d. from the mean structure (Ǻ)a 0.444 ± 0.066 
     
 Residues in most favored regions [A,B,L]b 70.1% 
 Residues in additional allowed regions[a,b,l,p]b 24.5% 
 Residues in generously allowed regions [~a,~b,~l,~p]b 3.0% 
 Residues in disallowed regionsb 2.4% 
Rv1827 pThr 22, PknB-phosphorylated Rv1827 full length; NMR, nuclear 
magnetic resonance; NOE, nuclear overhauser effect. 
aPairwise r.m.s. deviation and r.m.s. deviation from the mean structure were 
calculated among 20 lowest energy structures out of 50 refined structures 
(residues 21-25 and 55-149). 
bStructure quality was analysed using PROCHECKnmr (Laskowski 
et al, 1996) over structured regions (residues 21-25 and 55-149). 
 
Table 9.1  Rv1827 pThr 22 solution structure statistics for 20 lowest energy structures shown in 
Figure 6.5 (D). 
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Plot statistics
Residues in most favoured regions  [A,B,L]   1248  70.1%
Residues in additional allowed regions  [a,b,l,p]    436  24.5%
Residues in generously allowed regions  [~a,~b,~l,~p]     53   3.0%
Residues in disallowed regions     43   2.4%
  ---- ------
Number of non-glycine and non-proline residues   1780 100.0%
Number of end-residues (excl. Gly and Pro)      0       
Number of glycine residues (shown as triangles)    160       
Number of proline residues     60       
  ----       
Total number of residues   2000       
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms
and R-factor no greater than 20%, a good quality model would be expected 
to have over 90% in the most favoured regions.
Model numbers shown inside each data point.
Figure 9.1.  Ramachandran plot of the final ensemble of 20 lowest energy structures shown in Figure 
6.5 (D). 
182
 
 
9.9 Tau values used in T1 and T2 relaxation experiments 
 
 
 
Rv1827 Rv1827 pThr 22 
T1 (ms) T2 (ms) T1 (ms) T2 (ms) 
8.6 8.6 8.6 8.6 
96.9 17.2 96.9 17.2 
193.2 34.4 193.2 25.8 
393.8 68.9 297.6 34.4 
696.6 94.7 393.8 51.6 
997.6 120.5 594.5 77.5 
1247 146.3 795.1 94.7 
1496.4 17.2 995.7 120.5 
193.2  1244.6 146.3 
  1493.3 34.4 
  393.8  
 
Table 9.2  Tau values used in the T1 and T2 relaxation experiments performed on Rv1827 and the 
PknB-phosphorylated form (Rv1827 pThr 22). 
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